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ABSTRACT 
 
ANNE M. HAKENEWERTH: Joint effects of alcohol consumption and  
polymorphisms in alcohol and oxidative stress metabolism genes  
on risk and survival from head and neck cancer 
(Under the direction of Dr. Andrew Olshan) 
 
Heavy drinking of alcoholic beverages increases risk of developing squamous cell 
carcinoma of the head and neck (SCCHN; oral, pharyngeal and laryngeal cancer). This 
study hypothesized that genetic variation in the ethanol metabolism and oxidative stress 
pathways may influence the occurrence of and survival from SCCHN.  
Interview and genotyping data were obtained from 1227 SCCHN cases and 1325 
controls from the Carolina Head and Neck Cancer Epidemiology study, a population-based 
case-control study of head and neck cancer conducted in North Carolina from 2002-2006. 
Vital status through 2008 was obtained from the National Death Index. A panel of 45 single 
nucleotide polymorphisms (SNPs) in the ethanol and 19 SNPs in the oxidative stress 
metabolism pathways were evaluated in relation to the risk of SCCHN using logistic 
regression and in relation to all-cause and cancer-specific survival using Cox regression. 
Bonferroni- corrected p-values were also estimated.  
Two SNPs were associated with SCCHN risk: ADH1B rs1229984 A allele [odds ratio 
(OR)=0.7, 95% confidence interval (CI)=0.6-0.9)] and ALDH2 rs2238151 C allele (OR=1.2, 
95% CI=1.1-1.4). Three SNPs were associated with cancer risk in anatomic sub-sites: 
ADH1B rs17028834 C allele (larynx, OR=1.5, 95% CI=1.1-2.0), SOD2 rs4342445 A allele 
(oral cavity, OR=1.3, 95% CI=1.1-1.6), and SOD2 rs5746134 T allele (hypopharynx, 
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OR=2.1, 95% CI=1.2-3.7). Four SNPs in alcohol metabolism genes interacted with level of 
alcohol consumption: ALDH2 rs2238151, ADH1B rs1159918, ADH7 rs1154460, and 
CYP2E1 rs2249695. No interactions with alcohol were found for oxidative stress pathway 
SNPs.  
Minor alleles of two SNPs in CYP2E1 – the ‘C’ allele of both rs3813865 and 
rs8192772 – were associated with increased hazard of cancer-specific death [hazard ratio 
(HR)=2.09,  95%CI=1.38‐3.18; HR=1.71, 95% CI=1.23‐2.37, respectively]. No associations 
with survival were found for SNPs in ADH1B, ADH1C, ADH4, ADH7, ALDH2, GPx2, GPx4, 
and CAT.  
Previously unreported associations of SNPs in ALDH2, CYP2E1, GPX2, SOD1, and 
SOD2 with tumor incidence, and in CYP2E1 with cancer-specific survival, warrant further 
investigation. Associations with cancer incidence provide evidence that genetic variation in 
alcohol and oxidative stress pathways influence SCCHN carcinogenesis.  
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CHAPTER 1   
BACKGROUND AND REVIEW OF LITERATURE 
1.1 INTRODUCTION 
Head and neck cancers and their treatment differ from other human cancers in 
important ways. Not only do organs in the head and neck provide speaking ability, they also 
provide four of the five senses -- sight, hearing, taste, and smell -- as well as enable the 
essential life functions of breathing and eating. We interact with our environment primarily 
through the head and neck. Since cancers occurring in this region and their treatment may 
therefore result in deficits in any of these organs and their corresponding function, quality of 
life for people with head and neck cancer is more negatively impacted than for people with 
most other cancers. Pain, noticeable disfigurement and disability, and depression are 
common sequelae. Consequently, people with head and neck cancer require more 
rehabilitation and emotional support compared to those with most other cancers.  
1.2 TUMOR CHARACTERISTICS AND DESCRIPTIVE EPIDEMIOLOGY     
1.2.1 Tumor characteristics 
Cancers of the head and neck are defined by location, histology, and the fact that 
most are associated with use of tobacco and alcoholic beverages. Cancers of the head and 
neck (or upper aerodigestive tract/UADT) usually include cancers of the oral cavity (lip, 
tongue, gum, floor of mouth, other mouth, salivary glands); pharyngeal cancer 
(nasopharynx, hypopharynx, oropharynx, pharynx NOS); cancers of the nose, nasal cavity 
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and nasal sinuses; and laryngeal cancer. More than 90% of these cancers are squamous 
cell carcinoma (SCC). Excluded from the group are cancers of the skin, bone, pituitary 
gland, pineal gland, thyroid, eye, ear, brain, and meninges.  
Nasopharyngeal cancer and cancer of the nose, nasal cavity and nasal sinuses are 
rare in comparison to cancers of the other upper aerodigestive sites, and are inconsistently 
associated with tobacco and alcohol use. In addition, non-squamous cell cancers may well 
have a different etiology and risk factors than SCCs. Therefore these cancers are not 
included in this study.  
This dissertation analyzed case-control data from CHANCE, the Carolina Head and 
Neck Cancer Epidemiologic study. CHANCE enrolled cases of invasive squamous cell 
carcinomas of the head and neck (SCCHN), encompassing cancers of the oral cavity 
including lip, tongue, gum, floor of mouth, and other mouth; cancers of the pharynx including 
oropharynx, hypopharynx, and pharynx NOS; and laryngeal cancers. It excluded patients 
with nasopharyngeal cancer and cancers of the nose, nasal cavity, and nasal sinuses. 
CHANCE enrolled a small number of cases with lip cancer (n=21) and included them in its 
definition of SCCHN; however, this dissertation project excluded lip cancers from final 
analyses because the etiology of lip cancer (sunlight exposure in addition to alcohol and 
tobacco) differs from other SCCHNs. 
1.2.1.1 Anatomic distribution 
In the United States, the age-adjusted incidence rate of cancer of the oral cavity, 
larynx, and pharynx (excluding salivary gland and nasopharynx), averaged from 2002-2006, 
was 12.0 cases per 100,000. Slightly more than half of these occurred in the larynx and 
tongue, and over 80% occurred in the larynx, tongue, oropharynx, tonsil, gum and other 
mouth (Table 1).  
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Table 1. Anatomic distribution of head and neck cancers included in 
this study, United States 2002-2006 
Anatomic Location Annualized age-adjusted incidence rate per 100,000 (%)* 
Cumulative 
% 
 
Larynx 3.5 (29.2) 29.2 
Tongue 2.8 (23.3) 52.5 
Oropharynx and tonsil 1.9 (15.8) 68.3 
Gum and other mouth 1.5 (12.5) 80.8 
Lip 0.8 (6.7) 87.5 
Hypopharynx 0.7 (5.8) 93.3 
Floor of mouth 0.6 (5.0) 98.3 
Other oral cavity and pharynx 0.2 (1.7) 100.0 
ALL SITES COMBINED 12.0 (100)  
*SEER incidence data used in calculating the rates are from the 17 SEER areas (San 
Francisco, Connecticut, Detroit, Hawaii, Iowa,   New Mexico, Seattle, Utah, Atlanta, San 
Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia,   California). Rates 
are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).   
 
1.2.1.2 Pathogenesis and premalignant lesions 
Oral and many pharyngeal cancers are often clinically preceded by precursor lesions 
and conditions. The best-characterized such lesions include oral leukoplakia, erythroplakia, 
and oral submucous fibrosis. Oral leukoplakia and erythroplakia are diagnoses of exclusion; 
they are defined as adherent white (leukoplakia) or red (erythroplakia) patches on the 
mucous membranes of the oral cavity that cannot be defined as another type of lesion. Oral 
submucous fibrosis is a chronic debilitating disease characterized by inflammation and 
progressive fibrosis of submucosal tissues, resulting in stiffness of the mucosa.  
Erythroplakia is much more likely than leukoplakia to contain epithelial dysplasia, 
thus resulting in higher risk of eventual progression to cancer. Most oral lesions are found to 
be leukoplakia, in which 4 to 18% have been found to progress to cancer (1). Similarly, an 
Indian study reported that about 8% of oral submucous fibrosis cases eventually progress to 
cancer (2). In contrast, although much less common than leukoplakia, almost all 
erythroplakia lesions are found to be dysplastic or already-cancerous at the time of 
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diagnosis (1). Oropharyngeal tumors associated with human papillomavirus (HPV) infection 
almost exclusively occur in tonsillar crypts, where even small tumors often first present as 
regionally metastasized, with little evidence of precursor lesions. 
Laryngeal cancers are associated with a sequence of changes in the laryngeal 
epithelial mucosa that often includes laryngeal keratosis. These usually white, sometimes 
red, plaques appear similar to oral leukoplakia, and may present with or without atypia. They 
are often found near tumors and have a high transformation rate of from 1 to 40% (3) that is 
correlated with the amount of atypia. However, a significant percentage of laryngeal cancers 
present at an advanced stage without evidence of precursor lesions.  
1.2.1.3 Molecular characteristics 
SCCHN has traditionally been regarded as a homogeneous disease requiring a 
relatively common therapeutic regimen. However, differences in epidemiological risk factors 
and incidence and mortality trends among SCCHNs arising from different anatomic sites 
have supported the view that head and neck cancers form a heterogeneous group with 
distinct etiologies and prognoses that may require distinct treatments.  
 Tobacco smoking is the most well characterized risk factor for SCCHN. Although 
heavy alcohol consumption is a documented risk factor in its own right, its effects are usually 
manifested in its ability to synergistically enhance the effects of tobacco smoking. The risk of 
cancer development is much higher for those who heavily drink and smoke than would be 
expected by examining the risks for smoking and drinking alone (4). Although tobacco and 
alcohol exposure are responsible for the large majority of SCCHNs in the oral cavity, larynx, 
and hypopharynx, their role in carcinogenesis in the oropharynx is much reduced. 
Oncogenic HPV infection, especially type 16, has been identified as a causal agent in about 
70% of oropharyngeal SCCHN, and in HPV-associated cases, alcohol and tobacco are not 
associated as risk factors (5). 
  5 
 
Much research has investigated the relative order of genetic and epigenetic changes 
that occur during carcinogenesis. An understanding of the type and order of such changes 
may provide insight into the carcinogenetic process ending in SCCHN. Early changes may 
be most common and therefore might be suitable targets for early therapeutic intervention, 
while later alterations may be less common but might serve as prognostic factors and 
therapeutic targets for certain subsets of tumors. Clinical and histologic progression from 
squamous hyperplasia to dysplasia, carcinoma in situ, and eventually invasive carcinoma 
are driven by progressive accretion of chromosomal genetic alterations (Figure 1). The 
transition from normal mucosa to hyperplasia is driven by loss of heterozygosity (LOH) at 
chromosome 9p21, which inactivates p16 (CDKN2A), a cell cycle negative regulator. The 
transition from hyperplasia to dysplasia is accompanied by LOH at 3p21 and 17p13, causing 
p53 mutation and/or up-regulation. Transition from dysplasia to carcinoma in situ is 
facilitated by LOH at 11q13, 13q21, and 14q32, resulting in Cyclin D1 amplification. Cyclin 
D1 functions as a regulatory subunit of CDK4 and CDK6, whose activity is required for cell 
cycle G1/S transition; it has been shown to be positively regulated by interaction with 
retinoblastoma (Rb) protein. The final transformation to frank carcinoma is mediated by 
additional LOH at 6p, 8, 4q27, and 10q23, which inactivates the PTEN tumor suppressor 
gene (5).  
In almost all SCCHNs, the tumor-protein p53 (TP53) and Rb gene pathways are 
disrupted. TP53 regulates the cell cycle and is a tumor suppressor; over 50% of SCCHN 
tumors contain inactivating TP53 mutations or chromosomal loss at 17p where the TP53 
gene resides (5). The most common mutation in the Rb pathway is the p16INK4A tumor 
suppressor gene. Lippman et al. demonstrated a wide range of p53 protein expression in 
90% of SCCHN tumors, compared with no expression in any normal oral cavity epithelium 
(6). Boyle et al. demonstrated that mutation in the TP53 gene occurred in 19% of  
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non-invasive lesions (severe dysplasias and carcinoma 
in situ), increasing to 43% of invasive carcinomas (7). 
Such studies indicate abnormal increases in p53 
expression may occur early in carcinogenesis, but that 
p53 mutations may occur later in the process. TP53 
mutations have been found to occur more frequently in 
smokers than in non-smokers (8), though not uniformly 
so. The pattern of base pair changes in TP53 is 
different between smokers and non-smokers, with 
significantly more mutations occurring in CpG islands in 
the nonsmokers than in smokers (8). 
Although HPV-related SCCHNs also display 
abnormal amounts of p53 and Rb, they most often do 
not contain TP53 or Rb mutations, thus implying the 
presence of alternative (to mutation) oncogenic 
mechanisms. In most of these tumors, p53 and Rb 
proteins are bound and degraded by the viral 
oncoproteins E6 and E7, respectively, rendering 
upstream mutation of the gene unnecessary to the 
oncogenic process. (5) 
Subsequent tumors, in people with primary 
SCCHN tumors that were completely surgically removed, are often fatal and develop not 
only in the head and neck but also in the lungs or esophagus. Ten to forty percent of 
patients experience such a secondary tumor (9-11). This observation led to the 1953 field 
cancerization theory of Slaughter (12) which postulates that large portions of the epithelial 
Figure 1. Genetic progression 
model of SCCHN 
tumorigenesis* 
 
 
Clinical and histologic progression from 
squamous hyperplasia through 
progressively more advanced stages of 
dysplasia, resulting eventually in 
invasive SCCHN, are driven by 
progressive accumulation of genetic and 
epigenetic transformations.  
* adapted from Pai and Westra (5). 
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surface of the respiratory tract are damaged simultaneously (although not identically) by 
carcinogen exposure. According to this theory, multiple lesions are thought to develop 
independently of each other, and therefore would most likely have non-identical mutations. 
Recent research (13) supports the field cancerization theory: nearby secondary SCCHN 
tumors often have genetically identical mutations, while more distant secondary tumors 
almost always have different mutations than the original lesion. The realization that the 
pathologist or surgeon cannot accurately identify all damaged sections of epithelium that 
should be removed is fueling a search for biomarkers that could be used in diagnosis and 
treatment planning.(5) 
1.2.2 Descriptive epidemiology 
1.2.2.1 Incidence and mortality in the United States  
SCCHN is one of the ten most frequently diagnosed cancers in men in the United 
States; three-quarters of incident cases and deaths occur in men. There were estimated to 
be 52,140 new cases of oropharyngeal and laryngeal cancer and 11,460 deaths in the U.S. 
in 2011 (14). SCCHN patients have a relatively poor prognosis compared to those 
diagnosed with other cancers and experience significant morbidity, including disfigurement 
and psychosocial sequelae, related to the cancer and its treatment (15, 16). SCCHN 
incidence increases with age and is more common in all races for men than women by a 
factor of 2 to 3 for oropharyngeal cancers, and by a factor of 5 to 9 for laryngeal cancers 
(Table 2). Incidence rates of oropharyngeal cancer are about the same in African-Americans 
and in whites, while rates of laryngeal cancer are much higher in African-Americans than 
whites. Compared to both African-Americans and whites, the lowest incidence and mortality 
rates of SCCHN in both men and women occur in Hispanics, Asian/Pacific Islanders, and 
Native Americans. Five-year relative survival rate and median survival time for both 
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oropharyngeal and laryngeal cancers are both lower among African-Americans compared to 
whites (5-year survival, African-Americans versus whites: 41% vs. 61% for oropharyngeal 
and 51% vs. 64% for laryngeal cancer) (15). 
1.2.2.2 Time trends in the United States  
In the U.S., between 1984-86 and 1999-01, age-adjusted incidence rates of all first 
primary tumors of the upper aerodigestive tract (UADT) declined from 13.0 (12.7-13.3) to 
10.2 (10.0-10.4). However, there was no significant change in incidence of cancer of the 
oropharynx (including the tonsils, base of the tongue, and surrounding epithelium); in fact 
there was an increased incidence in white men younger than 60. During the same time, 5-
year relative survival rates for UADT increased from 48.1% to 52.4% in the U.S., driven 
largely by a dramatic increase in relative survival for cancers of the oropharynx, from 35.3% 
Table 2. SCCHN incidence and mortality rates by anatomic location, sex and race, 
United States 2002-2006 (15) 
Sex and race 
Incidence rate* Mortality rate** 
Oral cavity 
& pharynx Laryngeal 
SCCHN 
(combined)# 
Oral 
cavity & 
pharynx Laryngeal 
 
 
SCCHN 
(combined)# 
Men – All races 15.4 6.2 21.6 3.9 2.3 6.2 
     White 15.6 6.2 21.8 3.7 2.1 5.8 
     Black 16.7 10.5 27.2 6.5 4.7 11.2 
     Asian/Pacific Islander  10.8 2.7 13.5 3.2 0.7 3.9 
     Native Americans 9.2 2.4 11.6 3.6 1.9 5.5 
     Hispanic 9.0 4.9 13.9 2.5 1.9 4.4 
Women – All races 6.1 1.3 7.4 1.5 0.5 2.0 
     White 6.1 1.3 7.4 1.4 0.5 1.9 
     Black 5.8 2.0 7.8 1.6 0.7 2.3 
     Asian/Pacific Islander  5.4 0.3 5.7 1.3 0.1 1.4 
     Native Americans 5.1 --- 5.1 1.5 --- 1.5 
     Hispanic 3.5 0.6 4.1 0.8 0.2 1.0 
 
*SEER incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, 
Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California). 
Rates are annualized per 100,000 population and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-
1130).   
**US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 
population and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).   
#SCCHN rates are computed by adding separate rates for oral cavity and pharynx cancers, and laryngeal cancers. 
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to 51.0%.(17) Small increases in relative survival were also observed for cancers of the oral 
cavity and hypopharynx, but not for laryngeal cancer. These trends are consistent with the 
hypothesis that that there has been a change in the etiology of oropharyngeal cancer in the 
U.S. especially in younger men, related to a rise in pharyngeal HPV infection and that 
accompanies a change in its response to therapy (17).  
Ninety-six percent of the population in North Carolina self-declares their 
race/ethnicity as Black (African-American) or White (European-American), with other race-
ethnicities (4% total) each comprising less than 2% of the population. The proportion of the 
population in North Carolina that is African-American (21.6%) is much larger than in the U.S. 
as a whole (12.8%), so health disparities that negatively affect African-Americans have a 
proportionately larger effect in North Carolina. For cancers of the tongue, mouth floor, 
gum/other, tonsils, oropharynx, hypopharynx, other oral cavity and pharynx, and larynx, 
incidence rates among African-American men in the U.S. have, since 1973, been much 
higher than rates in white men and all women (see Figure 2), while rates in white women are 
lowest. Rates in African-American men climbed steeply from 1973 to the 1980s, then began 
a sharp decline continuing through the 1990s to the present. This is thought to be related 
mostly to changing rates of smoking. In contrast, white men experienced a small increase 
from 1973 to a peak in 1981, after which rates declined consistently until 2000, and 
remained stable thereafter. Rates in both African-American and white women were much 
lower than in men from 1973-2005; African-American women experienced higher rates than 
white women during the 1980s but since then have experienced a slow decline, and 
currently experience about the same rate as white women.  
 
  
  10 
Figure 2. Time trends of incidence of oropharynx and larynx cancers, U.S., 1973-2005* 
 
* Data from: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: 
Incidence - SEER 9 Regs Limited-Use, Nov 2008 Sub (1973-2006) , National Cancer Institute, DCCPS, Surveillance Research 
Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission. Oropharyngeal cancer is 
defined as cancer of the tongue, mouth floor, gum/other, tonsils, oropharynx, hypopharynx, other oral cavity and pharynx, and 
larynx. Rates are age-adjusted and standardized to the 2000 U.S. population. 
 
1.2.2.3 International incidence rates and trends 
Internationally, in both men and women, incidence rates are higher in more 
developed than in less developed regions. For example, the age standardized rates (world) 
in men living in more developed regions are 7.9 per 100,000 for oral cavity cancer and 6.9 
for laryngeal cancer, compared to 5.7 and 4.3, respectively, in less developed regions. In 
women, rates are much lower than in men (e.g. 7.9 for men in more developed countries 
versus 2.4 for women in the same countries) and there are no consistent differences 
between women living in more and less developed countries. In men, mortality rates are 
also higher in more developed regions, but in women the reverse is true (18).  
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Between 1975 and 1995, laryngeal cancer incidence rates declined in both men and 
women in almost all countries with the exception of Japan. Although incidence rates for 
pharyngeal, oral cavity, and lip cancers have generally declined in both men and women 
over the same time period, there have been plateaus or increases in oropharyngeal cancer 
in the region of the base of the tongue and the tonsils in younger men (age 20-44 years) in 
the U.S. (19) and many parts of Europe (20). The tongue and tonsils have been shown to be 
the predominant region of oropharyngeal HPV infection that progresses to cancer (21).  
1.3 RISK FACTORS      
1.3.1  Heredity 
Epidemiologic studies of familial clustering of SCCHN cases provide suggestive 
evidence for genetic predisposition. Such evidence implies shared genes, shared exposure, 
or both. In a Brazilian case-control study of 754 cases of SCCHN and 1,507 age- and 
gender-matched hospital-based controls with non-malignant diseases (22), investigators 
found that the relative risk (RR) for developing SCCHN was doubled in cases who had a 
first-degree relative with any cancer, 3.65 (95%CI=1.97-6.76) if the first-degree relative had 
head and neck cancer, and 8.57 (95% CI=2.72-27.04) if the first-degree relative with head 
and neck cancer was a sibling. The same authors reported a similar increased risk for 
developing SCCHN (OR=3.79; 95% CI=1.11-13.0) in a Canadian population if first-degree 
relatives also had SCCHN (23). A comparable study in Puerto Rico on 342 cases with oral 
cavity or pharyngeal cancer and 521 controls found an increased OR of 2.6 (95% CI=1.4-
4.8) in cases with first-degree relatives with any upper aerodigestive tract (UADT) tumor 
(24). Ankathil et al. (25) created a detailed pedigree analysis for each of their Indian oral 
cancer patients, based on a questionnaire eliciting information about family history of cancer 
and especially SCCHN. They observed, as with other familial cancers, that a family history 
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of SCCHN was associated with an early age of onset. In addition, family members who did 
not use tobacco products or smoke were also affected. Such familial aggregation was 
observed in 1% of their oral cancer cases. The authors therefore postulate the existence of 
an oral cancer susceptibility gene. Morita et al. (26) compared family cancer history in 167 
patients with hypopharyngeal or cervical esophageal cancers versus 167 controls with 
benign diseases. The odds ratio for cases with family history of UADT tumors in relation to 
controls was 2.6 (95% CI=1.1-6.3), and these cases were significantly younger than cases 
whose relatives had another type of cancer or no cancer. In contrast, a study by Goldstein et 
al. (27) found only non-significant excess risk among those with a family history of 
oropharyngeal tumors (OR=1.2, 95% CI=0.7-2.3) or esophageal/laryngeal cancers (OR=1.6, 
95% CI=0.7-3.8). They found that excess familial risk of oropharyngeal cancers was 
associated with smoking-related cancers among male but not female relatives, and 
conclude that it is likely that environmental factors such as smoking and drinking contribute 
to the familial tendencies they observed; they were unable to discriminate genetic from 
environmental factors in their study. A recent pooled analysis of 8,967 head and neck 
cancer (HNC) cases and 13,627 controls from 12 case-control studies found that a family 
history of HNC in first degree relatives increased the risk of HNC (OR=1.7; 95% CI: 1.2-2.3) 
(28). The risk was higher when the affected relative was a sibling (OR=2.2, 95% CI: 1.6-3.1) 
rather than a parent (OR=1.5, 95% CI=1.1-1.8). The OR was also higher in subjects 
exposed to tobacco, and rose to 7.2 (95% CI=5.5-9.5) in subjects with family history who 
also used alcohol and tobacco. Interestingly, the study found a small but significant 
association (OR=1.1, 95% CI=1.0-1.2) with family history of other tobacco-related cancers, 
particularly with laryngeal cancer (OR=1.3; 95% CI=1.1-1.5). No association was found 
between family history of non-tobacco-related tumors and risk of HNC.  
The Swedish Family-Cancer Database was used to investigate familial clustering of 
cancers at HPV-associated sites, including cervical, anogenital, UADT and skin (29). 
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Investigators calculated standard incidence ratios (SIR) for offspring site-specific cancer 
risks according to site-specific cancers in sibling and parental probands. Risk of UADT 
cancers in offspring were increased by having a parent or sibling with certain cancers; for 
women, risk was increased by having a sister with cervical SCC (SIR=1.37; 95% CI=1.03-
1.79), a mother with skin SCC (SIR=1.50; 95% CI=1.00-2.18), or a father with UADT SCC 
(SIR=1.92; 95% CI=1.09-3.12); for men, risk was increased by having a sibling or father with 
UADT SCC (SIRs=2.36, 1.66) or a mother with vulvar SCC (SIR=2.47; 95% CI=1.41-4.02).  
1.3.2  Primary environmental exposures 
1.3.2.1 Tobacco  
Two International Agency for Research on Cancer (IARC) Working Groups stated 
that there was sufficient evidence to conclude that tobacco is carcinogenic to humans and 
that the occurrence of malignant tumors of the respiratory and upper digestive tract is 
causally related to the smoking of different forms of tobacco (cigarettes, cigars, pipes, bidis, 
etc.) (30, 31). It is estimated that tobacco smoking confers an increased risk of 4 to 5 times 
for oral cavity, oropharyngeal, and hypopharyngeal cancers, and 10 times for laryngeal 
cancers (32).  
Tobacco smoke. An increased risk of head and neck cancer in tobacco smokers was 
reported in the first IARC tobacco monograph in 1986 (30), and reiterated in the updated 
report issued in 2004 (31). The 2004 monograph reported that from 1987 to 2002 numerous 
studies measured the association between tobacco smoking and head and neck cancers in 
various regions of the world including North and South America, Europe, and Asia: three 
cohort and 16 case-control studies on oral cavity cancer; three cohort and 12 case-control 
studies on oropharyngeal, hypopharyngeal, or pharyngeal cancers in general; and five 
cohort and 26 case-control studies on laryngeal cancer. Most studies reported dose-
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response relationships between cancer risk and frequency (e.g. cigarettes per day), duration 
(years), and lifetime consumption (e.g. pack-years).  
In an attempt to distinguish the often-correlated effects of lifetime consumption and 
exposure rate, Lubin et al. (33) used pooled data from 15 case-control studies to compare 
excess odds ratios (EOR) for lifetime tobacco (smoking) consumption accumulated at high 
frequency but short duration, with the same lifetime consumption accumulated at lower 
frequency and longer duration. Above 15 cigarettes per day, the EOR per pack-year 
decreased, suggesting that more cigarettes per day for shorter duration was less hazardous 
than fewer cigarettes per day for longer duration. Estimates of EOR per pack-year were 
similar for oral cavity, pharyngeal and laryngeal cancers, but the effects of cigarettes per day 
differed and were higher for laryngeal cancers, indicating that increased risk of laryngeal 
cancer is more affected by cigarettes per day effects rather than pack-years.  
While all types of tobacco smoking increase SCCHN risk, smokers of black tobacco 
experience a higher cancer risk than smokers of blond tobacco, and hand-rolled cigarettes 
confer a higher risk than manufactured cigarettes (31). Other types of smoked tobacco, 
including cigars and pipes, also confer increased risk of head and neck cancer, but it hasn’t 
been possible to precisely quantify differences in risk between types of smoked tobacco 
because of the small number of people who smoke only cigars or pipes. The few studies to 
examine this question among exclusive users of cigars or pipes did not observe differences 
in their risk compared to the risk among cigarette smokers (31). Another type of commonly 
smoked tobacco product in Southeast Asia is bidi. A meta-analysis of 12 case-control 
studies reported approximately triple the risk of head and neck cancer among bidi users 
compared to never smokers (34). A multi-center case-control study from India reported that 
bidi smoking was a stronger risk factor than cigarette smoking for cancers of the 
hypopharynx (OR 6.80 versus OR 3.82) and supraglottis (OR 7.53 versus OR 2.14) but 
about the same for cancer of the glottis (35).  
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The primary hypothesis explaining the risk difference between smokers of black and 
blond tobacco is that smokers of black tobacco are exposed to more N-nitrosamines and 
aromatic amines. These compounds require metabolic activation by N-acetylation and O-
acetylation to form acetoxy intermediates which can form DNA adducts. Genes coding for N-
acetyltransferase enzymes (NAT1 and NAT2), which are active in both N- and O-acetylation, 
are highly polymorphic, with different variants having strikingly different rates of enzyme 
activity. Fast acetylators are hypothesized to incur higher SCCHN risk. Although NAT1 and 
NAT2 polymorphisms have been definitely implicated as increasing risk for bladder cancers, 
studies examining their role in head and neck cancer have not consistently shown increased 
risk for SCCHN (36). 
Age at which smoking began appears to be associated with risk of head and neck 
cancer, if frequency and duration aren’t taken into account (37-40). This association may 
appear because smoking of longer duration is probably associated with age at start of 
smoking. However, studies that investigated age at start and cancer risk, and adjusted 
estimates for tobacco smoking habits, have shown inconsistent results. For example, a 
Cuban study that adjusted for tobacco smoking habits reported higher risk among those who 
began smoking when <17 years of age compared to those who began smoking when older 
(41), while studies in France (42) and India (43) reported no difference in cancer risk based 
upon age at start.  
Cessation of tobacco smoking has been consistently shown to reduce the risk of 
many types of head and neck cancer, such that former smokers have consistently lower 
relative risks compared to current smokers. The 2004 IARC monograph summarized one 
cohort study and eight case-control studies of oral cancer that reported lower risk for former 
compared to current smokers (31). Seven of the case-control studies reported a negative 
trend for risk of oral cancer with time since quitting, and a rapid decline in relative risks 
compared to nonsmokers after 10 or more years. A similar reduction in risk of pharyngeal 
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cancer was reported by one cohort study and two case-control studies. A pooled analysis by 
the International Head and Neck Cancer Epidemiology (INHANCE) Consortium showed that 
cancer risk 1-4 years after quitting was reduced to 70% of that experienced by current 
smokers (OR=0.70; 95% CI: 0.61-0.81) with complete risk reduction down to that of 
nonsmokers after 20 or more years of not smoking (OR=0.23; 95% CI: 0.18-0.31) (44). 
Environmental tobacco smoke. In a 2008 pooled analysis of 542 cases and 2,197 
controls who reported never using tobacco, no effect of environmental tobacco smoke (ETS) 
was found for those ever-exposed (45). However, risk increased significantly for those who 
reported more than 15 years of exposure at home (OR=1.60; 95% CI=1.12-2.28) or at work 
(OR=1.55; 95% CI=1.04-2.30). The effect of duration of ETS exposure at home was 
stronger for pharyngeal and laryngeal cancers compared to other sites. Increased risk of 
similar magnitude also occurred in those who reported using neither tobacco nor alcohol but 
were exposed to ETS for more than 15 years. A larger 2009 study of 2103 UADT cases and 
2221 controls (46) reported increased risk for ever-exposure only at home (OR=1.49; 95% 
CI=0.90-2.48), only at work (OR=1.79; 95% CI=1.03-3.13, and both home and work 
(OR=1.68; 95% CI=1.00-2.83). 
Smokeless tobacco. Smokeless tobacco products are ingested without burning. Oral 
products are placed in the mouth, cheek or lip and are sucked (“dipped”) or chewed. In the 
United States, most oral tobacco products can be classified as loose leaf (air cured and 
sweetened), plug (heavier tobacco leaves, sweetened and compressed), twist (air- or fire-
cured leaves, flavored and twisted), and snuff (finely cut or powdered tobacco; moist snuff 
contains water, while dry does not). In 2000, 4.4% of US men and 0.3% of women used 
snuff or chewing tobacco (47). Worldwide a variety of products are used; for example 
tobacco pastes or powders which are applied to gums or teeth, and products which contain 
tobacco as one ingredient (e.g. snus; some betel quid products). Use varies widely between 
countries and within countries based on age, sex, ethnicity, and socioeconomic status. 
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Epidemiologic data from the United States and Asia report an increased risk of oral 
cancer (RR=2.6; 95% CI=1.3-5.2), while northern European studies reported no increased 
risk (RR=1.0; 95% CI=0.7-1.3) (48). In India, more than half of oral cancers are estimated to 
be attributable to smokeless tobacco products, while in the United States 6.6% of oral 
cancers in men are estimated to be attributable to such products (48). SCCHN risk of 
smokeless tobacco users lies between the rates of non-tobacco users and smokers. 
Population attributable risk. The INHANCE Consortium analyzed individual-level 
pooled data from 17 European and American case-control studies (11,221 cases and 
16,168 controls). They estimated that the population attributable risk for tobacco alone was 
33% (49).  
1.3.2.2 Alcohol 
The International Agency for Research on Cancer (IARC) concluded in 1988 that there 
was sufficient evidence of the carcinogenicity of alcohol for cancers of the oral cavity, 
pharynx, and larynx, as well as esophagus and liver (50). Evidence from many studies of 
various design and in different international populations has consistently demonstrated that 
daily consumption of about 50 grams of ethanol increases the risk for oral cavity and 
pharyngeal cancer three-fold, and the risk for laryngeal cancer two-fold. For these cancers, 
the effects of drinking and smoking are multiplicative (51). 
Independent effect. Due to the small number of alcohol-drinking non-smokers in 
most populations, estimates from smaller studies of the independent effect of alcohol on risk 
of head and neck cancer have been difficult to measure precisely. Therefore, in order to 
estimate the effect of alcohol drinking apart from smoking, the risk of developing head and 
neck cancer in alcohol drinkers who had never smoked was investigated by the INHANCE 
Consortium (52). This study pooled individual-level data from 15 case-control studies that 
included 10,244 head and neck cancer cases and 15,227 controls; of these, 1,072 cases 
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and 5,775 controls were never-users of tobacco. Their results (Table 3) suggest that the 
association between alcohol consumption and the risk of head and neck cancer is weak for 
low frequency drinking (<3 alcoholic drinks per day) and is apparent only at higher frequency 
and only for pharyngeal and laryngeal cancers. The dose-response trend for frequency of 
alcohol drinking was strongest for cancers of the pharynx and larynx and weakest for oral 
cancers. The results of two smaller studies (that were not included in their analysis) also 
suggested an increased head and neck cancer risk at high frequency of alcohol intake in 
never smokers (53, 54).   
Dose-response. The 2008 IARC monograph on alcohol (55) reported that between 
1988 (the publication date of the previous IARC monograph on alcohol) and 2007, 58 
epidemiologic studies of head and neck cancer were published in the literature: 5 cohort 
studies on oral cavity and pharyngeal cancers, and 53 case-control studies (8 on oral cavity 
cancer, 9 on pharyngeal cancer, 18 on oral cavity and pharyngeal cancers combined, and 
18 on laryngeal cancer). The study populations included Europeans, North and Latin 
Americans, and Asians. Most adjusted for tobacco smoking and consistently reported a 
strong dose-response relationship between frequency of drinking (i.e. drinks per day or per 
week) and risk of head and neck cancer. Hashibe et al. (52), using data from the INHANCE 
Consortium on never-smokers, found no dose-response relationship between duration of 
alcohol drinking and risk of oral cavity, pharyngeal, and laryngeal cancers (52). Lubin et al. 
(33) examined total alcohol exposure (drink-years) and exposure rate (drinks per day) and 
the risk of head and neck cancer in the INHANCE pooled data. Their analyses suggest that 
for participants who drank fewer than 10 drinks per day, at fixed total alcohol exposures, 
exposure to higher frequency of drinking (drinks per day) brought higher risk of head and 
neck cancer than exposure to lower frequency of drinking over longer duration. There were 
few participants who reported drinking more than 10 drinks per day, so no conclusions could 
be drawn about such exposure frequencies. The association of alcohol drinking with greater 
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risk of oral cavity and pharyngeal cancers than of laryngeal cancer was confirmed in their 
study, and results suggested that these risk differences by site were more attributable to 
cumulative alcohol consumption (drink-years) rather than frequency (drinks per day).  
Age at start of alcohol drinking. Only a few studies have reported on the association 
between age at start of drinking alcoholic drinks and risk of head and neck cancers. Two 
early studies which didn’t control for smoking or drinking habits reported that starting age 
wasn’t associated with head and neck cancer risk (40, 56). One study which adjusted for 
tobacco smoking also showed no effect of age when drinking began on head and neck 
cancer risk (57). Two studies that adjusted for both tobacco and alcohol habits reported the 
same lack of effect (41, 43).  
Cessation of alcohol drinking. There are few published studies on the risk of head 
and neck cancer associated with discontinuance of alcohol drinking. Such studies may be 
confounded by indication because pre-cancerous and early lesions of the oral cavity and 
pharynx could themselves cause alcohol cessation. To summarize four studies from 1988 to 
2004, for recent quitters, risk for oral and pharyngeal cancers rises above current drinkers; 
as the number of years increases, the risk slowly drops below the risk of current drinkers 
and approaches the levels of non-drinkers after 10-20 years (55). In the INHANCE pooled 
analysis, a beneficial effect on the risk of head and neck cancer compared with current 
drinkers was only observed after 20 or more years of quitting alcohol (OR=0.60, CI=0.40–
0.89), when the risk was reduced to the level of never drinkers (44). This is in contrast to the 
benefit for quitting smoking, which is observed as early as 1 to 4 years after quitting.  
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Table 3. Alcohol drinking frequency and risk of head and neck cancer, overall and by 
anatomic sub-site, among never-users of tobacco* 
Drinking 
variable 
All sites‡ Oral cavity€ Oropharynx and 
hypopharynx‡ 
Oral cavity and 
pharynx€ 
Larynx€ 
 # cases / 
# controls 
OR  
(95% CI) 
# cases / 
# controls 
OR  
(95% CI) 
# cases / 
# controls 
OR  
(95% CI) 
# cases / 
# controls 
OR  
(95% CI) 
# cases / 
# controls 
OR  
(95% CI) 
Frequency, drinks/day 
 Never 541/2482 1.00 (ref) 243/2482 1.00 (ref) 153/2482 1.00 (ref) 80/1982 1.00 (ref) 40/1788 1.00 (ref) 
 <1 164/899 1.04  
(0.79-1.38) 
44/899 1.14  
(0.8-1.63) 
73/899 1.39  
(0.99-1.96) 
25/834 1.08  
(0.67-1.75) 
15/724 0.92  
(0.5-1.69) 
 1-2 202/1324 1.30  
(0.94-1.80) 
60/1324 1.64  
(1.19-2.25) 
83/1324 1.66  
(1.18-2.34) 
26/1171 1.24  
(0.77-1.99) 
28/1155 1.26  
(0.77-2.07) 
 3-4 59/536 1.82  
(1.10-2.99) 
10.536 1.11  
(0.57-2.15) 
24/536 2.33  
(1.37-3.98) 
13/495 2.32  
(1.24-4.34) 
11/480 1.24  
(0.62-2.45) 
 ≥5 65/389 2.81  
(1.49-5.27) 
8/389 1.23  
(0.59-2.57) 
29/389 5.50  
(2.26-13.36) 
4/382 0.77  
(0.27-2.18) 
22/349 2.98  
(1.72-5.17) 
 Ptrend  0.001  0.032  <0.001  0.891  <0.001 
 Phet†  <0.001  0.913  <0.001  0.202  0.006 
*reported by Hashibe et al. (2007) (52) 
†Two-sided test for heterogeneity between studies 
‡Random-effects model. Study-specific ORs adjusted for age, sex, race/ethnicity, and education level.  
€ Fixed-effects model, adjusted for age, sex, race/ethnicity, education level, and study center. 
 
Types of alcohol beverages. Nine studies conducted between 1988 and 2007 
examined differences in risk by type of alcoholic beverage, including wine, beer, and liquor 
(55). Highest risks were observed for beer in North America, wine in Europe, and hard 
liquors in Latin America. The consensus is that the most common alcoholic beverage in the 
region studied produced the greatest risk. Because most drinkers consume more than one 
type of beverage, it is difficult to separate their effects; to overcome this, a recent INHANCE 
Consortium analysis studied risk in each beverage type among individuals who drank only 
one type (58). Risk of head and neck cancer was doubled over that of non-drinkers for those 
who drank 16-30 beer or liquor beverages per week, while risk for drinkers of 16-30 glasses 
of wine per week was not significantly increased. However, above 30 drinks per week, all 
alcoholic beverages were associated with increased risk: odds ratios were about 4 for liquor, 
5 for beer, and 6 for wine. Confidence intervals overlapped, suggesting no significant 
differences. Risk estimates by geographic region (North America, Latin America, Europe) for 
those drinking more than 15 drinks per week suggested somewhat higher risk for beer in 
North America and Europe, higher risk for liquor in North and Latin America, and higher risk 
for wine in Europe. Odds ratios were stronger for oral and pharyngeal cancer than for 
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laryngeal cancer and among smokers compared with never smokers. The pattern of 
associations across beverage types did not change with anatomic site or smoking status 
(58). 
Alcohol and tobacco interaction. Between 1988 and 2007, two prospective cohort 
and 15 case-control studies in the United States, Europe, Asia, and Australia described and 
estimated the joint effects of alcohol drinking and tobacco smoking on risk of oropharyngeal 
cancer. The studies differed in their method of assessing effect measure modification, 
ranging from descriptive to estimation of interaction coefficients in multivariate regression 
models (55). All of the studies found that alcohol ingestion and tobacco smoking have a 
synergistic effect on risk of oropharyngeal cancer. The large majority of studies (n=14) 
demonstrated greater than multiplicative interaction, while a few (n=3) found greater than 
additive but less than multiplicative interaction (55). The largest of the case control studies 
(1560 cases and 2948 hospital controls) had the most precise estimates; the OR for the 
highest frequency of smoking in non-drinking or occasional-drinking men was 2.0 (95% 
CI=1.1-3.6), OR for highest frequency of drinking in men who never smoked was 2.9 (95% 
CI: 1.1-8.1), and OR for the highest frequencies of both smoking and drinking in men was 
20.1 (95% CI: 12.9-31.5), much higher than multiplicative (59). Results in women were 
similar. The second-largest study (1,114 cases and 1,268 population controls) categorized 
alcohol intake by frequency and cigarette smoking by frequency only in those who had 
smoked for 20 or more years; the OR for the highest alcohol intake in non-smokers was 5.8, 
OR for the highest smoking frequency was 7.4, and OR for the highest frequencies of both 
smoking and drinking in men was 37.7, or approximately multiplicative (56). One study in 
India of 591 cases of oral cancer and 582 controls reported no interaction between tobacco 
(in paan) chewing (as opposed to smoking) in never/current users of alcohol: OR for oral 
cavity cancer for current drinkers who didn’t chew paan was 2.83 (95% CI: 1.58-5.09), OR 
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for current paan chewers who never drank was 7.31 (95% CI: 3.79-14.10); and OR for 
current drinkers and paan users was 8.62 (95% CI: 4.12-18.06) (43).  
For laryngeal cancer, 16 studies published from 1982 through 2002 computed risk 
estimates for the highest level of consumption of both tobacco smoking and alcoholic 
beverage drinking, and concluded that a multiplicative risk model best fit the data (55). For 
example, Talamini et al. reported in 2002 that the OR for non-smokers in the highest 
drinking category was 8.5 (95% CI: 2.4-30.2), the OR for non-drinkers in the highest 
smoking category was 18.9 (95% CI: 5.7-62.7), and the OR for the highest frequencies of 
both smoking and drinking was 177.2 (95% CI: 65.0-483.3), or approximately multiplicative 
(4).  
In order to estimate the extent of interaction between alcohol and tobacco exposures 
and the risk of head and neck cancer, as well as population attributable risk (PAR), the 
INHANCE Consortium analyzed individual-level pooled data from 17 European and 
American case-control studies (11,221 cases and 16,168 controls). They reported a greater 
than multiplicative joint effect between ever-use of both tobacco and alcohol: for oral, 
pharyngeal, and laryngeal cancers combined, the OR for the highest rate of tobacco use 
(>20 cigarettes/day) in alcohol abstainers was 4.2 (95% CI: 2.4-7.1), the OR for the highest 
rate of alcohol use (≥3 drinks/day) in never-smokers was 1.9 (95% CI: 1.3-2.9), and the OR 
for the highest category of use for both alcohol and tobacco was 14.2 (95% CI: 8.3-24.4) 
(49).  
Population attributable risk. The INHANCE Consortium study estimated that the 
population attributable risk for tobacco or alcohol at 72% (95% CI: 61-79%), of which 4% 
was due to alcohol alone, 33% to tobacco alone, and 35% to use of both alcohol and 
tobacco. Interestingly, the total population attributable risk differed by anatomic subsite of 
the cancer (64% for oral cavity, 72% for pharynx, 89% for larynx), by sex (74% for men, 57% 
for women), by age (33% for cases <45 years, 73% for cases >60 years), and by 
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geographic region (84% in Europe, 51% in North America, 83% in Latin America) (49). The 
researchers noted that a substantial fraction of head and neck cancers in certain sub-groups 
cannot be attributed to tobacco and alcohol use; in particular, their use does not explain 
one-third of oral cavity cancers, more than 40% of head and neck cancers in women, and 
two-thirds of young-onset cases.  
Mechanisms of carcinogenesis.  
Long-term alcohol intake is positively associated with cancer of the aerodigestive 
tract as well as cancers of the liver and breast. Numerous epidemiologic studies show that 
ingestion of all types of alcoholic beverages increases cancer risk, suggesting that ethanol is 
the common factor that causes this effect. The association with cancer strongly suggests 
that prolonged alcohol consumption somehow results in DNA mutations. Because there is 
no evidence that alcohol in and of itself is carcinogenic (55), mutagenic, or clastogenic (50), 
the mechanism must be indirect. Much persuasive research indicates that the primary 
means by which alcohol increases risk of head and neck cancer, as well as esophageal 
cancer, is related to the amount of acetaldehyde produced in the metabolism of alcohol (60-
62). Other byproducts of alcohol metabolism, including reactive oxygen species (ROS), are 
believed to act as additional components. In other organs where alcohol causes cancer, 
such as liver, colon, rectum, and breast, other mechanisms may become more important, 
such as changes in methionine and folate metabolism, repression of DNA methylation and 
DNA repair, changes in retinoid metabolism, suppressed immune function and induction of 
angiogenesis (61, 63-66).  
There are three paths by which ethanol is metabolized to acetaldehyde (Figure 3): 
(1) alcohol dehydrogenase (ADH), (2) cytochrome P450 2E1 (CYP2E1), and (3) catalase 
(CAT); afterward, acetaldehyde is converted to acetate by aldehyde dehydrogenase 
(ALDH). In addition to producing acetaldehyde, ADH-mediated ethanol catabolism 
generates reduced nicotinamide adenine dinucleotide (NADH), which is re-oxidized to NAD+ 
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in the mitochondria and in the process produces reactive oxygen species (ROS). ADHs are 
ubiquitous in bacteria and yeasts, so that these UADT organisms are also a significant 
source of acetaldehyde (50, 61) in the saliva in addition to that produced endogenously in 
humans. In fact, such organisms can be significant sources of local oxidation of ethanol and 
production of acetaldehyde in the lower gastrointestinal tract or wherever microbial 
overgrowth occurs (55). Several human isoforms of ADH and ALDH are genetically 
polymorphic, which can cause the rate of production and/or oxidation of acetaldehyde to 
differ between individuals. Likewise, CYP2E1-mediated ethanol catabolism generates a 
large volume of reactive oxygen species (ROS). CYP2E1 is also polymorphic with SNPs that 
affect enzyme activity, and most importantly, chronic ethanol exposure can induce it to 
produce functional enzyme product even in tissues where it is not constitutively expressed, 
such as UADT mucosal cells (67). Increased CYP2E1 activity leads not only to increased 
generation of damaging ROS, which can cause DNA breaks and oxidative base damage, 
but also to activation of other environmental pro-carcinogens present in tobacco smoke and 
certain foods that require CYP2E1 to be converted into carcinogens. Ethanol oxidation by 
CAT appears to be of quantitatively lesser importance, except in the fasted state, in 
diabetics, and persons eating a high-fat diet (68), although it has recently been shown to be 
inducible in the presence of alcohol when methyl donor supplements are added to the diet 
(69). 
Acetaldehyde. The first metabolite of ethanol is acetaldehyde, a highly reactive 
compound that can react with amino groups of proteins resulting in acetaldehyde-protein 
adducts. Acetaldehyde from alcohol beverages, along with ethanol in such beverages, has 
been classified by IARC as a Group 1 carcinogen (70). Acetaldehyde can be present in the 
alcoholic beverage itself (especially in dark liquors) besides being formed in vivo from 
ethanol metabolism (71). Acetaldehyde has been shown to cause laryngeal cancer in 
inhalation experiments and other UADT tumors in ingestion experiments with animals. 
  25 
Based on epidemiological findings as well as on research with cell lines in vitro, 
experimental animals (55, 72), and human subjects, acetaldehyde is considered a mutagen 
(73) that can directly react with DNA to form adducts.  
 
Figure 3. Schematic of ethanol metabolism and its role in carcinogenesis  
 
Ethanol is converted to acetaldehyde by alcohol dehydrogenases (ADH),cytochrome P450 2E1 (CYP2E1), and 
catalase (CAT). Acetaldehyde is converted to acetate by aldehyde dehydrogenases (ALDH). Reactive oxygen 
species (ROS) produced during these reactions can genetically damage cells by forming DNA adducts. See text 
for detailed discussion.  
(modified from Seitz & Stickel, 2007 (60)) 
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One highly mutagenic adduct of acetaldehyde that has been studied is 1,N2-
propano-2’-deoxyguanosine (PdG). PdG adducts can exist in either a closed-ring or an open 
chain form, which may continuously interconvert during replication and transcription. The 
closed-ring form is more likely to exist in conjunction with single-stranded DNA where it is 
likely to be mutagenic because it interferes with replication and transcription. The open 
chain form is more likely to occur in a double-stranded DNA lesion, where the free aldehyde 
group permits formation of DNA-protein or DNA-DNA cross-links. Because acetaldehyde 
has been shown to increase chromosomal abnormalities and sister chromatid exchanges in 
human cells in vitro, and is also capable of forming DNA interstrand cross-links (ICLs) that 
are found in white blood cells of alcoholics but not controls, it has been suggested that ICLs 
may be the mechanism by which acetaldehyde causes chromosomal aberrations (73). 
Much data on acetaldehyde-DNA reactions comes from in vitro studies that have 
provided support for the hypothesis that alcohol-related UADT cancer risk is mediated by 
acetaldehyde. How this is related to what actually happens in vivo has been investigated in 
a number of studies. Acetaldehyde-fed rats developed severe hyper-regeneration of the 
upper gastrointestinal mucosa (62), very similar to structural changes that occur after 
chronic alcohol consumption in humans (74). However, these changes only occurred if the 
animals had intact salivary glands; after removal of the salivary glands the proliferation 
disappeared (74), thus supporting the theory that salivary acetaldehyde supports 
carcinogenesis. Besides being produced by ADH in epithelial cells, and by ADH in the liver 
where it is released into the bloodstream, acetaldehyde is also produced by oral bacteria. 
After ingestion of a moderate dose of alcohol, acetaldehyde can be detected in the saliva of 
healthy volunteers, where the levels are ten to twenty times higher than those in systemic 
blood, even at higher alcohol intake (61). Interestingly, salivary levels of acetaldehyde can 
be greatly reduced by using an antiseptic mouthwash before alcohol intake, thus 
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emphasizing the important role of oral bacteria in acetaldehyde production (61). It has been 
demonstrated that alcoholics with oropharyngeal cancer who also smoke have very high 
salivary acetaldehyde concentrations, which may be caused by a smoking-associated 
transition in bacterial flora from primarily gram-negative to gram-positive species (67). As a 
general rule, gram positive bacteria are capable of much higher acetaldehyde production 
than gram negative bacteria. In addition, Candida albicans, also frequently present in 
smokers, converts alcohol into acetaldehyde. Poor oral hygiene, which is common in heavy 
drinkers, is associated with bacterial overgrowth, periodontal disease, caries, and increased 
salivary acetaldehyde concentrations (75). Acetaldehyde in saliva would have to enter cells 
in the basal (regenerative) layer of the epithelium of the aerodigestive tract in order to initiate 
carcinogenesis. Research in rats that were fed alcohol over 6 months found enlarged nuclei 
in basal cells in the oral mucosa along with an increased proportion of cells in the S-phase 
and a reduction of the epithelial thickness indicating mucosal atrophy and hyperproliferation, 
as compared to controls (76). Finally, acetaldehyde would have to enter cell nuclei in order 
to damage nuclear DNA; a 1995 study (77) used a very sensitive 32P-postlabeling method to 
show that N2-ethyl-deoxyguanosine (a DNA adduct formed from acetaldehyde) becomes 
detectable in nuclear DNA of liver cells in mice treated for 6 weeks with 10% alcohol in their 
drinking water. The adduct was not detected in control mice that were not given alcohol. 
This demonstrates that acetaldehyde can enter cell nuclei in vivo to cause DNA lesions.  
Reactive oxygen species (ROS). Free radicals are atoms, molecules, or 
compounds that are chemically unstable due to their distribution of electrons; such entities 
react easily with other chemicals to produce stable compounds. A ROS is any free radical 
with at least one oxygen atom in its structure, mainly including superoxide anion radical  
(O2.-), hydroxyl radical (.OH), and peroxide (O2=). Peroxide normally exists in the cell as 
hydrogen peroxide (H2O2) and is considered a precursor of .OH. Superoxide, peroxide, and 
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the hydroxyl radical are considered the primary ROS. Reactions of molecular oxygen that 
produce ROS along the pathway to water can be summarized as follows (78): 
 
          e.                    e.                 2H+                 e., H+                            e., H+ 
 O2 -----> O2-. -----> O2= -----> H2O2 -----> H2O + .OH -----> H2O 
 
molecular oxygen → superoxide → peroxide → hydrogen peroxide → water + hydroxyl radical → water 
 
 (with enzymes, cofactors, and electrons and protons required along the pathway) 
 
ROS are produced from endogenous sources as by-products of usual and essential 
metabolic reactions, primarily mitochondrial energy production and detoxification reactions 
of the cytochrome P-450 enzyme system (which includes CYP2E1 and others). It has been 
estimated that only about 2-3% of the molecular oxygen consumed by the mitochondrial 
respiratory process is converted to ROS (78). At low to moderate concentrations ROS play 
an essential role, along with reactive nitrogen species, in cellular defense against infectious 
agents, functioning of many cell signaling pathways, and induction of cell division (79). In the 
amounts normally produced endogenously, several classes of cellular enzymes (described 
below) are able to chemically reduce most of the ROS to a stable, non-reactive form before 
they cause oxidative damage (80). 
In addition to endogenous sources, ROS can also come from exogenous sources 
such as cigarette smoke, excess alcohol consumption, and ionizing radiation. When ROS 
levels increase dramatically during occasions of environmental stress, the resulting oxidative 
stress can overwhelm the cellular defenses that would normally remove the ROS or repair 
ROS damage, resulting in significant damage to DNA and other cell structures. ROS can (1) 
cause permanent structural changes to DNA such as base-pair mutations, deletions, 
insertions, rearrangements, and amplification; (2) initiate lipid peroxidation; (3) activate 
cytoplasmic and nuclear signal transduction pathways; and (4) modulate activity of stress 
proteins and genes that regulate genes related to growth, differentiation, and cell death (80). 
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When human tissues are subjected to high concentrations of alcohol for a week or more, 
CYP2E1 is induced (via protein stabilization rather than transcription or translation (81)) and 
becomes active in processing ethanol to acetaldehyde. These CYP2E1-catalyzed reactions 
produce large amounts of ROS. Many studies of the effects of administering ethanol to 
CYP2E1-knockout mice (i.e., mice without CYP2E1 protein) have shown that ethanol-
induced oxidative stress and subsequent liver damage is completely prevented in these 
mice. CYP2E1 also activates many other toxicologically important chemicals besides 
ethanol, including carbon tetrachloride, acetaminophen, benzene and many halogenated 
substrates. Toxicity of all these compounds is enhanced after induction of CYP2E1 and 
reduced by inhibitors of CYP2E1. CYP2E1 is normally a minor pathway of ethanol oxidation, 
responsible for less than 10% of ethanol conversion to acetaldehyde in the liver. However, 
this percentage is increased after chronic ethanol exposure induces CYP2E1 protein 
stabilization (81). 
Cells normally protect themselves from ROS damage by three systems: those that 
suppress the generation of ROS in the first place; those that scavenge and remove ROS 
after they have been created but before they have damaged the cell; and those that repair 
damage caused by ROS. The systems that remove ROS after they have been created 
include the enzymes superoxide dismutase (SOD), glutathione peroxidase (GPx), and 
catalase (CAT) (78, 82, 83), which remove superoxide and hydrogen peroxide. (See below 
for detailed descriptions of these enzymes.) Levels of ROS in blood lymphocytes of oral and 
laryngeal cancer patients, as well as SOD and catalase activities, have been shown in small 
studies to be altered compared to healthy controls. In addition, SOD and catalase levels in 
cancerous oral and laryngeal tissues were shown to be altered compared to nearby non-
cancerous tissues as well as tissues from control subjects. Some effects appeared to 
increase along with stage. Direction of effect was inconsistent between studies, which may 
have been partly due to the low number of subjects as well as differences in measurement 
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protocols. (84-90) However, these studies do provide tantalizing evidence that anti-oxidant 
activities are altered during carcinogenesis in the aerodigestive tract.  
Summary. Epithelial tissues of the upper aerodigestive tract appear to express ADHs 
but have relatively low ALDH2 activity, which may make them more susceptible to toxicity 
mediated by acetaldehyde (either produced locally or from other sources such as saliva or 
microbes). Chronic drinking of alcoholic beverages induces CYP2E1 metabolism, most 
prominently in the liver but also at lower levels in the oropharynx and nasal mucosa, 
although the latter is not well characterized in humans. The relationship between oxidative-
stress-induced DNA damage and drinking of alcoholic beverages has not been well 
established. (51)  
Although the exact mechanisms that explain the carcinogenic effects of alcohol are 
not fully characterized, the direct and well-documented DNA damaging effects of 
acetaldehyde suggest that the enzymes controlling this reaction, primarily ADH, ALDH and 
CYP2E1, are excellent candidates for investigation as susceptibility factors for SCCHN. 
Because DNA-damaging ROS are also produced by these enzymes as by-products of 
alcohol metabolism, polymorphisms in the genes coding for SOD, GPx, and CAT are also of 
great interest, because these enzymes are the primary de-activators of ROS, and because 
there is evidence that their activity is altered in red blood cells and tumor tissue from people 
with oral and laryngeal cancers. Polymorphisms in any of these genes may affect levels of 
enzyme activity in UADT epithelial tissues, especially in conjunction with exposures such as 
alcohol and tobacco, which in turn may affect carcinogenesis and subsequent survival.  
1.3.2.3 Human papillomavirus 
HPV-associated SCCHNs occur more frequently in younger, male patients, and most 
often in the oropharynx. In fact, up to 70% of SCCHNs occurring in the oropharynx are 
associated with the presence of HPV DNA. The most common type is HPV 16, the same 
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type associated with cervical cancers. These tumors are generally more poorly 
differentiated, but, perhaps surprisingly, the patients have a better prognosis than those 
patients whose tumors are not associated with HPV (5, 21). HPV 16-related tumors are not 
associated with chronic alcohol or tobacco exposure (91).  
1.3.3 Other potential factors – nutrition and dental 
The association between diet and risk of SCCHN is among the strongest for any 
cancer. Many studies have found strong, consistent inverse associations between risk of 
SCCHN and fruit and vegetable consumption that are independent of the effects of alcohol 
and tobacco (92). In the IARC multinational case-control study of 1670 oral cancer cases, 
ever-drinkers with the highest quartile of fruit and vegetable intake experienced reduced 
cancer risk (OR=0.4, 95% CI=0.3-0.6) compared to those in the lowest quartile (93) . This 
protective effect was not observed among never-drinkers (OR=1.0; 95%CI=0.6-1.6). The 
authors conclude that vegetables and fruits may modify the carcinogenic effects of alcohol 
(as well as tobacco). The benefits of a diet high in fruits and vegetables are apparent 
regardless of the location of tumors in the oral cavity and oropharynx, age (stratified at 60 
years), and sex (92). Most studies suggest that diet is associated with risk of oral cancer 
only in the presence of at least some level of alcohol and tobacco consumption. In a related 
vein, studies examining the influence of BMI on risk of oral and oropharyngeal tumors 
suggest that low BMI is not an independent risk factor for SCCHN, but is probably a 
biomarker of chronic nutritional deficiencies, whether they be secondary to alcohol and 
tobacco use as they are in developed countries, or whether they be due to dietary 
insufficiency irrespective of alcohol and tobacco use as they are in less developed countries 
(92). 
Poor oral health is associated with multiple measures of oral hygiene, including 
frequency of toothbrushing and visits to a dental care provider. Clinical findings such as 
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mucosal irritation, cavities, and tartar are also associated with a two- to four-fold increased 
risk, but the strongest, most consistent risk factor is presence/absence of tooth loss as well 
as number of teeth lost. It appears most likely that poor oral health is an independent risk 
factor for SCCHN, probably due to type and number of oral bacteria, for which tooth loss 
serves as a surrogate measure. (92) 
1.4 EPIDEMIOLOGIC STUDIES OF GENETIC POLYMORPHISMS AND CANCER INCIDENCE 
1.4.1 Polymorphisms of alcohol metabolism genes 
1.4.1.1 Alcohol dehydrogenases (ADH) 
Human ADH is a dimeric protein consisting of two subunits with a molecular weight 
of 40kD each. It is actually a complex enzyme family and, in humans, five classes are 
categorized based on structural and kinetic properties. At least seven different genetic loci 
code for human ADH subunits that combine with other members in the same class as 
dimers, resulting in more than 20 known ADH isozymes. Such variation is unique to 
humans. The ADH1A, ADH1B, and ADH1C genes have several variants with different 
enzymatic activity that are distributed differently across racial groups (Table 4). Such 
variation was predicted to increase ethanol metabolic rates if the more active forms of the 
enzyme were present, but this has been hard to demonstrate because any one isozyme 
constitutes only a fraction of the total alcohol oxidizing capacity in any given tissue and 
because alcohol elimination rates are variable even among people with the same ADH 
genotype, or even twins. Increased blood levels of acetaldehyde in people with higher 
activity ADHs has only been demonstrated in those individuals who also have inactive 
ALDH2 (see below) (55). The ADH isozymes with high Km for ethanol, for example β3, π, 
and σ, are predicted to be more active when blood ethanol concentrations are high or in 
tissues of the UADT that are directly exposed to ethanol in alcoholic drinks, though this 
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hasn’t been tested directly in humans due to ethical concerns (55). The ADH family of 
enzymes metabolizes a wide variety of substrates besides ethanol, including retinol, other 
aliphatic alcohols, hydroxysteroids, and lipid peroxidation products. The liver expresses the 
highest levels of ADH classes I, II, and III, but many other tissues also express ADH, where 
it may play a role in the toxicity or carcinogenicity of alcohol and its catabolites. Little detail is 
known about expression of ADH outside the liver, except for gastric ADH, which is reduced 
with age, in women, and with heavy drinking according to some investigators (55). These 
variants have been shown to influence drinking levels and therefore the risk of developing 
alcohol abuse or addiction, and in fact these associations are the strongest and most widely 
replicated of any gene with risk of alcoholism (94). ADH expression can be induced at the 
mRNA level.  
The variant allele ADH1B*2 encodes a superactive subunit of ADH1B, whose 
homodimers have 40 times higher maximum velocity than heterodimers ADH1B*1/*2 (95). 
The enzyme encoded by ADH1B*1/*1 has only 1% or less of the oxidation capability of 
enzymes encoded by ADH1B*1/*2 and ADH1B*2/*2 (96). ADH1B*1 is the predominant 
allele in Europeans and Africans, with ADH1B*2 frequency not exceeding 15% (63, 97), but 
ADH1B*2 is common in Asian populations where its frequency varies from 10% to 90%.  
Most studies of ADH1B polymorphisms and alcohol exposure have examined the 
risks of esophageal cancer in Asians. Surprisingly, those studies found that significantly 
increased risk was associated with the ADH1B*1 (slow) allele in moderate to heavy drinkers, 
compared to moderate to heavy drinkers with the ADH1B*2 (fast) allele (98-102). Three of 
these studies reported 45% to 65% increased risk in those with the *1/*1 genotype 
compared to other genotypes (OR=1.56, 95% CI=1.01-2.39 (98); OR=1.65, 95% CI=1.02-
2.68 (101); OR=1.45, 95% CI=0.97-2.16 (100)); one reported that the *1/*1 genotype 
quadrupled cancer risk compared to other genotypes (OR=4.11; 95% CI=2.08-8.12 (102)); 
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and one reported that the *1/*1 genotype quadrupled the cancer risk of *2/*2 (OR=3.99; 95% 
CI=2.13-7.48 (99)).  
Two recent studies in European countries of UADT cancer, and one recent study in 
Brazil of SCCHN, found the reverse to be true: a protective effect (50% reduced risk) of the 
slow allele in drinkers compared with drinkers homozygous for the fast allele (103, 104) 
(Table 5). Two recent Japanese studies reported conflicting results: One reported a doubling 
in risk due to the fast allele (105), and the other reported a similar effect for the slow allele 
(106) (Table 5). Most studies of ADH1B *1 and *2 alleles report both a main effect of the 
gene on head and neck cancer, along with significant interaction with alcohol exposure 
(Tables 5 and 6); magnitude of interaction varied along the complete spectrum from greater 
than additive but less than multiplicative, to multiplicative, to greater than two times the 
expected multiplicative odds ratio. However, a 2003 study in Caucasian Germans found no 
significant association between ADH1B genotype and risk of laryngeal cancer (107).  
The results for ADH1B polymorphisms don’t consistently support the “acetaldehyde 
hypothesis,” which speculates that the much-less-active ADH1B*1 allele should decrease 
the risk of cancer in drinkers, because they would have less exposure to the carcinogenic 
and mutagenic acetaldehyde product. Some researchers have hypothesized that the higher 
risk for ADH1B*1/*1 homozygotes may be due to an absence of alcohol flushing (which is 
caused by acetaldehyde & is an uncomfortable sensation) so that the person is more likely 
to become a heavy drinker.  
The ADH1C gene has two alleles in most populations, ADH1C*1 and ADH1C*2. 
ADH1C*1 isoenzymes metabolize ethanol into acetaldehyde 2.5 times faster than the 
ADH1C*2 allele. In European Caucasians, the frequency of the ADH1C*1 (fast) allele is 
about 50%, but in Africans the frequency is 75-90% and in Asians even higher (63, 97). 
Individuals homozygous for the ADH1C*1 fast allele were found to have elevated salivary 
acetaldehyde levels, which is hypothesized to cause increased UADT cancer risk (108).  
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Eight small studies (each ncases<500), most conducted prior to 2006, mostly reported 
no main effect of ADH1C on head and neck cancer, although a few found an effect in heavy 
drinkers. (Table 5) Since 2006, three of four large studies in European Caucasians and Latin 
Americans, Brazilian Caucasians and Blacks and Mullatos, and Japanese populations (103-
105, 109) reported that genotypes containing the *2 slow allele increase the risk of cancer 
by 20 to 50%, and two reported greater risks in heavy drinkers (105, 109). Interaction with 
alcohol exposure was reported as greater than additive in the Japanese population and 
more than two times the expected multiplicative value in whites and African-Americans 
(Table 6). Overall, recent large studies on ADH1C polymorphisms and head and neck 
cancer risk have produced consistent evidence of increased risk associated with the slow 
allele, but a smaller effect than that of the ADH1B polymorphisms previously described.  
The largest and most comprehensive epidemiologic study to date on the 
relationships between multiple ADH genes and UADT cancers combined participant-level 
data from five smaller studies conducted in Europe and Latin America (104) (Tables 5 & 6: 
Hashibe et al. 2008). It found that UADT cancers are associated with rs1229984 ADH1B*2 
(fast) allele (OR=0.56; 95% CI=0.47-0.66) and rs1573496 variant G allele in ADH7 
(OR=0.68; 95% CI=0.60-0.78), but not with rs1984362 in ADH4 (104). It estimated greater 
than additive but less than multiplicative interaction. A recent case-control study in Japan 
(Tables 5 & 6: Oze et al. 2009) found significant independent associations of rs3737482 in 
ADH7 and rs4148887 in ADH4 on risk of UADT cancers, and possibly a small effect of 
rs1229984 in ADH1C that was not completely explained by linkage with ADH1B. It reported 
a suggestive increase in risk with increasing alcohol use related to the ADH4 SNP (105), 
and estimated greater than additive interaction.  
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1.4.1.2 Aldehyde dehydrogenase (ALDH) 
Two primary ALDH enzymes metabolize the acetaldehyde produced during ethanol 
oxidation. ALDH1A1 (old name ALDH1) is found in the cytosol, while ALDH2 is found in the 
mitochondria (Table 4). It is estimated that about 30% of total liver ALDH activity is from 
ALDH2 with the rest contributed by ALDH1A1, ALDH9A1 and possibly ALDH1B1 (55). Both 
ALDH1A1 and ALDH2 have similar structure with 13 exons, and the proteins they encode 
are 70% identical in sequence and have very similar structure. ALDH transcripts of all four 
types (Table 4) are found in almost every tissue of the body (55). Low levels of ALDH 
mRNAs have been found in placenta, brain, and pancreas; because these are target organs 
for alcoholic pathology, these data are consistent with the hypothesis that the presence of 
ALDHs is protective against acetaldehyde toxicity (55). A polymorphism of ALDH2 exists 
that has no enzymatic activity. ALDH2*1 is the active allele, and ALDH2*2 is the inactive 
allele. ALDH2*2/*2 homozygotes have no enzyme activity, while ALDH2*1/*2 heterozygotes 
have 6% residual activity. The ALDH2*2 mutant allele is prevalent in Asians up to a 
frequency as high as 40%, but its frequency in European and African populations is less 
than 5%. In an animal model mimicking the human ALDH2*2/*2 genotype, knock-out mice 
lacking ALDH2 activity have reduced alcohol preference, and when forcibly exposed to 
higher doses of ethanol, they exhibit elevated acetaldehyde in blood, liver, and brain (110). 
These mice have been used for toxicological studies of alcohol and acetaldehyde (55).  
For cancer of the UADT, many studies have reported increased risk of esophageal 
cancer in Asians with the ALDH2*2 (inactive) allele who were moderate or heavy drinkers 
(98-102, 111, 112). Two small studies of cancer (each ncases<250) of the UADT, oral cavity, 
or oropharynx in Asian populations found significant interaction between ALDH2*1/*2 
genotype and heavy or moderate/heavy alcohol intake (106, 113); in contrast, two other 
studies in Asians reported no interaction (111, 114). Only the largest of these four studies 
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(ncases=239) reported a significant main effect of the gene – i.e., a 66% increase in UADT 
cancer risk associated with the null phenotype. These results are consistent with the 
hypothesis that reduced ALDH2 activity exposes the body to more mutagenic acetaldehyde. 
In addition, people with ALDH2 deficiency have higher acetaldehyde levels in their serum 
and saliva than occur in people with the wild type genotype, and higher frequency of 
acetaldehyde adducts, sister chromatid exchanges, and micronuclei have been reported in 
Asian drinkers with the heterozygous genotype compared with the wild type (60).  
In central and eastern Europeans, in whom the ALDH2*2 inactive mutant allele is 
almost completely absent, one study of three other, previously unstudied, variants in ALDH2 
(103) reported 30% increased risk of UADT cancers as a main effect of the variant allele, 
and even higher risk in medium to heavy drinkers (defined as more than 2 drinks per week) 
(Tables 5&6: Hashibe et al. 2006 (103)). The GG genotype of rs886205 in the 5’ 
untranslated region was associated with increased UADT risk compared to the AA genotype 
(OR=1.29; CI=1.03-1.60), as was the CC genotype of rs440 in intron 6 compared to the TT 
genotype (OR=1.32; 95% CI=1.06-1.65), and the CC genotype of rs441 in intron 6 
compared to the TT genotype (OR=1.33; 95% CI=1.07-1.66). In medium/heavy drinkers, 
these risks were increased to ORs of 4.38 (95% CI=1.32-14.53), 5.79 (95% CI=1.49-22.52), 
and 5.79 (95% CI=1.49-22.49), respectively. Effect measure modification was estimated to 
be greater than multiplicative. Risk was higher for esophageal cancer than for oral cavity, 
pharynx, and larynx cancers. A second large 2009 study of European Caucasians (115) 
found no main effect of two additional SNPs in ALDH2, rs886205 in the 5’UTR and 
rs4646777 in intron 8, and no interactive effect with alcohol (Tables 5&6: Canova et al. 2009 
(115)), although a 2006 study of 436 cases with alcoholism and 365 controls in the U.S. 
(116) reported that these two SNPs are associated with alcoholism in both whites and 
African-Americans.  
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Table 4. Human ADH and ALDH isozymes (55, 68, 94, 117) 
Class  Official gene name  
(old name) 
Allele  
(old 
name) 
SNP 
(nucleotide) 
Chromo-
somal 
location 
Protein 
subunit 
Amino acid 
differences 
between 
alleles 
Km 
sub-
strate 
(mM) 
Vmax 
(min-1) 
Ethnic/ 
national 
distribution 
Human alcohol dehydrogenase (ADH) isozymes 
I ADH1A (ADH1) ADH1A  4q22 α  4 54 Europe, Africa 
 ADH1B (ADH2) 
ADH1B*1 
(ADH2*1) 
 
rs1229984 (A) 
rs2066702 (C) 4q22 β1 
Arg48, 
Arg370 0.05 9 
Europe, Africa 
  ADH1B*2 (ADH2*2) 
rs1229984 (G) 
rs2066702 (C)  β2 
His48, 
Arg370 0.9 400 
Asia 
  ADH1B*3 (ADH2*3) 
rs1229984 (A) 
rs2066702 (T)  β3 
Arg48, 
Cys370 34 300 
Africa, Native 
American 
 ADH1C (ADH3) ADH1C*1 (ADH3*1) 
rs1693482 (G) 
rs698 (A) 4q22 γ1 
Arg272, 
Ile350 1.0 87 
All 
  ADH1C*2 (ADH3*2) 
rs1693482 (A) 
rs698 (G)  γ2 
Gln272, 
Val350 0.63 35 
Europe 
  ADH1C*3 rs35719513 (A)   Thr352*   Native 
A i  II ADH4 ADH4*1 rs1126671 (A) 4q21-25 π Ile309 34 40 All 
  ADH4*2 rs1126671 (G)   Val309   Sweden 
III ADH5   4q21-25 Χ  1000  All 
V ADH6   4q21-25 ADH6  30 ? All 
IV ADH7   4q23-24 σ,μ  20 1510 All 
Human aldehyde dehydrogenase (ALDH) isozymes 
 ALDH1A1 (ALDH1)   9q21.13   30  All 
 ALDH2 ALDH2*1 rs671 (G) 12q24.2  Glu504 1  All 
  ALDH2*2 rs671 (A)   Lys504   Asia 
   rs886205 (G)      All 
   rs886205 (A)      All 
   rs440 (C)      All 
   rs440 (T)      All 
   rs441 (C)      All 
   rs441 (T)      All 
 ALDH1B1 (ALDH5) ALDH1B1  9p11.1   ?   
 ALDH9A1 ALDH9A1  9q21.13   30  All 
*ADH1C*352Thr has been found in Native Americans as an additional variation on chromosomes that have the Val350 
characteristic of ADH1C*2. The protein has not been isolated for study. 
NOTE: Km indicates the concentration of substrate at which the enzyme works at 50% capacity. Vmax (turnover) indicates how 
many molecules of product are formed by the enzyme in 1 minute at saturating substrate concentrations.  
1.4.1.3 Cytochrome P450-2E1 (CYP2E1) 
Alcohol can be metabolized by cytochrome P450s, with CYP2E1 being the most 
active in this regard. CYP2E1 is associated with microsomes in the endoplasmic reticulum, 
where it reduces molecular oxygen to water as ethanol is oxidized to acetaldehyde. Its Km 
for ethanol is about 10mM (fairly high), and CYP2E1 probably assumes a larger role in 
metabolizing ethanol when blood alcohol levels are high. When metabolizing alcohol, 
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CYP2E1 generates a large number of ROS including hydroxyl radicals, superoxide anion, 
hydrogen peroxide, and hydroxyethyl radicals; therefore it is a major source of oxidative 
stress. (55) CYP2E1 enzyme production is induced by chronic drinking and also by fasting, 
diabetes, and a high-fat diet. It is expressed at highest concentrations in the liver but is also 
expressed in numerous other tissues, including esophageal and nasal mucosa among many 
others. One animal study found that after chronic alcohol feeding, CYP2E1 was found in 
squamous epithelial cells of the cheek mucosa, tongue, esophagus, and fore-stomach 
(118). Some individuals experience a very low extent of induction of CYP2E1 after alcohol 
ingestion, whereas others show a high extent (119); thus, variation in the extent of induction 
may modulate alcohol-associated carcinogenesis (67), although it is unknown whether these 
differences are affected by CYP2E1 polymorphisms. A recent study (69) found that, in mice, 
dietary supplementation with methyl donor supplements (which are associated with 
reduction in alcohol-induced liver injury) led to a 35% increase in blood alcohol elimination 
rate. While the supplements caused no difference in alcohol metabolism in the stomach, 
there was a tremendous effect in the liver: the catalase-dependent pathway of alcohol 
metabolism was induced, at the same time that CYP2E1 induction was blunted. This 
research is consistent with the hypothesis that CYP2E1 alcohol metabolism is responsible 
for much of the liver damage associated with alcoholism. Four major polymorphisms of 
CYP2E1 are the best characterized, but there exist numerous un- or little-studied 
polymorphisms:  
1.  the wild-type RsaI+ (c1) and the variant RsaI- (c2) located in the 5’-flanking region of 
the CYP2E1 gene in a region that interacts with HNF1 (also known as CYP2E1*5A 
and *5B, RsaI/PstI RFLP, rs2031920). The c2 (T) variant is associated with a 10 times 
higher transcriptional activity, elevated protein levels, and increased enzyme activity 
compared to the c1 (C) allele (120). The c2 variant is present in 2-8% of Caucasians 
and 25-36% of East Asians. A dozen small studies (Table 5), with number of cases 
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ranging from 75 to 408, in Brazil, China, India, Europe, the U.S., and Japan, have 
studied the effects of c2 on risk of head and neck cancer (111, 121-131). Eight of 
these studies reported no main effect or interaction with alcohol. Three studies, 
conducted in France, India, and Japan (125, 128, 131) reported significantly increased 
risk of head and neck cancer (ORs=2.6, 2.4, and 3.4 respectively), and the French and 
Indian studies also reported interactive effects with alcohol. (See Table 6 re: 
interactions.) The Indian study (125) reported greater than additive but less than 
multiplicative interaction, and the French study (128) reported more than 2x 
multiplicative interaction. A study conducted in Brazil (124) reported no main effect of 
the c2 polymorphism but did report greater than 2x multiplicative interaction with 
alcohol exposure. Yang et al. reported no main effect of this polymorphism on risk of 
esophageal cancer in an Asian population, and no interactive effect with alcohol (100). 
Several studies reported increased risk for gastric and rectal cancers. A meta-
analysis published in 2007 reported a possible increased risk of gastric cancer in 
Asians homozygous for the c2 allele (132). A Chinese study (133) found that the 
CYP2E1 c2/c2 genotype increases susceptibility to rectal (but not colon) cancer 
(OR=1.64; 95% CI=1.12-2.41) compared to c1 allele carriers, and gene-environment 
interactions between the CYP2E1 polymorphism and smoking or alcohol drinking were 
found to exist for colorectal neoplasia in general. 
2.  the DraI polymorphism located in intron 6 (also known as CYP2E1*6, DraI RFLP, 
T7632A SNP, and rs6413432), for which the variant is found in 10% of Caucasians 
and about half of East Asians. A study in the Caucasian French population (128) 
reported a two-fold increased risk of oral cavity/ pharyngeal cancer (OR=2.0; 95% 
CI=1.0-3.9) and laryngeal cancer (OR=1.8; 95% CI=1.0-3.5) in carriers of the T variant 
allele compared to AA individuals. (See Tables 5&6.) The highest risk of oral 
cavity/pharyngeal cancer was observed among the heaviest drinkers (oral 
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cavity/pharyngeal cancer: OR=5.8, 95% CI=1.9-18.2; laryngeal cancer: OR=4.6, 95% 
CI=1.5-14.1), with the interactive effect being greater than 2x multiplicative. More 
precise estimates were not possible due to the rarity of the variant allele in the 
Caucasian French population. A 2009 Indian study (125) and a 2006 Japanese study 
(131) reported increased risk of head and neck cancer with the T risk allele (OR=1.55, 
2.28 respectively), but no interactive effects with alcohol. Two studies reported no 
main or interactive effects of DraI on risk of head and neck cancer (121, 126).   
3.  the -71G>T polymorphism located 5’ of the gene, which occurs in about 10% of 
Caucasians (also known as CYP2E1*7B, DdeI RFLP, G-71T SNP, and rs6413420). 
There are no studies of this polymorphism and risk of head and neck cancer.   
4.  a 96-bp insertion polymorphism located in the regulatory region, which is found in 15% 
of Asians and 2% of Caucasians. There are no studies of this polymorphism and risk 
of head and neck cancer.  
In summary, studies investigating the effects of these CYP2E1 polymorphisms on 
risk of alcoholic complications or cancer risk have small study populations and have 
produced inconsistent results (55). 
1.4.2 Polymorphisms of oxidative stress metabolism genes 
1.4.2.1 Catalase (CAT) 
CAT is expressed in almost all tissues, where it is primarily found in peroxisomes, 
and also by colonic microorganisms in the lower gastrointestinal tract, where it contributes to 
formation of acetaldehyde from ethanol. In peroxisomes it primarily catalyzes a reaction 
between hydrogen peroxide molecules, resulting in the formation of water and O2, but it can 
also facilitate the reaction of hydrogen peroxide with hydrogen donors so that the hydrogen 
peroxide is converted to one molecule of water and the reduced donor (e.g., ethanol) 
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becomes oxidized. It can be upregulated by oxidative stress (134). In a study using ADH-
deficient deermice, ethanol oxidation was highly sensitive to inhibition by a known catalase 
inhibitor (135). Some Asians do not have active CAT, and a number of SNP polymorphisms 
in the 5’ untranslated region and introns have been reported, but these have not been 
studied in terms of their influence on enzyme activity or on responses to ethanol (55). A 
common C/T polymorphism has been identified in the promoter region, and the variant 
affects transcriptional activity and CAT enzyme levels in red blood cells (136). Associations 
of CAT polymorphisms with risk of SCCHN have not been studied. Polymorphisms of CAT 
were not associated with lung cancer risk in a Chinese population (137), non-Hodgkin’s 
lymphoma in the United Kingdom (138), or prostate cancer in the United States (139).  
1.4.2.2 Superoxide dismutase (SOD) 
SOD enzymes serve an important antioxidant role by catalyzing the conversion of 
superoxide free radicals into oxygen and hydrogen peroxide. Humans have three forms of 
SOD, whose genes are located on different chromosomes, and which are active in different 
locations. The gene for SOD1, also known as copper-zinc superoxide dismutase, is located 
on chromosome 21; its isozyme is a soluble cytoplastmic and intra-membrane mitochondrial 
protein. The gene for SOD2, also known as manganese superoxide dismutase, is located on 
chromosome 6; its product is active in the mitochondrial matrix. The gene for SOD3 is 
located on chromosome 4; its product is a major extracellular antioxidant enzyme expressed 
in many tissues, especially blood vessels (140, 141). Most studies report no association 
between SOD1 polymorphisms and cancer. The only study of SOD polymorphisms and risk 
of head and neck cancer – a 2009 study in European Caucasians (115) – found no 
association between rs2758346 in SOD2 and cancer risk (Table 5, last entry). A variant non-
synonymous SNP polymorphism in exon 2 of SOD2 (rs1799725) has been independently 
associated with 20-30% elevated risk of prostate cancer in Caucasians (Val/Ala versus 
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Val/Val: OR=1.17; 95% CI=0.97-1.42; Ala/Ala versus Val/Val: OR=1.28; 95% CI=1.03-1.60 
(142)). Another study (143) found that white women with the Ala allele were at increased 
risk of ovarian cancer (OR=2.1; 95% CI=1.1-4.0). And Wang et al. (144) reported that, in a 
U.S. study population, Ala homozygotes were at increased risk for B-cell lymphomas 
compared to other genotypes (OR=1.3; 95% CI=1.0-1.6). A 2007 study reported that SNPs 
in SOD3 were not associated with prostate cancer in a U.S. population (142).  
1.4.2.3 Glutathione peroxidases (GPx/GPX) 
GPX’s are a family of selenium-dependent enzymes that remove hydrogen peroxide. 
There are four isoenzymes characterized to date. GPX1 was the first identified and is widely 
expressed in the cytoplasm of human cells, protecting cells against oxidative damage by 
reducing hydrogen peroxide and other peroxides. The glutathione peroxidase system 
consists of several components, including the GPx enzyme, glutathione reductase and 
cofactors glutathione (GSH) and reduced nicotinamide adenine dinucleotide phosphate 
(NADPH). Associations of GPx polymorphisms with risk of SCCHN have not been studied. 
However, a SNP resulting in a non-synonymous amino acid substitution at codon 198 
(Pro198Leu) has been studied for other cancer associations by several different groups. 
Arsova-Sarafinovska et al. (145) reported an overall protective effect of the variant Leu allele 
on prostate cancer risk; heterozygous carriers of the variant Leu (T) allele had reduced risk 
of prostate cancer compared with homozygous wild-type (OR=0.38; 95% CI=0.20-0.75). In a 
Danish study (146), carriers of the Leu variant were at 1.43-fold higher risk of breast cancer 
compared with non-carriers (95% CI=1.07-1.92). In a lung cancer study also conducted in 
Denmark (147), the odds of developing lung cancer were reduced by 40% (OR=0.60; 95% 
CI=0.35-1.05) when homozygous carriers of the variant allele were compared with the 
homozygous carriers of the wild type. A Japanese study (148) found that the risk of bladder 
cancer more than doubled with the Pro/Leu genotype compared with the wild-type Pro/Pro 
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(OR=2.63; 95% CI=1.45-4.75). However, these results are not consistent in all populations 
(141). GPX2 (extracellular intestinal enzyme), GPX3 (extracellular and common in plasma), 
and GPX4 (which has high affinity for lipid hydroperoxides) have not been studied for their 
association with cancer.  
Table 5. Case control studies examining main effects of alcohol and oxidative 
metabolism genes on risk of SCCHN  
(studies examining the same gene polymorphism and effect direction are grouped together and 
shaded alike) 
Authors Year 
Subjects’ race 
# cases/# 
controls 
Gene 
tested** 
SNP, 
variant & referent 
groups OR (95% CI) 
Significant at 
α=0.05 for: 
Main 
effect 
of 
gene? 
Interaction 
of gene 
with 
alcohol 
exposure? 
Garcia et al.(123) 2010 
Brazilian 
Caucasians, 
Blacks, Mulattos 
207/244 
ADH1B 
rs2066702 *3 allele 
TT+TC (also fast) 
versus CC 
0.60 (0.27-1.32)   
Canova et al.(115) 2009 
European 
Caucasians 
1511/1457 
ADH1B rs17033 A>G GG versus AA 1.35 (0.46-3.94)   
Hashibe et al.(104) 2008 
European 
Caucasians & 
Latin Americans  
3449/5278 
ADH1B rs6413413 TT+TA versus AA 1.07 (0.70-1.63)   
Garcia et al.(123) 2010 
Brazilian 
Caucasians, 
Blacks, Mulattos 
207/244 
ADH1B 
rs1229984  
GG+GA (fast) versus 
AA 
0.42 (0.21-0.85)   
Oze et al. (105) 2009 Japanese 585/1170 ADH1B 
rs1229984  
GG+GA (fast) versus 
AA 
2.20 (1.46-3.32)   
Hashibe et al.(103) 2006 
European 
Caucasians 
811/1083 
ADH1B 
rs1229984 
AA+GA (fast) versus 
GG 
0.47 (0.32-0.70)   
Risch et al.(107) 2003 
German 
Caucasians 
245/251 
ADH1B rs1229984 GA (fast) versus AA 0.86 (0.41-1.82)   
McKay et al.(149) 2011 
Europeans, Latin 
& North Americans 
of European 
descent, African-
Americans 
8527/11653 
ADH1B 
rs1229984 
log-additive model, 
additional risk for 
each A allele 
0.62 (0.56-0.68)   
Hashibe et al.(104) 2008 
European 
Caucasians & 
Latin Americans  
3449/5278 
ADH1B 
rs1229984 
AA+GA (slow) versus 
GG (fast) 
0.56 (0.47-0.66)   
Asakage et al.(113) 2007 Japanese 96/642 ADH1B 
rs1229984 
AA+AG (slow) versus 
GG 
Not stated; NS   
Hiraki et al.(106) 2007 Japanese 239/716 ADH1B 
rs1229984 
AA (slow) versus GG 2.67 (1.51-4.75)   
McKay et al.(149) 2011 
Europeans, Latin 
& North Americans 
of European 
descent, African-
Americans 
7890/10938 
ADH1C 
rs698 
log-additive model, 
additional risk from 
each G allele 
1.10 (1.05-1.15)   
Garcia et al.(123) 2010 
Brazilian 
Caucasians, 
Blacks, Mulattos 
207/244 
ADH1C 
rs698  
GG+GA (slow) 
versus AA 
1.37 (0.95-1.99)   
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Table 5. Case control studies examining main effects of alcohol and oxidative 
metabolism genes on risk of SCCHN  
(studies examining the same gene polymorphism and effect direction are grouped together and 
shaded alike) 
Authors Year 
Subjects’ race 
# cases/# 
controls 
Gene 
tested** 
SNP, 
variant & referent 
groups OR (95% CI) 
Significant at 
α=0.05 for: 
Main 
effect 
of 
gene? 
Interaction 
of gene 
with 
alcohol 
exposure? 
Oze et al. (105) 2009 Japanese 585/1170 ADH1C 
rs698  
each G (slow) allele 1.38 (1.02-1.87)   
Hashibe et al.(104) 2008 
European 
Caucasians & 
Latin Americans  
3449/5278 
ADH1C 
rs698 
GG+GA (slow) 
versus AA 
1.16 (1.05-1.29)   
Hashibe et al.(103) 2006 
European 
Caucasians 
811/1083 
ADH1C rs698 GG (slow) versus AA 1.38 (1.01-1.88)   
Oze et al. (105) 2009 Japanese 585/1170 ADH1C 
rs1693482  
Allelic model (A vs G) 1.37 (1.01-1.85)   
Hashibe et al.(104) 2008 
European 
Caucasians & 
Latin Americans  
3449/5278 
ADH1C 
rs1693482 
AA+AG (slow) versus 
GG 
1.20 (1.08-1.32)   
Asakage et al.(113) 2007 Japanese 96/642 ADH1C 
rs1693482 
AA+AG (slow) versus 
GG 
Not stated; NS   
Hashibe et al.(103) 2006 
European 
Caucasians 
811/1083 
ADH1C rs1693482 AA (slow) versus GG 1.49 (1.08-2.05)   
Peters et al.(109) 2005 EA*, AA* (4%) 521/599 ADH1C 
*2/*2 (slow) versus  
*1/*2 & *1/*1 Not stated; NS   
Wang et al.(150) 2005 EA*, Other (4%) 348/330 ADH1C 
*1/*1 (fast) and *1/*2 
versus *2/*2 Not stated; NS   
Risch et al.(107) 2003 
German 
Caucasians 
245/251 
ADH1C *1/*1 (fast) versus  *1/*2 and *2/*2 1.06 (0.70-1.62)   
Zavras et al.(151) 2002 Greeks 93/99 ADH1C 
*1/*1 (fast) versus  
*2/*2 0.9 (0.3-2.5)   
Olshan et al.(152) 2001 EA*, AA* (24%) 182/202 ADH1C 
*1/*1 (fast) versus  
*2/*2 0.9 (0.4-1.9)   
Schwartz et al.(153) 2001 EA*, AA* (6%) 333/541 ADH1C 
(1) *1/*1 (fast) vs 
*2/*2 
(2) *1/*2 vs *2/*2 
(1) 1.0 (0.7-1.5) 
(2) 1.3 (1.0-1.8) 
 
 
 
 
Bouchardy et al.(128) 2000 
French 
Caucasians 
250/172 
ADH1C  *1/*1 (fast) versus  *1/*2 and *2/*2 
OC/pharynx: 1.4 (0.8-
2.3) 
larynx: 0.7 (0.4-1.3)  
 
Canova et al.(115) 2009 
European 
Caucasians 
1511/1457 
ADH1C rs1662058 A>G GG versus AA 1.12 (0.88-1.42)   
Canova et al.(115) 2009 
European 
Caucasians 
1511/1457 
ADH1C rs2241894 A>G GG versus AA 1.01 (0.72-1.42)   
Oze et al. (105) 2009 Japanese 585/1170 ADH4 
rs4148887 
TT+TC versus CC 1.96 (1.34-2.87)   
Hashibe et al.(104) 2008 
Europeans & Latin 
Americans  
3449/5278 
ADH4 rs1984362 TT+TC versus CC 1.03 (0.94-1.14)   
Oze et al. (105) 2009 Japanese 585/1170 ADH7 
rs3737482 
CC+CT versus TT 1.62 (1.18-2.24)   
McKay et al.(149) 2011 
Europeans, Latin 
& North Americans 
of European 
descent, African-
Americans 
8545/11657 
ADH7 
rs1573496 
log-additive model, 
additional risk for 
each C allele 
0.74 (0.69-0.80)   
Hashibe et al.(104) 2008 
Europeans & Latin 
Americans 
3449/5278  
ADH7 rs1573496 CC+CG versus GG 0.68 (0.60-0.78)   
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Table 5. Case control studies examining main effects of alcohol and oxidative 
metabolism genes on risk of SCCHN  
(studies examining the same gene polymorphism and effect direction are grouped together and 
shaded alike) 
Authors Year 
Subjects’ race 
# cases/# 
controls 
Gene 
tested** 
SNP, 
variant & referent 
groups OR (95% CI) 
Significant at 
α=0.05 for: 
Main 
effect 
of 
gene? 
Interaction 
of gene 
with 
alcohol 
exposure? 
Canova et al.(115) 2009 
European 
Caucasians 
1511/1457 
ALDH2 rs886205 (+82A>G) GG versus AA 1.09 (0.72-1.67)   
Hashibe et al.(103) 2006 
European 
Caucasians 
811/1083 
ALDH2 rs886205 (+82A>G) GG+GA versus AA 1.29 (1.03-1.60)   
Hiraki et al.(106) 2007 Japanese 239/716 ALDH2 
rs671 
AG (null) versus GG 1.66 (1.20-2.31)   
Asakage et al.(113) 2007 Japanese 96/642 ALDH2 
rs671 
AA (null) versus GG Not stated; NS   
Hashimoto et al.(114) 2006 Japanese 192/192 ALDH2 
rs671 
AA+AG (null) versus 
GG 
Not stated; NS   
Katoh et al.(111)  1999 Japanese 92/147 ALDH2  
rs671 
AA+AG (null) versus 
AA 
1.10 (0.61-1.99)   
McKay et al.(149) 2011 
Europeans, Latin 
& North Americans 
of European 
descent, African-
Americans 
8232/11064 
ALDH2 
rs4767364 
log-additive model, 
additional risk for 
each A allele 
1.12 (1.07-1.17)   
Canova et al.(115) 2009 
European 
Caucasians 
1511/1457 
ALDH2 rs4646777 G>A AA versus GG 1.08 (0.71-1.63)   
Hashibe et al.(103) 2006 
European 
Caucasians 
811/1083 
ALDH2 rs441 CC+CT versus TT 1.33 (1.07-1.66)   
Hashibe et al.(103) 2006 
European 
Caucasians 
811/1083 
ALDH2 rs440 CC+CT versus TT 1.32 (1.06-1.65)   
Ruwali et al.(125) 2009 Indians 350/350 CYP2E1 
rs6413432 (DraI) 
TT+TA versus AA 1.55 (1.08-2.22)   
Boccia et al.(121) 2008 
European 
Caucasians 
210/245 
CYP2E1 rs6413432 (DraI) TT+TA versus AA 0.87 (0.43-1.76)   
Soya et al.(126) 2008 Indians 408/220 CYP2E1 
rs6413432 (DraI) 
TT versus AA 0.94 (0.36-2.46)   
Sugimura et al.(131)  2006 Japanese 122/241 CYP2E1 
rs6413432 (DraI) 
TT versus AA 2.28 (1.06-4.91)   
Bouchardy et al.(128) 2000 
French 
Caucasians 
250/172 
CYP2E1 rs6413432 (DraI) TT+TA versus AA 
OC/pharynx: 2.0 (1.0-
3.9) 
larynx: 1.8 (1.0-3.5) 
 
 
 
 
Garcia et al.(123) 2010 
Brazilian 
Caucasians, 
Blacks, Mulattos 
207/244 
CYP2E1 rs2031920 (RsaI) TC (fast) versus CC 1.53 (0.76-3.09)   
Tai et al.(127) 2010 Chinese 278/278 CYP2E1 
rs2031920 (RsaI) 
TC (fast) versus CC 0.97 (0.66-1.43)   
Olivieri et al.(124) 2009 
Brazilian 
Caucasians, 
Blacks, Mulattos 
153/145 
CYP2E1 
rs2031920 (RsaI) 
TT (fast) +TC versus 
CC 
Not given   
Ruwali et al.(125) 2009 Indian 350/350 CYP2E1 
rs2031920 (RsaI) 
TT (fast) +TC versus 
CC 
2.40 (0.98-5.85)   
Boccia et al.(121) 2008 
European 
Caucasians 
210/245 
CYP2E1 
rs2031920 (RsaI) 
TT (fast) +TC versus 
CC 
0.72 (0.33-1.63)   
Buch et al.(122) 2008 EA* 197/416 CYP2E1 
rs2031920 (RsaI) 
TT (fast) +TC versus 
CC 
Not given   
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Table 5. Case control studies examining main effects of alcohol and oxidative 
metabolism genes on risk of SCCHN  
(studies examining the same gene polymorphism and effect direction are grouped together and 
shaded alike) 
Authors Year 
Subjects’ race 
# cases/# 
controls 
Gene 
tested** 
SNP, 
variant & referent 
groups OR (95% CI) 
Significant at 
α=0.05 for: 
Main 
effect 
of 
gene? 
Interaction 
of gene 
with 
alcohol 
exposure? 
Soya et al.(126) 2008 Indians 408/220 CYP2E1 
rs2031920 (RsaI) 
TT (fast) +TC versus 
CC 
1.03 (0.36-2.94)   
Sugimura et al.(131)  2006 Japanese 122/241 CYP2E1 
rs2031920 (RsaI) 
TT (fast) versus CC 3.38 (1.22-9.36)   
Bouchardy et al.(128) 2000 
French 
Caucasians 
250/172 
CYP2E1 
rs2031920 (RsaI) 
TT (fast) + TC versus 
CC 
OC/pharynx: 2.6 (1.0-
6.6) 
larynx: 1.4 (0.5-4.0) 
 
 
 
 
Katoh et al.(111)  1999 Japanese 92/147 CYP2E1 
rs2031920 (RsaI) 
TT (fast) + TC versus 
CC 
1.45 (0.80-2.62)   
Morita et al.(130) 1999 Japanese 145/164 CYP2E1 
rs2031920 (RsaI) 
TT (fast) + TC versus 
CC 
Not stated; NS   
Gonzalez et al.(129) 1998 
Spanish 
Caucasians 
75/200  
CYP2E1 
rs2031920 (RsaI) 
TT (fast) + TC versus 
CC 
Not stated; NS   
Soya et al.(126) 2008 Indians 408/220 CYP2E1 
*1B 
A1A1 versus A2A2 0.52 (0.16-1.66)   
Canova et al.(115) 2009 
European 
Caucasians 
1511/1457 
SOD2 rs2758346 G>A AA versus GG 0.98 (0.78-1.22)   
* AA=African American, EA=European American/white 
** This column lists only those genes also being tested in this study (ADH, ALDH, CYP2E1, SOD, GPX, CAT) 
 
Table 6. Case control studies examining interaction between alcohol and oxidative 
metabolism genes and alcohol in production of SCCHN 
 
Authors Year Subjects’ race 
Genes 
tested** 
Evidence of 
interaction found 
Case/control 
source 
# cases/ 
# controls 
McKay et al.(149) 2011 
Europeans, Latin & 
North Americans of 
European descent, 
African-Americans 
ADH1B, 
ADH1C, 
ADH7, 
ALDH2 
rs1229984 in ADH1B 
protective in drinkers 
15 UADT studies: 
11 hospital-based, 
4 population-based 
8744/11982 
Garcia et al.(123) 2010 
Brazilian 
Caucasians, 
Blacks, Mulattos 
ADH 
rs1229984 in ADH1B ↑ 
HNC risk in heavy 
alcohol drinkers 
(>additive, 2x 
multiplicative) 
hospital/clinic 207/244 
Tai et al.(127) 2010 Chinese CYP2E1 none hospital/clinic 278/278 
Oze et al. (105) 2009 Japanese ADH 
1 in ADH1B, 2 SNPs in 
ADH4, 1 in ADH7 ↑ risk 
of UADT; greater 
magnitude in heavy 
drinkers (>multiplicative) 
hospital/clinic 585/1170 
Olivieri et al.(124) 2009 
Brazilian 
Caucasians, 
Blacks, Mulattos 
CYP2E1 
rs2031920/*5B/RsaI  
↑risk in alcoholics versus 
non-alcoholics (2x 
multiplicative) 
hospital/hospital 153/145 
Ruwali et al.(125) 2009 Indian CYP2E1 
* rs2031920/*5B/RsaI 
/rs6413432*6/DraI  
↑ risk in alcoholics 
versus non-alcoholics 
(>additive, < 
multiplicative) 
hospital/hospital 350/350 
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Table 6. Case control studies examining interaction between alcohol and oxidative 
metabolism genes and alcohol in production of SCCHN 
 
Authors Year Subjects’ race 
Genes 
tested** 
Evidence of 
interaction found 
Case/control 
source 
# cases/ 
# controls 
Boccia et al.(121) 2008 Caucasian CYP2E1 none hospital/hospital 210/245 
Buch et al.(122) 2008 Caucasian CYP2E1 none hospital/population 197/416 
Hashibe et 
al.(104) 
2008 European & Latin American  ADH 
rs1229984 in ADH1B 
>additive, <multiplicative 
rs1573496 in ADH7  
heterogeneous effect but 
can’t evaluate additive 
interaction 
hospital/hospital 3449/5278 
Soya et al.(126) 2008 Indian CYP2E1 
*1B variant homozygote 
↑ risk only in regular 
alcohol users (>additive, 
<multiplicative) 
hospital/hospital 408/220 
Asakage et 
al.(113) 2007 Japanese 
ADH, 
ALDH 
ADH1B rs1229984 
> additive hospital/clinic 96/642 
Hiraki et al.(106) 2007 Japanese ADH, ALDH 
ADH1B Arg/Arg, ALDH2 
Glu/Lys ↑ risk in heavier 
drinkers (>additive, 
<multiplicative for both) 
hospital/clinic 239/716 
Hashibe et al. 
(103) 
2006 European Caucasian 
ADH, 
ALDH 
ADH1B*2 ↓ risk in 
heavier drinkers 
(>additive, 
<multiplicative), 3 ALDH 
polymorphisms ↑ risk in 
heavier drinkers (>2x 
multiplicative) 
hospital & 
clinic/hospital & 
clinic 
811/1083 
Hashimoto et 
al.(114) 
2006 Japanese ALDH none hospital/mixed 192/192 
Sugimura et 
al.(131)  2006 Japanese CYP2E1 none hospital/hospital 122/241 
Peters et al.(109) 2005 EA*; AA* (4%) ADH 
ADH1C*2-2 homozygote 
↑ risk in heavy drinkers 
(>additive, >2x 
multiplicative) 
hospital/population 521/599 
Wang et al.(150) 2005 EA*; Other (4%) ADH1C none hospital/clinic 348/330 
Risch et al.(107) 2003 German Caucasian  
ADH1B, 
ADH1C none 
population 
recruits/population 245/251 
Zavras et al.(151) 2002 Greek ADH 
ADH1C*2-2 homozygote 
↑ risk as alcohol 
consumption ↑ 
(>additive, >2x 
multiplicative) 
hospital/hospital 93/99 
Olshan et al.(152) 2001 EA*; AA* (24%) ADH1C none hospital/hospital 182/202 
Schwartz et 
al.(153) 
2001 EA*; AA* (6%) ADH 
ADH1C*2-2 homozygote 
↑ risk as alcohol 
consumption ↑ 
(>additive, 
>multiplicative) 
population/ 
population 333/541 
Bouchardy et 
al.(128) 
2000 French Caucasian ADH, CYP2E1 
ADH1C - none 
CYP2E1 Dral C allele, 
Rsal c2 allele both ↑ risk 
in heaviest drinkers (>2x 
multiplicative) 
hospital/hospital 250/172 
Katoh et al.(111)  1999 Japanese ALDH CYP2E1 none hospital/hospital 92/147 
Morita et al.(130) 1999 Japanese CYP2E1 none unknown/clinic 145/164 
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Table 6. Case control studies examining interaction between alcohol and oxidative 
metabolism genes and alcohol in production of SCCHN 
 
Authors Year Subjects’ race 
Genes 
tested** 
Evidence of 
interaction found 
Case/control 
source 
# cases/ 
# controls 
Gonzalez et 
al.(129) 
1998 Caucasian CYP2E1 none hospital/blood donors 75/200 
* AA=African American/black; EA=European American/white 
** This column lists only those genes also being tested in this study (ADH, ALDH, CYP2E1, SOD, GPX, CAT) 
 
1.5 EPIDEMIOLOGIC STUDIES OF GENETIC POLYMORPHISMS AND SURVIVAL AFTER SCCHN 
DIAGNOSIS 
Of all the ADH genes, only ADH1C polymorphisms have been studied for effect on 
survival. Wang et al.(150) found higher recurrence and poorer overall and disease-specific 
survival among homozygotes for both the fast (*1) and slow (*2) alleles of ADH1C, as 
compared to *1/*2 heterozygotes. Overall and disease-specific hazard of survival in *1 
homozygotes was 30% of that observed in heterozygotes (HRoverall=0.3, 95% CI=0.2-0.6; 
HRdisease-specific=0.3, 95% CI=0.1-0.8), and overall and disease-specific hazard of survival in 
*2 homozygotes was 40% of that of heterozygotes (HRoverall=0.4, 95% CI=0.2-0.9; HRdisease-
specific=0.4, 95% CI=0.2-1.1).  
Olivieri et al.(124) reported that, in addition to being present more frequently in 
alcohol users in cases than alcohol users in controls, the CYP2E1*5B c2 (highly active) 
variant was significantly associated with advanced clinical stage (T3 and T4) at diagnosis.  
Although many studies (154-165) have analyzed and discussed the significance of 
somatic mutations and variant protein expression in tumor cells, no studies have tested the 
germline ALDH, CYP2E1, SOD, GPx, and CAT genes for possible survival differences.
  
 
CHAPTER 2   
AIMS AND METHODS  
2.1 SPECIFIC AIMS 
The overall goal of this dissertation project was to evaluate the relationship between 
polymorphisms of genes that, in combination with exposure to alcohol, may modify the risk 
of developing SCCHN or survival after diagnosis. The genes were selected on the basis of 
their potential functional importance related to alcohol metabolism, alcohol-induced 
carcinogenesis and previous epidemiologic literature on these genes and the risk of 
SCCHN.  
The Carolina Head and Neck Cancer Epidemiologic study (CHANCE), a large 
population-based case-control study (n=1389 cases and 1396 controls), is the parent study 
upon which this research is based. It was designed to assess modifications of cancer risk 
due to genes in specific metabolic pathways that have been shown to affect cancer risk in 
prior studies of head and neck cancer and/or other types of cancer. Such candidate gene 
studies are designed to estimate the effect of genetic variants on population risk, in contrast 
to genome-wide association studies that attempt to identify chromosomal regions that are 
linked to the disease by ranking p-values, and do not estimate risk alterations. This 
dissertation project evaluated variants of the major genes that are active in metabolizing 
alcohol in the mouth, pharynx, and larynx in terms of their effect on SCCHN risk and 
survival: (1) alcohol dehydrogenase (ADH) genes; (2) acetaldehyde dehydrogenase (ALDH) 
genes; and (3) the cytochrome P450 gene CYP2E1. In addition, I examined variants of the 
primary oxidative stress genes and their effect on SCCHN risk and survival, including 
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glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT). These 
genes encode enzyme products that process carcinogenic oxygen free radicals produced 
primarily in the course of reactions catalyzed by CYP2E1 (166, 167). The prevalence of 
variants in these genes was compared between case and control groups to determine the 
risk of SCCHN. In addition, I obtained vital status of all CHANCE case participants from the 
National Death Index (NDI) in order to compare all-cause and cancer-specific death rates 
among patients by different polymorphisms of the aforementioned genes.  
The primary specific aims of this study were as follows: 
1. Estimate the main effects of each genetic polymorphism (SNPs and haplotypes) on the 
risk of developing SCCHN. My hypothesis: The polymorphisms are not associated with 
SCCHN risk in non-drinkers and light drinkers. If, however, some polymorphisms are 
found to be independently associated with risk in the absence of alcohol exposure, one 
may conclude either that study subjects misreported their drinking to be lower than it 
really is, and/or that a mechanism other than mutagenic alcohol metabolites is affecting 
cancer risk.  
2. Estimate the interactive effect of alcohol exposure with each polymorphism on the risk of 
developing SCCHN. My hypothesis: Some polymorphisms will be associated with 
SCCHN risk in the presence of alcohol exposure. If, however, no polymorphism*alcohol 
interaction is found, one may conclude that either my study was under-powered to detect 
interactions, my study did not identify the important polymorphisms using the SNPs we 
genotyped, and/or that alcohol does not interact with the major gene polymorphisms that 
are present in whites and African-Americans.  
3. Compare death rates of cases with different gene polymorphisms in order to identify 
survival differences associated with particular polymorphisms. My hypothesis: 
Polymorphisms associated with SCCHN risk in heavy drinkers at baseline will also be 
associated with their survival. If, however, this is found not to be the case, one may 
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conclude either that the lack of complete follow-up measures of alcohol intake in 
participants who were heavy drinkers before their cancer diagnosis prevents us from 
discovering whether behaviors after prognosis are associated with survival, or that the 
mechanisms that affect cancer incidence are not the same as those that affect mortality 
once cancer has occurred.  
Knowledge of higher-risk genotypes provides new insights about disease 
mechanisms, which can suggest new strategies for prevention, screening, diagnosis, and 
treatment. This may be especially useful for African-American men, who develop and die 
from SCCHN at much higher rates than white men, and women of both races.  
2.2 STUDY POPULATION 
Study area. The CHANCE geographic area (Figure 4) includes a population that is 
about one-third African American and two-thirds white, and a mix of rural and urban areas. 
Since head and neck cancers disproportionately afflict African Americans, and existing 
studies (Table 6) don’t include enough African Americans to enable precise measurement of 
odds ratios, the CHANCE study population provides valuable information on an under-
studied population (168). 
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Figure 4. Forty-six North Carolina counties from which CHANCE participants were 
enrolled. Participating counties are highlighted in white. 
 
Examination of data on county of residence compared to county of diagnosis or treatment showed a 
total of only 5 cases (0.3%) resident in the entire 46-county study area that were diagnosed outside 
the study area in a single year; therefore almost all cases occurring in the study area during the study 
enrollment period were identified as eligible for enrollment, rendering the cases population-based. 
North Carolina incidence and mortality for oral cavity and pharyngeal cancer are higher than the 
national average (15, 169, 170), such that a sufficient number of cases (>1500) were expected to 
occur in the 46 counties over the four years of the study.  
 
Cases. Cases were adults aged 20-80 with a newly diagnosed first primary invasive 
squamous cell carcinoma of the head and neck (pharynx, larynx, oral cavity) between 
January 1, 2002 and February 28, 2006. To be eligible, cases had to be residents of a 46-
county region in North Carolina. People with carcinomas of other histologies or carcinomas 
at other head and neck sites, or a history of recurrent or second primary tumors, were not 
eligible. 
Specifically included were oral cavity, including lip (mucosa) and pharynx (ICD-O-3 
topography codes CO.OO to C14.8), and larynx (C32.0 to C32.9). Excluded were tumors of 
the salivary glands (C07.9, C08.0 to C08.9), nasopharynx (C11 .0 to C11.9), nasal cavity 
(C30.0), and nasal sinuses (C31.0 to C31 .9). Tumors with the following histologies were 
included (ICD-O-3 morphology codes): 8010/3 (epithelial neoplasm, carcinoma, NOS); 
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8051/3 (verrucous carcinoma, NOS); 8070/3 (SCC, NOS); 8083/3 (basaloid SCC); 8071/3 
(SCC, keratinizing, NOS); 8072/3 (SCC, large cell, nonkeratinizing, NOS); 8073/3 (SCC, 
small cell, nonkeratinizing); 8074/3 (SCC, spindle cell); and 8076/3 (SCC, microinvasive). 
Excluded histologies included: 8010/0 (epithelial tumor, benign); 8010/2 (carcinoma, in situ, 
NOS); 8050/0-3 (papillary carcinoma); 8052/0-3 (papillary carcinoma); and 8075/3 (SCC, 
adenoid). 
To minimize recall bias and to include later stage and terminally ill subjects in the 
study, rapid identification of newly-diagnosed cancer cases was conducted by the North 
Carolina Central Cancer Registry (CCR) to ensure that pathology reports were sent from 
hospitals to the CCR more rapidly than usual. The CCR team contacted the cancer 
registrars of 54 hospitals in the study area on a monthly basis to identify potentially eligible 
head and neck cancer cases. Pathology reports were usually sent to the CCR within four 
weeks of diagnosis. Staff entered basic data on age, pathology, tumor site, and physician 
name from each report into a database, and the information was then downloaded and 
delivered to the study office at the University of North Carolina at Chapel Hill.  
Patient physicians were then notified by mail of their patient’s eligibility for the study, 
and physicians were given the opportunity to refuse to give permission to the investigators 
to contact their patient. (To promote physician cooperation, all physicians practicing in the 
study area who were listed as head and neck or ENT surgeons in the North Carolina 
Medical Society and Medical Board lists were mailed a letter and brochure at the start of the 
study describing the study and soliciting their support.) After physician notification, 
potentially eligible cases were mailed a brochure with answers to commonly asked 
questions about the study, and a letter from the CCR describing the purpose of the Cancer 
Registry and the CCR’s mission to work with researchers seeking to improve the health of 
North Carolina residents. The introduction letter explained the study purpose, the 
questionnaire, and biologic specimen collection (blood and/or mouth rinse). The letter 
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indicated that the study was completely voluntary, that participants would be paid $50 for 
completing the questionnaire, and that a study nurse would contact them by telephone to 
answer questions and schedule an appointment. Nurse-interviewers subsequently contacted 
the subjects to verify eligibility and schedule an interview in the subject’s home or other 
convenient location. Written informed consent for the interview, collection of biologic 
specimens, and collection of cases’ medical records were obtained prior to conducting the 
interview. Medical records were reviewed to verify that potential cases did indeed have one 
of the specified head and neck cancer histological types. 
Of 1827 eligible SCCHN cases, 1337 (73%) personally completed the interview, and 
of these, 1313 (96%) also provided a biological sample with sufficient DNA for analysis 
(Figure 5). 
Controls. Potentially eligible controls from the same counties as cases were 
identified through North Carolina Department of Motor Vehicles (DMV) records. Controls 
were frequency-matched to cases using random sampling with stratification on age, race, 
and sex to obtain comparability to the expected case distribution on these factors. Of 3035 
potential controls with whom contact was attempted, 1379 (45%) personally completed the 
interview (Table 7), and of these, 1368 (99%) also provided a biologic sample with sufficient 
DNA for analysis (Figure 5). 
The CHANCE study was very successful in locating eligible cases (97% located) and 
obtaining their cooperation (81%), yielding an excellent 79% case response rate of self-
completion of an interview. As with most recent population-based case-control studies, 
locating and recruiting controls was more difficult. Among potentially eligible controls, 22% 
could not be located despite intensive tracing. About 37% of eligible and located controls 
refused to participate, compared to 17% of cases, which resulted in an adequate contact 
rate of 78% and cooperation rate of 61% but an overall response rate of 47%. The overall 
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response rate for African-American controls (36% versus 51% for whites) was lower largely 
due to the greater number of unlocatable subjects. (Table 7) 
The few living participants who only completed the questionnaire without providing 
DNA (less than 1% of both cases and controls) did not differ significantly in terms of 
demographics or major risk factors (alcohol, smoking) from those who provided both 
questionnaire and DNA data. The 4% of cases (compared to 1% of controls) who died 
before they could complete the questionnaire and provide a DNA sample are also a small 
portion of the study participants; however, if survival is associated with gene variants as 
hypothesized, the associations measured in this study may be attenuated due to missing 
genotyping data for the mostly rapidly fatal cases. Therefore the source population for this 
proposed study is very similar, though not identical, to the CHANCE study population, and 
differs mainly because (1) 21 cases of lip cancer were excluded; (2) 46 cases of other race-
ethnicity were excluded; and (3) genotype data on a small percentage of rapidly fatal cases 
are not available. (Reasons for excluding lip cancer and those of “other” race-ethnicity are 
explained later in this chapter.) 
Institutional Review Board. Written informed consent was obtained from all subjects. 
The CHANCE parent study and this study were approved by the Biomedical Institutional 
Review Board at the University of North Carolina at Chapel Hill.  
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Table 7. CHANCE response rates by race  
Study subject 
status 
Total Whites African-
Americans 
Other1 Unknown 
N % N % N % N % N % 
CASES           
 Sampled 2135  1524  546  39  26  
 Ineligible 268 (12.6) 184 (12.0) 69 (12.8) 7 (17.9) 9 (34.6) 
 Physician refusal 39 (1.8) 29 (1.9) 9 (1.6) 1 (2.6) 0 - 
 Eligible (A) 1827  1311  468  31  17  
  Unlocatable (B) 50 (2.7) 27 (2.1) 19 (4.1) 1 (3.2) 3 (17.6) 
  Subject refusal 311 (17.0) 224 (17.1) 75 (16.0) 2 (6.5) 10 (58.8) 
  Deceased, no proxy 77 (4.2) 50 (3.8) 23 (5.0) 0 - 4 (23.5) 
 Eligible (A’)2 1698  1231  424  30  13  
  Completed interview – self (C’) 1337  980  330  27  0  
  Completed interview – proxy 52  30  21  1  0  
  Total interviews (C) 1389  1011  351  28  0  
 Contact rate = (A’-B)/A’ (self) 0.971  0.978  0.955  0.967  0.769  
 Cooperation rate = C’/(A’-B) (self) 0.811  0.814  0.815  0.931  -  
 Response rate = C’/A’ (self) 0.788  0.796  0.778  0.900  -  
 Response rate = C/A (self+proxy) 0.760  0.770  0.750  0.903  -  
CONTROLS           
 Sampled 4049  2803  1170  76  0  
 Ineligible 234 (5.8) 165 (5.9) 57 (4.9) 12 (15.8) 0 - 
 Not initiated 780 (19.3) 406 (14.5) 349 (29.8) 25 (32.9) 0 - 
 Eligible (A) 3035  2232  764  39  0  
  Unlocatable (B) 655 (21.6) 369 (16.5) 272 (35.6) 14 (35.9) 0 - 
  Subject refusal 875 (28.8) 672 (30.1) 196 (25.7) 7 (17.9) 0 - 
  Deceased, no proxy 109 (3.6) 77 (3.4) 32 (4.2) 0 - 0 - 
 Eligible (A’) 2909  2141  729  39  0  
  Completed interview – self (C’) 1379  1100  261  18  0  
  Completed interview – proxy 17  14  3  0  0  
  Total interviews (C) 1396  1114  264  18  0  
 Contact rate = (A’-B)/A’ (self) 0.775  0.828  0.627  0.641  -  
 Cooperation rate = C’/(A’-B) (self) 0.612  0.621  0.571  0.720  -  
 Response rate = C’/A’ (self) 0.474  0.514  0.358  0.462  -  
 Response rate = C/A (self+proxy) 0.460  0.499  0.346  0.462  -  
1 American Indian, Asian/Pacific Islander, and Other 
2 A’ is the sum of self-completed interview (C’), unlocatable (B), and number of subjects who refused to enroll. 
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Figure 5. Flowchart of biological sample processing in CHANCE cases and controls 
  
 
2.3 MEASUREMENTS 
2.3.1 Outcomes 
2.3.1.1 Incidence of head and neck cancer 
See the “Cases” portion of Section 2.2 (Study population), above.  
2.3.1.2 Mortality 
In May 2011, determination of whether death had occurred in study participants by 
December 31, 2008, and, if so, the time and cause, was obtained from the National Death 
Index (NDI), a national file of identified death record information compiled from computer 
files submitted by State vital statistics offices. The NDI is considered the gold standard for 
identifying U.S. deaths; it demonstrated the highest sensitivity ratings, as compared to other 
databases of death information, in a 2002 study (171). Currently, it is also the only source at 
the national level with a cause of death field useful for research purposes; the discrepancy 
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rate between coded cause of death in the NDI and specialist-verified coded cause of death 
is estimated to be about 4%.(171) Death records are added to the NDI file annually, 
approximately 12 months after the end of a particular calendar year. The CHANCE study 
collected excellent matching data in multiple fields: social security number (SSN), date of 
birth (DOB), sex, race, state of residence, and name. Therefore there was a high proportion 
(75%) of perfect/very close to perfect matches on SSN, DOB, and sex. A small number of 
partial matches (e.g. a few SSN digits, parts of DOB) were examined case-by-case and a 
determination was made whether to accept or not. Using NDI vital status as of December 
31, 2008, the follow-up time on CHANCE participants ranged from 2.8 to 7 years.  
2.3.2 Main exposures 
2.3.2.1 Alcohol drinking  
Alcohol drinking exposure was measured in CHANCE by self-report answers to 
questions asked on the in-person nurse-administered questionnaire (Appendix B). 
Questions about alcohol use were based on previous questionnaires used in head and neck 
cancer studies and other cancer epidemiology and nutrition studies conducted at UNC. The 
questions were designed to estimate lifetime history of alcohol consumption prior to the year 
before diagnosis, and also asked about usual consumption prior to diagnosis of SCCHN. 
The questionnaire asked about beer, wine, and hard liquor separately. For each, it asked: 
(1) Did you drink [beer/wine/hard liquor]?  
(2) At what age did you start?  
(3) At what age did you stop?  
(4) For how many years did you drink [beer/wine/hard liquor] during this period?  
(5) How much [beer/wine/hard liquor] did you usually drink?  
Per day/week/month/year?  
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(6) What size did you usually drink?  
CHANCE participants include a high number and percentage of never-drinkers (416 
or 16%), which enabled precise risk estimates because never-drinkers were used as the 
referent category. The number and percentage of drinkers of only one type of alcoholic 
beverage were small (Table 8), and the resulting imprecision of estimates rendered it difficult 
to compare risks between beverage types. Drinking rate categories have large numbers in 
each class (Table 8), with the largest numbers in the light category (<3 drinks per day). 
When comparing cases to controls (Table 8), cases include a higher proportion of past 
drinkers and a lower proportion of never-drinkers than do controls (though, interestingly, the 
proportion of current drinkers among cases and controls is about the same). Cases also 
include a much smaller percentage of wine-only drinkers (1.2% of cases versus 5.3% of 
controls), and a much higher percentage of moderate and heavy drinkers (53% of cases 
versus 18% of controls).  
In the United States, the typical alcoholic drink (12 ounces of beer, 4 ounces of wine, 
1-1.5 ounces of liquor) contains about 12-14 grams of ethanol. By this measure, 5 drinks per 
day contain about 60-70 grams of ethanol, and 6-7 drinks per day contain about 80 grams of 
ethanol. Other countries consume different types of alcoholic drinks with different amounts 
of ethanol; for example, one “go” of sake (180 ml) contains about 27 grams of ethanol, while 
one beer (half-pint) in the United Kingdom contains about 8 grams (172). For each CHANCE 
subject, I used U.S. average estimates of ethanol volume in each type of beverage (beer, 
wine, liquor) to convert number of drinks per week of each type to milliliters of ethanol, and 
combined that information with duration of drinking to estimate the lifetime total of 
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Table 8. Distribution of alcohol-drinking behaviors in cases and controls 
Category All study participants 
(n=2657) 
#  (%)* 
Cases  
(n=1290) 
# (%)* 
Controls  
(n=1367) 
# (%)* 
Timing  
(# of participants with complete data on timing: ntotal=2641, ncases=1281, ncontrols=1360) 
     Never-drinkers 416 (15.8%) 124 (9.7%) 292 (21.5%) 
     Past drinkers 749 (28.4%) 434 (33.9%) 315 (23.2%) 
     Current drinkers 1476 (55.9%) 723 (56.4%) 753 (55.4%) 
Type of alcoholic drink  
(# of participants with complete data on type of drink: ntotal=2641, ncases=1281, ncontrols=1360) 
     N/A (never drinker) 416 (15.8%) 124 (9.7%) 292 (21.5%) 
     Beer only 169 (6.4%) 100 (7.8%) 69 (5.1%) 
     Liquor only 93 (3.5%) 48 (3.7%) 45 (3.3%) 
     Wine only 88 (3.3%) 16 (1.2%) 72 (5.3%) 
     Multiple types 1875 (71.0%) 993 (77.5%) 882 (64.9%) 
Drinking rate (past or current)  
(# of participants with complete data on maximum drinking rate: ntotal=2648, ncases=1283, ncontrols=1365) 
     N/A (never drinker) 416 (15.7%) 124 (9.7%) 292 (21.4%) 
     Light (≤ 2/day) 1313 (49.6%) 483 (37.6%) 830 (60.8%) 
     Moderate (3-5/day) 396 (15.0%) 248 (19.3%) 148 (10.8%) 
     Heavy (≥ 6/day) 523 (19.8%) 428 (33.4%) 95 (7.0%) 
*Numbers may not add to total n in column header due to missing data for some participants. Percentages are calculated with 
a denominator equal to the number of participants with data (excluding those with missing data). Percentages in each category 
may not total exactly 100 due to rounding. 
ethanol consumed for each beverage. I then summed the lifetime total for each beverage 
type to construct an estimate of lifetime ethanol consumption from all alcoholic beverage 
types. For purposes of comparing CHANCE risk-by-drinking-frequency estimates to those of 
INHANCE, I standardized CHANCE drink frequencies to the INHANCE definition of 15.6 ml 
ethanol per drink (of beer, wine, or liquor).  
Alcohol variable selection and construction. Based on literature review as 
summarized by IARC (51) that concluded that frequency of drinking alcoholic beverages is 
more consistently associated with risk of SCCHN than duration of smoking, it would have 
been most desirable to construct a single drinking frequency variable for CHANCE subjects 
that integrates frequency of drinking beer, wine, and liquor. Although this was not possible 
due to the way the questions were worded, it was possible to estimate lifetime ethanol 
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consumption in milliliters. Because this variable is not standard in the literature on gene-
ethanol interaction, I (a) examined smoothed splines of SCCHN odds versus duration, 
frequency, and lifetime intake of each alcoholic beverage, to determine general patterns; (b) 
calculated the correlation between drink frequencies for individual beverages and the 
lifetime ethanol intake for all beverages combined; and (c) examined smoothed splines of 
SCCHN odds versus lifetime intake of all beverages combined for purposes of determining a 
classification scheme that would best capture the odds pattern in CHANCE data.  
Splines examined in (a) (Figure 6) indicated that the odds of getting cancer 
increased monotonically as frequency increased from 0 to 100 drinks per week, while the 
pattern for increasing duration was not consistently monotonic for each beverage type. 
When excluding subjects within the top 5% of lifetime alcohol consumption, cancer odds 
increased monotonically as lifetime consumption (of all beverage types combined) increased 
(Figure 7). I concluded that lifetime intake in milliliters of all beverage types combined is a 
reasonable substitute measure for the frequency of drinking, in terms of its effect on cancer 
odds.  
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Figure 6. Splines of log-odds of SCCHN cancer in CHANCE, versus frequency and 
duration, separately for each beverage (excluding never-drinkers) 
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Figure 7. Splines of log-odds of SCCHN cancer in CHANCE, for lifetime intake 
(excluding never-drinkers and 5% of subjects whose lifetime intake was > 400 drink-
years) 
 
 
 
Correlations (b) indicated that the frequency of drinking each type of beverage is 
most highly correlated with the lifetime total consumed of that beverage (0.87 for liquor, 0.91 
for beer, 0.93 for wine), while duration variables have very low correlation (0.28 for liquor, 
0.36 for beer, 0.23 for wine), indicating that frequency contributes more significantly to the 
lifetime total variables than duration. In addition, the correlation between each frequency 
variable and lifetime intake in milliliters (summed over all types) is also relatively high (0.81 
for liquor, 0.64 for beer, 0.53 for wine), and is much higher than for duration variables. Thus 
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the metric available in CHANCE -- overall lifetime ethanol intake -- is highly correlated with 
the preferred metric of drink frequency.  
Finally, in an effort (c) to capture the risk profile for lifetime ethanol intake yet 
maintain a practical number of categories for estimating interaction with genetic 
polymorphisms, I explored various categorization schemes, finally settling on non-drinkers 
plus tertiles of lifetime drinking. It describes the risk profile observed in the splines 
reasonably well, and the average drink frequency of beer and liquor differs widely between 
categories (about 2 drinks/week, 7 drinks/week, and 40 drinks/week), thus mimicking 
frequency categories for which the literature has described very different risks.  
Follow-up questions about alcohol use. CHANCE nurse-interviewers attempted to 
contact all cases about six months after their initial questionnaire, to ask questions about 
alcohol use that occurred after diagnosis. For each type of alcoholic beverage (beer, wine, 
liquor), participants were asked if they drank it after being diagnosed with SCCHN, and if so, 
the duration (days, weeks, months), frequency (number of drinks per day/week/month), and 
portion size they usually drank. The follow-up survey was administered to 711 of our 1227 
cases (58%), but only 392 answered the alcohol questions; i.e. only 26% of cases answered 
questions about their post-diagnosis alcohol use. Because of the high rate of missingness 
and lack of understanding about who was interviewed post-diagnosis, when they were 
interviewed, and why so many did not answer the alcohol questions, I did not use these data 
in survival analyses.  
2.3.2.2 Genetic polymorphisms 
Biological sample collection. During the in-person visit by the research nurse-
interviewers, who were trained in phlebotomy, biologic samples were obtained with the 
consent of the subjects. Two 10 ml yellow-topped vacutainer tubes (containing acid citrate 
dextrose) and one red-topped tube of whole blood (no additives) were obtained by 
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venipuncture. One yellow-topped tube was used for plasma and collection of mononuclear 
cells for subsequent DNA extraction. The other yellow-topped tube was used for plasma, 
buffy coat and packed red blood cell separation. The buffy coat was stored frozen for 
subsequent DNA extraction. The red-topped tube was used to collect serum that was stored 
for potential use in future assays. The interviewers transported the blood samples back to 
the laboratory in coolers, usually within 12 hours. In most cases, specimens were processed 
within 12-72 hours of collection. If the subject was not willing or able to consent to the blood 
draw, they were asked to contribute a non-invasive sample of buccal cells by swishing 
vigorously with 1.5 ounces of mouthwash or saline for 30 seconds, spitting the solution into 
a container, and repeating. The sealed container was then put in a plastic bag and stored in 
a cooler.  
DNA extraction. DNA was extracted from either the fresh blood specimen from one 
yellow-topped tube or from buccal cells pelleted and frozen at -80°C using a modified salt 
procedure with Puregene chemistries. DNA samples were quantified in multi-spectral optical 
density spectrophotometers. The 260/280 ratio was used to assess sample quality. Ratios of 
>1.7 for DNA extracted from blood or >1.6 for buccal rinse samples were considered to be 
quality samples. In addition, each DNA sample was subjected to 0.4% agarose gel 
electrophoresis to assess DNA size. Greater than 96% of the blood samples’ genomic DNA 
was of high quality as demonstrated by a single large band of DNA with a size greater than 
25kb. DNA from some buccal samples was of insufficient quantity for genotyping. DNA was 
aliquotted into multiple vials which were stored at -80°C for long-term storage.  
SNP selection strategies. SNPs tested in CHANCE were from candidate genes 
identified in the literature as being part of alcohol and oxidative stress metabolic pathways. 
First, tag SNPs in these candidate genes were chosen using the Genome Variation Server 
(GVS) (accessed between 2/22/08 and 4/25/08), a local database hosted by the 
SeattleSNPs Program for Genomic Applications (PGA), with the following parameters: allele 
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frequency cutoff was set to 10% and monomorphic sites were excluded; the R2 threshold 
was set to 0.8; data coverage percent for tag SNPs was set to the default 85%; and data 
coverage percent for clustering was set to the default 70%. The data merge option selected 
was “combined samples with common variations.” The populations used were primarily the 
HapMap-Ceu (unrelated only) and HapMap-YRI (unrelated only), Release 2.  
For this dissertation project, 75 SNPs were selected in 12 genes: ADH1B, ADH1C, 
ADH4, ADH7, ALDH2, CYP2E1, SOD1, SOD2, GPX1, GPX2, GPX4, and CAT. Sixty-nine 
(92%) were selected as tag SNPs for candidate genes from the GVS, and the remaining six 
were not tag SNPs but were forced in because prior research found high association 
between the SNP and either the development of aerodigestive cancer, survival from breast 
cancer, alcohol dependence, or interaction with genes in the proposed carcinogenic 
pathway for vinyl chloride. In addition, 157 ancestry informative markers selected by J. 
Barnholtz-Sloan of Case Comprehensive Cancer Center at Case Western Reserve 
University were genotyped to permit adjustment for percent African ancestry; see details 
below in the “Genetic ancestry” sub-section under section “2.3.3 Covariates.” Genotyping of 
gene-related SNPs and tag SNPs was done on the same plates in the same laboratory, thus 
eliminating errors due to differences in laboratories and techniques.   
Genotyping and quality control. Exposure to selected gene polymorphisms was 
determined by genotyping of 75 SNPs located in exon, intron, untranslated (UTR) and 
nearby regions of the ADH1B, ADH1C, ADH4, ADH7, ALDH2, CYP2E1, SOD1, SOD2, 
GPX1, GPX2, GPX4, and CAT genes (see Table 9). Genotyping was done by the University 
of North Carolina at Chapel Hill, Mammalian Genotyping Core Facility, using the Illumina 
GoldenGate genotyping assay with Sentrix Array Matrix and 96-well standard microtiter 
plates (173),  a multiplexing technique that tests for 1,536  SNPs simultaneously. The SNPs 
in Table 9 that were analyzed in this dissertation project were genotyped as part of a larger 
panel of 1,536 SNPs.  
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The Illumina GoldenGate technology has been widely used, for example in phase I of 
the International HapMap Project (174). Locus specificity is attained by a two-step 
recognition that includes annealing of both upstream and downstream oligonucleotides to 
the SNP site, followed by enzymatic mismatch discrimination to attain additional genomic 
specificity and selectivity for a particular allele. This is followed by allele-specific primer 
extension and ligation, assay amplification, and hybridization of multiplex PCR amplification 
products to a universal array of address sequences. Strict washing protocols remove excess 
and incorrectly hybridized probes. When CHANCE samples were genotyped, technicians 
were blinded to case/control status of the samples, and samples from both cases and 
controls were tested on each plate, along with DNA controls and random sample duplicates. 
Assay intensity data and genotype cluster images for all SNPs were individually 
reviewed; as a result, 14 SNPs (including 12 AIMs) from this study were excluded from the 
dataset (6%) due to inadequate signal intensity or inability to distinguish genotype clusters. 
All specimens had less than 4% missing SNP results. Blind duplicates of 109 samples were 
genotyped to verify reliability of genotype calls. Among the 109 samples’ paired results, 
145,568 non-missing pairs of SNPs were examined for agreement; of these, five pairs 
(0.003%) were discrepant, but not for any of the SNPs and AIMs to be used in my analyses. 
Tests of Hardy-Weinberg equilibrium (HWE) were conducted in controls stratified by race; 
35 SNPs were judged to be out of HWE due to p-value less than 0.001, including one tag 
SNP each in ADH1C and ADH4 that were to be analyzed in this dissertation project (Table 
9). These two SNPs were excluded from all analyses.  
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Table 9. List of SNPs genotyped in or near metabolic genes, by gene, in 
ascending position order 
 
 
Gene SNP ID Alleles 
(ancestral/
variant) 
Average 
heterozygosity 
(140) 
Functional location 
within gene 
SNP 
selection 
method 
 
ADH1B (ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide [ Homo sapiens ])  
Location: 4q21-q23 
 
 rs12507573 A/C 0.420 vicinity of gene GVS-tag  
 rs1042026 A/G 0.493 exon 9 (3’ UTR) GVS-tag  
 rs170333 A/G 0.190 exon 9 (3’ UTR) GVS-tag  
 rs7673353 C/T 0.104 intron 8 GVS-tag  
 rs17028834 C/T 0.082 intron 7 GVS-tag  
 rs1693457 C/T 0.237 intron 5 GVS-tag  
 rs41475363 G/T 0.344 intron 3 GVS-tag  
 rs1229984 A/G 0.397 missense (104)  
 rs13536213 A/G 0.302 intron 1 GVS-tag  
 rs1159918 G/T 0.484 3’ near gene GVS-tag  
 rs1229982 G/T 0.346 3’ near gene GVS-tag  
ADH1C (alcohol dehydrogenase 1C (class I), gamma polypeptide [ Homo sapiens ]) 
Location: 4q21-q23 
 
 rs2298753 C/T 0.102 exon 9 (3’ UTR) GVS-tag  
 rs1614972 C/T 0.495 intron 8 GVS-tag  
 rs1391088 A/C 0.073 intron 8 GVS-tag  
 rs6983 A/(G/T) 0.389 exon 8 (both missense) (116)  
 rs1693482 G/A 0.366 exon 6 (missense) GVS-tag 
(116, 175-177) 
 
 rs1631460 C/G 0.239 intron 5 GVS-tag  
 rs22418943 A/G 0.487 exon 5 (synonymous) GVS-tag  
 rs37628961 C/T 0.496 intron 3 GVS-tag  
 rs11936869 C/G 0.478 intron 1 GVS-tag  
ADH4 (alcohol dehydrogenase 4 (class II), pi polypeptide [ Homo sapiens ]) 
Location: 4q21-q24; 4q22 
 
 rs29001227 A/T 0.083 intron 8 GVS-tag   
 rs1126672 C/T,A,G 0.214 exon 8 (T synonymous; 
A,G missense) 
GVS-tag  
 rs4699710 C/T 0.325 intron 6 GVS-tag  
 rs10017466 C/T 0.309 intron 5 GVS-tag  
 rs1800759 A/C 0.499 5’ near gene GVS-tag  
 rs1800761 A/G/T 0.435 5’ near gene GVS-tag   
 rs3762894 C/T 0.471 5’ near gene GVS-tag  
 rs41488843 A/G 0.347 5’ near gene GVS-tag  
ADH7 (alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide [Homo sapiens]) 
Location: 4q23-q24 
 
 rs284787 C/T 0.435 exon 9 (3’ UTR) GVS-tag  
 rs894369 C/G 0.325 exon 9 (3’ UTR) GVS-tag  
 rs17588403 A/T 0.178 intron 8 GVS-tag  
  70 
Table 9. List of SNPs genotyped in or near metabolic genes, by gene, in 
ascending position order 
 
 
Gene SNP ID Alleles 
(ancestral/
variant) 
Average 
heterozygosity 
(140) 
Functional location 
within gene 
SNP 
selection 
method 
 
 rs1154454 C/T 0.315 intron 7 GVS-tag  
 rs1154456 C/T 0.347 intron 7 GVS-tag  
 rs1154460 A/G 0.485 intron 6 GVS-tag  
 rs971074 G/A 0.221 exon 6 (synonymous) GVS-tag  
 rs1573496 G/C 0.172 exon 3 (missense) (104)  
ALDH2 (aldehyde dehydrogenase 2 family (mitochondrial) [Homo sapiens]) 
Location: 12q24.2 
 
 rs4767939 A/G 0.487 intron 1 GVS-tag  
 rs2238151 C/T 0.377 intron 1 GVS-tag  
 rs7312055 A/G 0.164 intron 2 GVS-tag  
 rs2158029 A/G 0.411 intron 12 GVS-tag  
 rs16941667 C/T 0.134 intron 12 GVS-tag  
 rs16941669 G/T 0.165 intron 12 GVS-tag  
CYP2E1 (cytochrome P450, family 2, subfamily E, polypeptide 1 [Homo sapiens]) 
Location: 10q24.3-qter 
 
 rs3813865 C/G 0.256 5’ near gene GVS-tag  
 rs3813867 C/G 0.153 5’ near gene (123, 178, 179)  
 rs9159063 C/T 0.469 intron 2 GVS-tag  
 rs8192772 C/T 0.269 intron 2 GVS-tag  
 rs64134191 G/A 0.101 exon 4 (missense) GVS-tag  
 rs915908 A/G 0.235 intron 5 GVS-tag  
 rs915909 C/T 0.064 exon 6 (synonymous) GVS-tag  
 rs7092584 C/T 0.416 intron 6 GVS-tag  
 rs743535 C/T 0.353 intron 6 GVS-tag  
 rs25156413 C/T 0.404 exon 8 (synonymous) GVS-tag  
 rs2249695 C/T 0.494 intron 8 GVS-tag  
 rs28969387 A/T 0.031 exon 9 (missense) GVS-tag  
 rs11101812 C/T 0.041 exon 9 (3’ UTR) GVS-tag  
SOD1 (superoxide dismutase 1, soluble [Homo sapiens]) 
Location: 21q22.11 
 
 rs11910115 A/C 0.070 5’ near gene GVS-tag  
 rs4998557 A/G 0.456 intron 1 GVS-tag  
 rs10432782 G/T 0.409 intron 2 GVS-tag  
 rs2070424 A/G 0.377 intron 3 GVS-tag  
 rs1041740 C/T 0.370 intron 4 GVS-tag  
SOD2 (superoxide dismutase 2, mitochondrial [ Homo sapiens ]) 
Location: 6q25.3 
 
 rs4342445 A/G 0.390 vicinity of SOD2 GVS-tag  
 rs2842980 A/T 0.471 3’ near gene GVS-tag  
 rs8031 A/T 0.380 intron 5 GVS-tag  
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Table 9. List of SNPs genotyped in or near metabolic genes, by gene, in 
ascending position order 
 
 
Gene SNP ID Alleles 
(ancestral/
variant) 
Average 
heterozygosity 
(140) 
Functional location 
within gene 
SNP 
selection 
method 
 
 rs5746134 C/T 0.104 intron 5 GVS-tag  
 rs2758331 A/C 0.393 intron 4 GVS-tag  
 rs48803 C/T 0.460 vicinity of SOD2 GVS-tag  
GPX1 (glutathione peroxidase 1 [Homo sapiens])  
Location: 3p21.3 
 
 rs8179172 A/T 0.070 vicinity of GPX1 GVS-tag  
 rs1800668 C/T 0.274 exon 1 (5’ UTR) GVS-tag  
 rs3811699 A/G 0.302 5’ near gene GVS-tag  
 rs3448 C/T 0.316 exon 5 (3’ UTR) GVS-tag  
GPX2 (glutathione peroxidase 2 (gastrointestinal) [Homo sapiens]) 
Location: 14q24.1 
 
 rs11623705 G/T 0.136 3’ near gene GVS-tag  
 rs2412065 C/G 0.367 intron 1 GVS-tag  
 rs2737844 C/T 0.474 intron 1 GVS-tag  
GPX4 (glutathione peroxidase 4 (phospholipid hydroperoxidase) [ Homo sapiens ]) 
Location: 19p13.3 
 
 rs757229 C/G 0.493 5’ near gene (180)  
CAT (catalase [Homo sapiens]) 
Location: 11p13 
 
 rs1049982 C/T 0.357 exon 1 (5’ UTR) (181) (2)   
1Genotype results questionable due to being out of Hardy-Weinberg equilibrium at the exact p<0.001 
level.  
2Also selected due to unpublished finding from the Carolina Breast Cancer Study.  
3Genotyping failed. 
 
 
Cross-checking of genetic data for inconsistencies was accomplished using 
computerized algorithms implemented in SAS. The algorithms checked that genetic sex 
determination matched the study sex variable; one sample was discrepant on sex so its 
genotyping results were discarded. In addition, genotyping of controls that was performed 
on each plate was determined to be accurate, and there were no identical genotypes among 
unique samples. Analysts also looked for patterns among samples that were unsuccessful, 
such as plate location, DNA concentration, volume, or total DNA amount. SNP 
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inconsistencies and plate problems were resolved, either by re-testing and calling, else 
being set to missing. 
As part of this dissertation project, statistical tests for Hardy-Weinberg equilibrium 
(HWE) of each SNP’s genotype distribution were conducted separately for each race in the 
control population, to verify previous HWE tests. DNA samples were not available from 52 
cases and 17 controls because they had died before they could be interviewed (their 
questionnaires were completed by a proxy). This represents 4% of all cases interviewed and 
1% of all controls interviewed, and therefore would have only a small effect on effect 
estimates.  
2.3.3 Covariates: potential confounders and effect measure modifiers 
A causal diagram for development of SCCHN is shown in Figure 8. There are known bi-
directional associations between ethanol/tobacco use and gene expression, ethanol/tobacco 
use and diet, and oral health and diet. Because all of the factors listed can conceivably 
affect both gene expression and cancer outcome, I included all these variables in the initial 
models, using a 10% (0.1) change in log-odds estimate from the full model as the criterion 
for final variable selection, and used the reduced model in regression analyses (182). 
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Figure 8. Causal diagram for development of SCCHN 
 
Dotted line indicates hypothesized causal connection between main exposure, gene 
sequence/expression, and SCCHN incidence. Note bi-directional, mutual effects of (1) ethanol 
ingestion and gene expression, (2) tobacco use and ethanol ingestion, (3) tobacco use and diet, (4) 
ethanol ingestion and diet, and (5) oral health and diet.  
 
Genetic ancestry. Case-control studies assume that, barring confounding effects, 
differences in allele frequency between cases and controls are related directly to the trait of 
interest. However, differences in allele frequency between cases and controls may be due to 
systematic differences in ancestry (i.e. population stratification) rather than the association 
of genes with disease, making ancestry a potential confounder of any association between 
gene and disease. Population stratification is present in recently admixed populations such 
as African Americans and Latinos, but also in European Americans and even in historically 
isolated populations such as Tibeto-Burmese and Icelanders (183). Most residents of North 
Carolina are of European and African ancestry, with only a small percentage reporting 
American Indian and Asian ancestry. Because this study excluded the small number of 
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those reporting “other” race-ethnicity (n=46), all remaining study participants are self-
identified as either African American or white. Therefore the appropriate ancestral 
populations for CHANCE participants are European and West African, whose genetic 
variations have been measured in the CEU and YRI HapMap populations, respectively.  
For population stratification to exist, both (1) the frequency of the SNP allele and (2) 
the background disease prevalence must vary significantly by race-ethnicity. First, SCCHN 
disproportionately affects a higher percentage of African-Americans than whites. Second, of 
the six non-synonymous candidate gene SNPs genotyped in CHANCE for this study, three 
have very different allele frequencies in HapMap CEU and YRI populations (HapMap Data 
Rel 27 Phase II+III, Feb09, on NCBI B36 assembly, dbSNP b126): 
1. rs1693482 (ADH1C): 48% of the CEU population carries the variant T allele, 
compared to only 5% of the YRI population;  
2. rs698 (ADH1C): 47% of the CEU population carries the variant C allele for compared 
to 6% of YRI;  
3. rs6413419 (CYP2E1): 2% of the CEU population carries the variant A allele 
compared to 30% of YRI.  
4. rs1573496 (ADH7): 9% of the CEU population carries the variant G allele compared 
to 0% of YRI 
5. rs28969387 (CYP2E1):  0% of the CEU population carries the variant T allele 
compared to 4% of YRI 
Therefore it is possible that genetic ancestry is a confounder in the CHANCE study 
population.  
Sometimes stratifying effect estimates by self-reported race-ethnicity may be 
sufficient to control for ancestry, but populations in the United States are recently admixed, 
causing increased inter-individual variation in ancestry. In the United States and many other 
countries, in addition to genetic ancestry, cultural and behavioral factors influence 
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individuals’ self-identified race-ethnicity, such that race-ethnicity should be recognized as a 
complex composite construct of genetic and environmental/social factors rather than a 
simple marker of genetic ancestry. One case-control study conducted in Detroit, Michigan, a 
highly admixed population with German, Polish, and African origins, reported that adjusting 
for ancestry provided better control of confounding by ancestry than adjusting for self-
reported race (184). Another study (not case-control) analyzed frequency of risk genotypes 
in six drug metabolizing genes in individuals from eight international populations (including 
Africans, Europeans, Ashkenazi Jews, Chinese, Pacific Islanders, and Afro-Caribbeans), 
and found not only that they varied by ancestral group, but that self-reported race was an 
inaccurate and insufficient marker of these ancestral clusters (185). 
Correcting for inter-individual differences in ancestry in the CHANCE study required 
genotyping additional SNPs. Genomic control (GC) was the first method described in the 
literature to adjust for potential population stratification. GC uses random genomic SNPs 
across the genome and calculates a single numeric adjustment to be applied to all 
association tests. A separate adjustment can be calculated for each race-ethnicity. It 
considers group-level stratification only (as defined by self-reported race-ethnicity), and 
controls for Type I error but not Type II. Although ancestry informative markers (AIMs), 
markers that have large allele frequency differences between ancestral populations, can 
also be used in genomic control methods, it is not recommended since additional Type I 
errors will result because the method will over-correct for the large differences in AIM 
frequencies between different populations.  
Because estimating individual ancestry has been shown to provide better control of 
confounding by ancestry than genomic control, CHANCE genotyped 157 SNP AIMs 
(Appendix A) on each participant. In order to obtain robust individual ancestry estimates, 
ideal AIMs would have one fixed, unique allele in each ancestral European and African 
population. It has been estimated that at least 72 ideal markers would be required to obtain 
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ancestry estimates with acceptable confidence limits (186). Since ideal markers are 
relatively rare in the genome, researchers must select the most informative markers from the 
remaining suboptimal markers (187). Both Bayesian and maximum likelihood estimation 
(MLE) methods can be used to calculate ancestry using the AIMs, and both methods 
produce similar results in information-rich scenarios (i.e. markers are informative and 
ancestral groups are large and accurate), but MLE is computationally much less intensive 
and does not require inclusion of genotype information from ancestral groups as the 
Bayesian methods do for estimation stability (188). In addition, interpretation of the results 
from the Bayesian methods can sometimes be confusing as it is not necessarily readily 
apparent which of the estimated clusters is related to which ancestral group. Therefore MLE 
was chosen to estimate ancestry in CHANCE participants.  
One disadvantage of MLE methods is that they cannot easily estimate percent 
ancestry of more than two ancestral groups, though this should not be a major problem in 
CHANCE. And our AIMs in particular were not selected to identify Asian or Native American 
ancestry, so that study subjects self-reporting their race as “Other” could not be included in 
analyses of all participants even if that analysis should be desired.  
Jill Barnholtz-Sloan, a CHANCE collaborator at Case-Western Reserve University, 
selected the CHANCE SNP AIMs to maximize (1) the difference in allele frequencies (delta) 
between European and African populations in the HapMap data (CEU versus YRI), and (2) 
the Fisher’s information criterion (FIC) which is the inverse of the maximum likelihood 
estimation (MLE) of the ancestral proportion and therefore is directly related to the precision 
of the ancestry estimate (187). FIC is calculated using the allele frequencies and the 
estimated proportions of mixture of the two populations. AIMs were prioritized based on 
having the highest delta values and the highest FIC values in the following order: 90% 
European/10% African, 10% European/90% African, and 50% European/50% African. This 
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prioritization scheme allowed AIMs to be chosen to represent the whole expected ancestral 
distribution of this population. Individual estimates of African ancestry were calculated from 
141 successfully genotyped AIMs using maximum likelihood estimation methods previously 
described by Barnholtz-Sloan (184, 189). MLEs were calculated using customized software 
written by Barnholtz-Sloan and her team; other software that also estimates individual 
ancestry using MLE, such as FRAPPE (188), could also have been used. AIMs were 
chosen to differentiate between African and European ancestry only, so individual ancestry 
proportions for the two groups sum to 1.0. Percent African ancestry of each participant was 
included as a continuous covariate in full/initial logistic and proportional hazard regression 
models using the entire study population. 
Demographics. Controls were matched to cases on age group, self-reported race, 
and sex, so were included as stratification variables in conditional logistic regression 
analyses. As another measure of the sociodemographic factors for which self-reported race-
ethnicity is a marker, CHANCE collected information on education level (less than high 
school, high school or above) and income (either above or below the federal poverty level, 
based on income and the number of people supported). I included both in full/initial 
regression models.  
Tobacco Use. Because tobacco use is known to be an important risk factor for 
SCCHN, CHANCE collected detailed self-reported information about each participant’s 
history of cigarette, cigar, pipe, snuff and chewing tobacco use. Subjects were asked the 
age they started using the specific form of tobacco, current status, if and when they stopped, 
years of use, and the number used. In addition, information about use of filter brand 
cigarettes, size of chewing tobacco and snuff packages, and time to completely use a 
container were obtained. Subjects were asked about smoking among other family members 
and individuals living in the same household to quantify potential environmental tobacco 
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smoke (ETS) exposures. With this information, indices of tobacco use were constructed, 
including average number of cigarettes smoked per week, years of smoking, and pack-
years. Based on current consensus in the literature, I adjusted for cigarette smoking by 
including duration of smoking in regression models. Exposure to environmental tobacco 
smoke (ETS) at home and at work was included in initial models as two separate 
dichotomous covariates. Smoking variables that changed the main effect estimate by 10% 
or more were retained in all subsequent models.  
Diet. Because fruit and vegetable intake is the major dietary influence on SCCHN, 
and intake patterns are altered among heavy drinkers (and ADH, ALDH, and possibly 
CYP2E1 are associated with alcoholism), the CHANCE diet questions focused primarily on 
fruit and vegetable consumption. However, in order to explore associations between other 
dietary components that may be related to SCCHN, CHANCE used an assessment that 
captures total diet. Dietary intake was measured using the 60-item version of a validated 
food frequency instrument (FFQ), the NCI Health Habits and History Questionnaire (190). 
This instrument assesses respondents' frequency of consumption and usual serving size for 
60 foods. It has been validated with various populations including low income and African-
American populations (191). A software package available from the National Cancer 
Institute, the Dietary Analysis Personal Computer System (DIETSYS.V30), uses this 
information and an updated database to compute nutrient intake based on nutrient content 
of each food and serving. Initially I intended to adjust separately for dietary intake of fruits 
and vegetables using a quintile-based categorization of number of fruits and vegetables 
eaten daily. However a large percentage of subjects were missing information on fruit and 
vegetable intake, and those missing the information were often at the high extreme of total 
caloric intake. I concluded that including these variables would inordinately bias effect 
estimates, so these variables were excluded from regression analyses.  
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Anatomic location and clinical factors. I included tumor location in five categories 
(oral cavity; oropharynx; hypopharynx; larynx; oral cavity, oropharynx, hypopharynx cancer 
NOS) as recommended by INHANCE (52) in logistic and Cox regression analyses having 
any SCCHN as the outcome. In secondary analyses, to explore risk factor differences by 
anatomic location of tumor, I stratified analyses by these five anatomic sub-sites.   
Survival analyses took into account TNM stage that was abstracted from patients’ 
medical records, which I divided into three ordinal variables (tumor, node, and metastasis 
stages). Cancer summary stage was abstracted from TNM staging that was obtained from 
patients’ medical records and was entered into models as an ordinal variable. Recent 
survival studies on head and neck cancer have usually controlled Cox regression analyses 
for stage using separate tumor and node variables, only including metastasis if any of their 
patients were diagnosed with metastatic disease. I included separate T, N, and M variables 
in my Cox proportional hazards models, but also ran analyses using the single ordinal 
summary stage variable, and results were similar.  
Treatment types were recorded as surgery, radiation, and chemotherapy, which I 
included in models as three dichotomous variables. Additional clinical information on 
presence of angiolymphatic invasion was included in Cox regression models as a 
dichotomous variable. Margin status, although available, was eliminated by backwards 
elimination and therefore excluded from final models. Information on extracapsular 
extension was available on less than 15% of subjects, so was excluded from all models.  
Four dichotomous variables representing selected co-morbid diseases were included 
in full/initial Cox models: liver disease and/or hepatitis, cardiovascular and/or lung disease, 
renal disease and/or diabetes, and other cancer. A numeric variable counting the number of 
co-morbid diseases was also included in initial logistic and Cox regression models, but did 
not change effect estimates and was excluded from final models.  
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Other Factors. Other factors for which CHANCE collected data are oral health and 
mouthwash use; medical history; and family history of cancer in first degree relatives.  
A recent study analyzing CHANCE data to investigate the association between oral 
health factors and incidence of SCCHN provided support for a modest association of 
SCCHN with periodontal disease, as measured by self-reported tooth loss indicators (such 
as tooth mobility, dichotomous, yes or no; having had one or more routine dental visits 
during the 10 years prior to SCCHN diagnosis, dichotomous, yes or no). However, there was 
no association between SCCHN and number of natural teeth lost excluding third molars and 
teeth extracted for orthodontic reasons (coded as a 3-level indicator variable for number of 
lost teeth: 0-5 (referent), 6-15, and 16-28). Consistent use of mouthwash (dichotomous, yes 
or no) showed evidence of a protective effect only for pharyngeal cancer (192). In addition, 
oral health factors are probably altered among heavy drinkers (and heavy drinking is 
associated with ADH and ALDH polymorphisms, and possibly CYP2E1 polymorphisms as 
well). Therefore I included, as dichotomous variables (yes/no), tooth mobility, routine dental 
visits, and mouthwash use in initial models, retaining them in all subsequent models if they 
change effect estimates by >10%. None of these variables were important in SCCHN 
incidence models, but routine dental visits and tooth mobility variables were retained in 
some survival models.  
Family history of cancer in first degree relatives, especially head and neck cancer, 
has been shown to increase risk of head and neck cancer in probands (see above, section 
1.3.1 “Heredity”) and may well be associated with the genetic polymorphisms under study. 
Therefore I included in initial models one dichotomous (yes/no) variable for having had any 
first degree relatives with head and neck cancer. However, this variable did not change 
effect estimates and was excluded in all final models.  
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2.4 STATISTICAL POWER 
Specific Aim 1: Main effects of genotype exposure on power of logistic regression 
analyses:  
(Refer to Table 10 for power estimates based on genotype prevalence and size of 
study.) At an α level of 0.05, for calculating the main effect of a binary genotype exposure 
(any minor allele versus none) occurring at a frequency of 0.10 to 0.30 in the entire study 
population, this study had insufficient power (defined as less than 80%) to detect an OR of 
1.2 but sufficient power to detect higher ORs. As it turned out, the minor allele of 80% of our 
SNPs had population prevalence >10%, so we had power to detect ORs of about 1.4 or 
higher for most SNPs. Power to detect main effects of genotype in the African-American 
participants was insufficient for genotype prevalence ≤20% when the OR is less than 2.0, 
but the study should have been able to detect main effects in the African-American 
population if the genotype prevalence is >20% (which occurred in 78% of SNPs in African-
American subjects) and the OR >=1.8. 
(Refer to Table 5 for estimates of main gene effects.) For genotype prevalence of 
10% in all study subjects combined, there was sufficient power to detect effects of 5 of 8 
SNPs in ADH1B, for which previously estimated protective effects ranged from 0.42 to 0.56 
and risk effects ranged from 2.20 to 2.67. There was marginal (70-80%) power to detect 
effects of ADH1C, for which previously measured risk effects ranged from 1.20 to 1.49 with 
one imprecise outlier of 7.39. The study had sufficient power to detect effects of SNPs in 
ADH4 and ADH7 with previously measured protective estimates of about 0.68 and risk 
estimates ranging from 1.62 to 1.96. The study had sufficient power to detect ORs of 1.30 
for ALDH2 polymorphisms common in European Caucasians, and ORs of 1.8 to 2.6 for 
CYP2E1 SNPs common in European Caucasians. Power estimates in whites should be 
similar to those of the entire group, though power was not sufficient to detect main effects of 
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ADH1C if OR<1.4. It should be noted that <10% minor allele prevalence occurred in one-
third of our ADH1B SNPs and half our CYP2E1 SNPs, so we had insufficient power to 
detect any effects of those SNPs.  
Because essentially no previous studies have measured gene effects in African and 
African-American populations, effect estimates were unknown in this population prior to this 
study. Assuming that effect estimates in European Caucasians and European Americans 
also apply generally to African-Americans, this study would have had insufficient power to 
detect effect estimates less than 2.0 in African-Americans (e.g. ADH1C, ADH4, ADH7, and 
ALDH2), but sufficient power to detect previously reported effects of some ADH1B and 
CYP2E1 polymorphisms. Power was insufficient to detect effects of ADH4 and ADH7 
polymorphisms except those that were present in 30% or more of the African-American 
population, which was the case for about half of ADH4 and ADH7 SNPs.  
For oxidative stress genes (CAT, SOD1, SOD2, GPX1, GPX2, and GPX4) this study 
had insufficient power to detect main effect ORs of 1.2 to 1.3 in the entire study population 
and in African-Americans and whites separately. ORs would have to be higher than that 
reported for most polymorphisms (at least 1.4) to detect a main effect in the entire study 
population, and at least 1.8 in the African-American participants. 
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Table 10. Study power for main gene effects  
 
Genotype 
prevalence 
 
Odds ratio 
 
Study power, all 
participants 
(ncases=1274, 
ncontrols=1343) 
 
Study Power,  
white 
participants 
(ncases=952, 
ncontrols=1089) 
 
Study Power, 
African-American 
participants 
(ncases=322, 
ncontrols=254) 
10% 1.2 30% 25% 8% 
 1.5 92% 84% 27% 
 1.8 >99% >99% 53% 
 2.0 >99% >99% 70% 
20% 1.2 48% 39% 12% 
 1.5 99% 97% 43% 
 1.8 >99% >99% 76% 
 2.0 >99% >99% 90% 
30% 1.2 58% 48% 14% 
 1.5 >99% >99% 52% 
 1.8 >99% >99% 85% 
 2.0 >99% >99% 95% 
 
Calculations were done in Episheet.xls as described in Rothman & Boice (193).  
Assumptions: α=0.05 and case/control ratio=1.054 
 
Specific Aim 2: Interactive effects of genotype and alcohol exposure on power of logistic 
regression analyses:  
Table 11 contains estimates of study power for detecting alcohol-SCCHN 
multiplicative interaction. At an α level of 0.05 the study would have >90% power to detect 
2X gene-alcohol multiplicative interactions, assuming:  
1. The prevalence of heavy drinking at 1 year prior to diagnosis for cases, and 
reference date for controls, defined as ≥6 drinks per day, is 19.8% (as shown in 
Table 8). 
2. The prevalence of SCCHN in low drinkers (<6 drinks per day) is 0.1%.  
3. An OR of 1.5 to 3.0 was assumed for the independent effect of heavy drinking on 
SCCHN risk, based on the literature review of risk in non-smokers (Table 3).  
4. The at-risk genotype had a prevalence of 20% or greater. There would be 
inadequate power (<80%) when prevalence is 10% or less.  
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When designing this study I had planned to test for departures from multiplicative 
interaction, but during the analysis phase, decided to test for departures from additive 
interaction instead, as it is thought to be more biologically relevant. At that time I re-
calculated our power for additive interaction, using the characteristics of my CHANCE-
derived study population to set parameters. 
Table 12 contains estimates of study power for detecting alcohol-SCCHN additive 
interaction. At an α level of 0.05 the study would have >80% power to detect 2.5X gene-
alcohol additive interactions in 1227 cases and 1325 controls, assuming: 
1. The prevalence of non-drinkers was 16%, and the proportion of drinkers in each 
category of lifetime drinking was about 28%.  
2. The minimum excess OR to be detected was set to 2.5. For additive interaction, 
this is equal to: (OR11-1) / (OR10-1 + OR01-1). 
We had sufficient power to detect 2.5x additive interactions only when the genotype 
distribution was either 50/50 or 40/60. This was true for 39 of our 64 SNPs (60%), including 
all but one of our ALDH2 SNPs and all our CYP2E1 SNPs. As a result we were not able to 
detect additive interaction, even if present, for most of our SNPs, unless the excess OR was 
larger than 2.5.  
(Refer to Table 6 for a list of studies that investigated gene-alcohol interaction.) 
Seven studies reported ADH1B interaction with alcohol exposure; two reported greater than 
multiplicative interaction, four reported interactions greater than additive though less than 
multiplicative, and one reported interaction with no information on type. Only one study 
reported no interaction of ADH1B with alcohol. Three studies reported ADH1C interaction 
with alcohol exposure; all indicated greater than both additive and multiplicative interaction. 
However four studies reported no interaction of ADH1C with alcohol. Four studies reporting 
CYP2E1 interactions with alcohol exposure reported greater than 2x multiplicative (1 study), 
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2x multiplicative (1 study), and greater than additive, less than multiplicative (one study), but 
seven studies reported no interaction with alcohol. It was often difficult to determine the type 
of gene-alcohol interaction (greater than additive, greater than multiplicative, or somewhere 
in between) because often the main effect OR for alcohol exposure was not provided. Our 
study had sufficient power to detect 2x multiplicative interaction when the variant genotype 
is present in at least 15% of participants, and sufficient power to detect 2.5x additive 
interaction when the variant genotype is present in at least 40% of participants. 
 
Table 11. Study power for detecting gene-alcohol multiplicative interactions 
Genotype 
prevalence 
Exposure 
prevalence  
Exposure OR Genotype OR 2x 
Interaction OR 
(in the doubly 
exposed) 
Study power 
30% 19.8% 3.0 1.5 9.0 96% 
  2.5  7.5 96% 
  2.0  6.0 96% 
  1.5  4.5 96% 
20% 19.8% 3.0 1.5 9.0 92% 
  2.5  7.5 92% 
  2.0  6.0 92% 
  1.5  4.5 91% 
10% 19.8% 3.0 1.5 9.0 74% 
  2.5  7.5 74% 
  2.0  6.0 74% 
  1.5  4.5 73% 
Calculations were done in POWER version 3.0 from the National Cancer Institute (194).  
Assumptions: α=0.05, case/control ratio=1.054 
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Table 12. Study power for detecting gene-alcohol additive interactions 
Genotype 
prevalence 
OR01 (only exposed to alcohol, not minor 
allele) = 2.0 
OR10 (only exposed to minor allele, non-
drinker) = 1.0 
 
OR01 (only exposed to alcohol, not minor 
allele) = 2.0 
OR10 (only exposed to minor allele, non-
drinker) = 0.6 
50% 0.94 0.81 
40% 0.92 0.78 
30% 0.87 0.73 
20% 0.76 0.61 
10% 0.49 0.39 
Calculations were done in POWER version 3.0 from the National Cancer Institute (194).  
Assumptions: α=0.05, case/control ratio=1.08 
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Specific Aim 3: Main effects of genotype exposure on power of survival analysis using 
cases only (195, 196) 
At an α level of 0.05, assuming frequency of all-cause deaths at 0.394 (based on the 
actual number of deaths in my study through 2008 from any cause), the study had sufficient 
power to detect a hazard ratio (HR) of 1.3 or greater for death from any cause (Table 13). 
Because the frequency of deaths from head and neck cancer is lower – 17.5% – we would 
have sufficient power to detect a hazard ratio of 1.5 or greater for cancer-specific death.  
The only study that has investigated overall and disease-specific hazard of survival 
in SCCHN patients (150) reported “hazard of survival” ratios of 0.3 to 0.4 which would 
correspond to a greater than 3.0 “hazard of death” ratio. This study would have good power 
to detect HRs of 2.0 to 3.0.  
 
Table 13. Study power for main gene 
effects on survival 
 
Hazard ratio Death rate = 
0.394 (death 
from any 
cause) 
Death rate = 
.175 (death 
from head and 
neck cancer) 
1.2 48% 24% 
1.3 78% 45% 
1.4 94% 65% 
1.5 99% 81% 
2.0 100% 100% 
 
Calculations were done in PASS 11 (195) 
Assumptions: α=0.05, number of cases=1227 
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2.5 ANALYSIS PLAN  
2.5.1 Issues for all analyses 
For use in all regression models, individual estimates of African ancestry were 
calculated from 157 AIMs using maximum likelihood methods (as described in (184, 189)). 
AIMs were selected to differentiate only between African and European ancestry, so 
participants with “Other” race-ethnicity were excluded from the primary analysis. Allele and 
genotype frequencies, and tests of HWE, were calculated using SAS Genetics (197). To 
identify ancestry outliers in the populations, I used a box test on the ancestry estimates 
(198). For application of this method the upper and lower fourth of the ordered observations 
are determined. Outliers are those values that exceed the upper or lower fourth by more 
than 1.5fs, where fs is the upper fourth minus the lower fourth (75% #–25% #). When testing 
the ancestry variable during backwards elimination from a full model, ancestry was not 
important to any of the SNP models, regardless of whether I used all calculated ancestry 
values or discarded the outliers identified by this method.  
Haplotypes have some advantages over single SNP tests of association, in that they 
can capture information about multiple causal/interacting cis-mutations in the same gene 
that are relevant to disease risk or survival. Although some authors have suggested that 
haplotype analysis is much less powerful than single SNP analysis when looking for gene-
disease association (199, 200), others (e.g. (201, 202)) suggest that haplotype analysis can 
be more powerful when the true causal SNPs are not typed (as in this study, since most are 
tag SNPs) and when there are multiple disease-causing alleles or even interactions. 
Because haplotyping can only be done on SNPs that are in high linkage disequilibrium (LD), 
I verified that the SNPs for each gene are indeed highly correlated using HaploView 4.2 
(203)  to make LD plots in African-American and white controls.  
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There are two main classes of statistical methods currently used for estimating 
haplotypes: expectation maximization (EM) based on likelihood theory, and Bayesian 
estimators (204). For this research I employed Haplo.stats (205), a widely used EM method 
implemented in S-Plus/R, to estimate haplotypes and test their association with SCCHN risk 
and survival. Haplo.stats assumes that all subjects are unrelated and that ambiguous 
haplotypes exist due to unknown linkage phase of genetic markers. It permits inclusion of 
environmental covariates and specification of haplotype effects as codominant, additive, 
dominant, or recessive, and compares each haplotype to a common referent. Haplo.stats 
also provides general linear models functionality for regression of the outcome on 
haplotypes, and can easily include covariates and interactions in the models.  
Correction for multiple statistical tests with highly correlated exposures. Both 
Bonferroni correction and controlling for false discovery rate (FDR) (206) assume 
independent test statistics, and although this assumption is false when testing multiple tag 
SNPs located in the same gene, many researchers use these techniques in an attempt to 
control Type I error. It has been noted that in settings involving a few tests (e.g. 10-20) up to 
a few hundred tests, Bonferroni correction is often robust in spite of linkage disequilibrium 
between some of the markers (207). But in settings with more tests, a Bonferroni correction 
can be too conservative, thereby causing the false negative rate to be too high. In order to 
better balance risk of Type I and Type II errors and avoid the extreme conservatism of the 
Bonferroni and related Family-wise error (FWE) correction methods, some researchers 
prefer controlling the False Discovery Rate (FDR) (206). The interpretation of p=0.05 in FDR 
correction means that 5% of the genes considered statistically significant after correction are 
false positives. FDR can be estimated by PROC MULTTEST in SAS®. In this method (208), 
the p-values of each SNP are ranked from smallest to largest, and all except the largest p-
value are corrected by multiplying by the total number of polymorphisms being tested 
divided by the p-value’s rank; thus the FDR correction becomes more stringent as the p-
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value decreases. In contrast to FWE and FDR error correction methods that assume 
independence of the tests, simulation-based resampling techniques attempt to control for 
multiple statistical tests by comparing observed p-values with p-values calculated from 
simple repeated perturbations of the data; of these methods, the permutation test is the 
most widely used (207). However, permutation methods can’t easily incorporate covariates. 
One recent (2007) study reported a method of computing p-values adjusted for correlated 
tests that gives similar results to permutation methods with much less computation time and 
more ease in including covariates (209). Interestingly, haplotyping is also sometimes used to 
reduce the number of tests performed, although it was not used primarily for that purpose in 
this project. Recently, several Bayesian methods have been proposed for appropriately 
controlling Type I error when handling highly correlated exposure data: the false positive 
report probability (FPRP) by Wacholder et al. in 2004 (210), and an extension of this method 
referred to by the author as Bayesian false-discovery probability (BFDP) proposed by 
Wakefield in 2007 (211). FPRP allows the prior probability of the hypothesis, study power, 
tolerance for a false-positive decision, as well as the p-value, to affect decisions about which 
findings are noteworthy, and unlike most Bayesian methods, dichotomizes findings into 
noteworthy and non-noteworthy categories. The BFDP extension of FPRP is designed to 
reduce Type I errors even further than FPRP and was designed especially for genome-wide 
association studies with multiple stages, substituting its Bayes factor for p-values in 
determining which SNPs to select for replication analysis.  
For this dissertation project, because the number of statistical tests is in the middle 
ground where FEW and FDR error corrections might be robust, I compared results of 
Bonferroni, FDR, and the Bayesian FPRP method, and planned to discuss any differences. 
Because the results and conclusions were essentially the same for all three methods, I have 
reported only Bonferroni-corrected p-values for this research.     
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Bias in measuring alcohol consumption. Reviews on the topic of validity of self-
reported alcohol consumption report a confusing set of results (212, 213). This results 
largely from the fact that there is no “gold standard” to which to compare self-reported 
alcohol consumption. Researchers investigating self-report of addictive behaviors have 
concluded that validity is increased if sensitivity of the information desired is minimal, the 
questionnaire is methodologically sophisticated, the interviewer is skilled at minimizing 
negative task characteristics (214, 215), and the recall period is sufficiently long (216). 
Personal characteristics of the respondent are felt to be less important than these factors 
(216). 
Because CHANCE used trained nurse interviewers to ask a standardized script of 
questions about legal behaviors (smoking and drinking) over a long period of time (lifetime), 
and because our classifications were quite broad (tertiles of lifetime alcoholic beverage 
consumption; number of years the subject smoked cigarettes) I believe our measures of 
smoking and drinking did not significantly bias our effect estimates.  
2.5.2 Analyses for specific aims  
Specific Aim 1: “Estimate the main effects of each genetic polymorphism (SNPs and 
haplotypes) on the risk of developing SCCHN.”  
Single SNP associations with SCCHN risk, and risk of each of the five sub-sites, 
were modeled in SAS® using conditional logistic regression. Unconditional logistic 
regression models, containing the frequency matched variables of age category, sex, race, 
and their two- and three-way interactions, often did not converge; therefore I used 
conditional logistic regression models instead. 
Almost nothing is known about the genetic models that govern the effects of these 
SNPs, so I began analysis using a co-dominant genetic model since it provides the most 
information about inheritance patterns. However, because so many of the SNPs had 
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insufficient numbers of subjects who were homozygous for the minor allele, which precluded 
calculation of precise effect estimates, I used instead a dominant genetic model in all 
regression analyses of SNP effects. These models compared cancer odds in carriers of any 
minor allele (either 1 or 2 copies) versus those homozygous for the major allele.  
A Bonferroni correction for 64 statistical tests (one for each SNP) was applied to the 
single-test alpha level of 0.05 (see more details, below). Initial/full models included tobacco 
exposure, proportion of African ancestry, and other potential socioeconomic, health, and 
exposures as described above. However main effects models for SNPs did not include 
alcohol consumption, because it may be in the causal pathway between SNP and cancer 
outcome.  
Haplotypes were constructed separately for whites and African-Americans using 
default D’ blocks created in Haploview 4.2 from the study genotyping data. The algorithm 
(217) constructs 95% confidence limits on D’ and each comparison is defined as either 
“strong LD”, “inconclusive” or “strong recombination”. A block is created if 95% of informative 
comparisons are in “strong LD”. The method ignores markers with minor allele frequency 
less than 5%. Assignment of most likely haplotype for individuals with ambiguous haplotype 
was done using an EM algorithm in haplo.stats (205), with minimum counts set to 10. 
Estimation of odds ratios and confidence intervals was accomplished using general linear 
methods implemented in haplo.stats 1.4.4. Bonferroni correction for multiple statistical tests 
was applied to beta coefficient p-values (13 tests – for 13 haplotypes -- for whites, 12 tests 
for African-Americans).  
 
Specific Aim 2: “Estimate the interactive effect of alcohol exposure with each polymorphism 
on the risk of developing SCCHN.” 
I had originally planned to test for both additive and multiplicative interaction between 
SNPs and alcohol consumption, but because additive interaction is believed to be more 
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relevant to biological mechanisms, I decided to calculate and report only measures of 
additive interaction.  
Departures from additive interaction were evaluated by computing interaction 
contrast ratios (ICRs), confidence intervals, and Bonferroni-corrected p-values. ICRs were 
calculated using cancer odds ratios of subjects in three categories: (1) the highest drinking 
category and no minor allele (i.e., those singly exposed to drinking only – OR01); (2) never-
drinkers with at least one minor allele (i.e., those singly exposed to only the variant allele – 
OR10); and (3) subjects in the highest drinking category and at least one minor allele (i.e., 
those doubly exposed to both alcohol and the variant allele – OR11), compared to never-
drinkers homozygous for the major allele (i.e., the referent group that was not exposed to 
either the variant allele or to drinking – OR00 = 1.0). ICR is calculated as follows: ICR=OR11 - 
OR01 - OR10 + 1. ICRs significantly different from zero indicate departure from additive 
interaction.  
This study’s power to detect interactions was marginal even when using the entire 
study population. Because haplotypes were constructed and analyzed separately for each 
race, there was insufficient statistical power to detect within-race interactions, so I did not 
test haplotypes for interaction with lifetime alcohol consumption.  
 
Specific Aim 3. “Compare death rates of cases with different gene polymorphisms in order to 
identify survival differences associated with particular polymorphisms.” 
All deaths that occurred in CHANCE subjects on or before December 31, 2008 were 
classified as all-cause events. If the initial three digits of the first-listed NDI cause of death 
code were head and neck cancers (C01-C06, C09, C10, C12-C14, or C32), the death was 
further classified as a cancer-specific death. For all-cause death, months of survival were 
calculated by subtracting the date of diagnosis from the date of death, and subjects who 
were still alive on 12/31/2008 were censored on that date. For cancer-specific death, 
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months of survival were calculated by subtracting the date of diagnosis from the date of 
cancer death, while subjects who died of another cause were censored as of the date of 
death; subjects who were still alive on 12/31/2008 were censored on that date.  
To ascertain SNP effects on all-cause and cancer-specific survival after SCCHN 
diagnosis, I used a dominant genetic model in SAS® 9.2 to calculate Kaplan-Meier survival 
curves with log-rank tests, and hazard ratios from Cox proportional hazards models (218). 
Tumor, node, and metastasis stage at diagnosis, presence/absence of angiolymphatic 
invasion and selected co-morbid diseases, dichotomous treatment variables (surgery, 
chemotherapy, and radiation), age, sex, self-reported race, percent African ancestry, 
tobacco exposure, and socioeconomic and health variables were entered into initial models, 
and covariates were tested and backwards-eliminated from full models by the 10% change 
rule as described above. Including TNM summary stage as an ordinal variable to control for 
stage, instead of separate T, N, and M stages, did not substantially change effect estimates. 
Alcohol consumption was not included in these main effects models because it may be in 
the causal pathway between SNP and cancer. I also did the same tests separately for 
whites and African-Americans to determine whether effect estimates were similar for the two 
races.  
2.6 STRENGTHS AND LIMITATIONS 
A major advantage of CHANCE is that both cases and controls were drawn from a 
large population at risk for SCCHN. This improves the generalizability of risk estimates 
associated with polymorphisms in alcohol-processing and oxidative metabolism genes. The 
large sample size permitted examination of gene-environment interactions in the overall 
study with sufficient statistical power for common genotypes. The study gathered extensive 
questionnaire and clinical data on all major risk factors for SCCHN, and genotyped more 
than 95% of study participants for polymorphisms in genes that may be related to disease 
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incidence and survival. Sufficient tag SNPs were genotyped in most of the genes such that 
haplotype analysis to comprehensively assess common variation over the entirety of each 
gene can be performed, with the goal of identifying risk haplotypes. Outcome, stage at 
diagnosis, and treatments were verified with medical records to reduce misclassification of 
outcome and clinical covariates. African Americans, an under-studied population, make up 
22% (615/2785 questionnaires) of participants.  
Limitations included low response rate of potential controls, and different response 
rates between white and African-American controls (50% versus 35%, respectively). The 
result was fewer African-American controls than there were African-American cases. 
Because response rate of cases was much higher than that of controls (76% versus 46%, 
respectively), participation bias may be present, and it is difficult to estimate how that might 
affect frequency of genotypes. Also, this study excluded enrolled cases who died without 
personally completing the questionnaire and providing a biological sample, thus eliminating 
the most rapidly fatal cases. If incidence and survival effects due to SNP polymorphisms are 
more pronounced in subjects with rapidly-fatal disease, this selection bias would tend to 
skew our effect estimates toward the null. 
A second limitation is that most covariates were measured by self-report at baseline, 
which can introduce misclassification of risk factors. However, nurse interviewers received 
extensive training to ask questions in a consistent manner of each subject, in order to 
reduce errors introduced by the way in which questions were phrased. Also, CHANCE did 
not measure alcohol and tobacco use after baseline, so could not address whether changing 
these behaviors after diagnosis improves survival.  
Finally, genotyping only tag SNPs, although less expensive than typing other 
variants, is likely to miss rare variants.  
  
 
 
 
 
 
CHAPTER 3   
 
JOINT EFFECTS OF ALCOHOL CONSUMPTION AND  
POLYMORPHISMS IN ALCOHOL AND OXIDATIVE STRESS METABOLISM  
GENES ON RISK OF HEAD AND NECK CANCER 
 
3.1 ABSTRACT 
Single nucleotide polymorphisms (SNPs) in alcohol metabolism genes are 
associated with squamous cell carcinoma of the head and neck (SCCHN), and may 
influence cancer risk in conjunction with alcohol. Genetic variation in the oxidative stress 
pathway may impact the carcinogenic effect of reactive oxygen species produced by ethanol 
metabolism. We hypothesized that alcohol interacts with these pathways to affect SCCHN 
incidence. 
 Interview and SNP genotyping data were obtained from 2552 white and African-
American subjects (1227 cases, 1325 controls) from the Carolina Head and Neck Cancer 
Epidemiology study, a population-based case-control study of SCCHN conducted in North 
Carolina from 2002-2006. We estimated odds ratios and 95% confidence intervals, adjusting 
for matching variables (age, sex, race) and duration of cigarette smoking. 
 Two SNPs were associated with altered SCCHN risk: ADH1B rs1229984 A allele 
(OR=0.7, 95% CI=0.6-0.9) and ALDH2 rs2238151 C allele (OR=1.2, 95% CI=1.1-1.4). Three 
were associated with sub-site tumors: ADH1B rs17028834 C allele (larynx, OR=1.5, 95% 
CI=1.1-2.0), SOD2 rs4342445 A allele (oral cavity, OR=1.3, 95% CI=1.1-1.6), and SOD2 
rs5746134 T allele (hypopharynx, OR=2.1, 95% CI=1.2-3.7). Four SNPs in alcohol 
metabolism genes showed evidence of additive interaction with level of alcohol 
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consumption: ALDH2 rs2238151, ADH1B rs1159918, ADH7 rs1154460, and CYP2E1 
rs2249695. No alcohol interactions were found for oxidative stress pathway SNPs.  
Previously unreported associations of SNPs in ALDH2, CYP2E1, GPX2, SOD1, and 
SOD2 with SCCHN and sub-site tumors provide evidence that alterations in alcohol and 
oxidative stress pathways influence SCCHN carcinogenesis, and warrant further 
investigation.  
3.2 INTRODUCTION 
Head and neck cancers typically include tumors of the oral cavity, pharynx, larynx, 
nose, nasal cavity and sinuses, and esophagus. This study focuses specifically on 
squamous cell cancers of the oral cavity, pharynx, and larynx (SCCHN).  
There were an estimated 49,260 new cases and 11,480 deaths from oropharyngeal 
and laryngeal cancer in the U.S. in 2010 (219). Globally in 2008, oral cavity tumors were 
among the top 10 incident cancers in men world-wide, and among the top 10 fatal cancers 
in men in developing countries (220).  
SCCHN incidence is higher in men than women, and, in the U.S., in African-
Americans and those of low socioeconomic status. A large proportion of this disparity is due 
to the higher incidence of laryngeal tumors among African-American men (221). 
SCCHN is strongly associated with smoking tobacco products and drinking alcoholic 
beverages, and recently with human papillomavirus infection. It is estimated that 75% of 
oropharyngeal cancer in the US is due to cigarette smoking and alcohol consumption (56). 
The effect of these exposures varies by anatomic sub-site, with smoking more associated 
with laryngeal tumors, and drinking with oral cavity tumors. However only a small fraction of 
people exposed to these carcinogens will develop SCCHN, suggesting that other factors, 
including genetic, must be considered. Inherited genetic variation in the metabolism of 
alcohol has been suggested as a potentially important contributor to SCCHN risk. 
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Investigation of the association between single nucleotide polymorphisms (SNPs) and 
SCCHN may help to identify high-risk groups and clarify carcinogenesis pathways.  
Many previous studies of the major genes in the alcohol metabolism pathway (ADH 
family, ALDH2, CYP2E1) have been limited by sample size, and, with one exception (152), 
none have included a significant percentage of African-Americans. Further, few studies have 
examined the influence of genetic variation in oxidative stress pathways (e.g., SOD, GPx, 
CAT). We examined the association between SNPs and haplotypes of genes in the alcohol 
metabolism and oxidative stress pathways and SNP-alcohol interactions using data from a 
large North Carolina (N.C.) population-based case-control study of SCCHN, including 22% 
African-Americans.  
3.3 METHODS 
3.3.1 Subject enrollment 
The Carolina Head and Neck Cancer Epidemiology study (CHANCE) is a population-
based case-control study upon which these analyses are based (222). 
All cases of squamous cell carcinoma of the oral cavity, pharynx, and larynx 
diagnosed in 46 N.C. counties between 1/1/2002 through 2/28/2006 were eligible for 
enrollment. Rapid case identification was conducted by the N.C. Central Cancer Registry. 
CHANCE cases included ICD-O-3 topography codes C0.00-C14.8, and C32.0-C32.9, 
excluding salivary gland (C07.9, C08.0-C08.9), nasopharynx (C11.0-C11.9), nasal cavity 
(C30.0), and nasal sinuses (C31.0-C31.9). ICD-O-3 morphology codes included were 
8010/3, 8051/3, 8083/3, 8071/3, 8072/3, 8073/3, 8074/3, and 8076/3. Benign tumors, 
carcinomas in situ, papillary carcinomas, and adenoid carcinomas were excluded. This 
analysis further excluded 21 lip cancers (C00.3-C00.9, C14.2), 46 of “other” race, and 96 
without genotyping data, producing a study composition of 1227 cases and 1325 controls.  
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Potentially eligible controls from the same counties as cases were identified through 
N.C. Department of Motor Vehicles records. Controls were frequency-matched to cases 
using random sampling with stratification on age, race, and sex.  
Trained nurse-interviewers conducted an in-person interview with each subject. For 
this analysis only self-reported, non-proxy data were included. Questions were asked about 
demographics (age, sex, race-ethnicity, education, income, health insurance), tobacco use, 
drinking of alcoholic beverages, diet, oral health, medical history, and family history of 
cancer.  
Blood samples were obtained by nurse-interviewers trained in phlebotomy. If the 
subject was not willing or able to consent to the blood draw, they were asked to contribute a 
buccal cell sample via mouthrinse.  
Written informed consent was obtained from all subjects. The study was approved by 
the Biomedical Institutional Review Board at the University of North Carolina at Chapel Hill.  
3.3.2 Outcome, exposure, and covariate measurement 
Outcome. Case tumors were classified into anatomic sub-sites according to the 
following 5 ICD-O categories used by the International Head and Neck Cancer 
Epidemiology Consortium (52): (1) oral cavity: C02.0-C02.3, C03.0, C03.1, C03.9, C04.0, 
C04.1, C04.8, C04.9, C05.0, C06.0-C06.2, C06.8, and C06.9; (2) oropharynx: C01.9, C02.4, 
C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0-C10.4, C10.8, and C10.9; (3) oral cavity-
oropharynx-hypopharynx NOS: C02.8, C02.9, C05.8, C05.9, C14.0, C14.2, and C14.8; (4) 
hypopharynx: C12.9, C13.0-C13.2, C13.8, and C13.9; and (5) larynx: C32.0-C32.3, and 
C32.8-C32.9.  
Alcohol and tobacco use. Questions about alcohol use were designed to estimate 
lifetime history of alcohol consumption, and usual consumption of each beverage type, prior 
to the year before diagnosis. Questions were asked about beer, wine, and hard liquor 
separately as follows: (1) Did you drink [beer/wine/hard liquor]? (2) At what age did you 
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start? (3) At what age did you stop? (4) For how many years did you drink [beer/wine/hard 
liquor] during this period? (5) How much [beer/wine/hard liquor] did you usually drink? Per 
day/week/month/year? (6) What size did you usually drink? 
To efficiently estimate odds ratios for the interactive effect of genotype and alcohol 
consumption, a single variable combining all three types of alcohol consumption was 
derived. As frequency of drinking has demonstrated stronger associations with SCCHN than 
duration (51), a single frequency measure that included all types of alcoholic beverages 
would have been optimal, although unavailable in CHANCE. We instead derived a lifetime 
measure of alcohol intake, in milliliters, for beer, wine, and liquor combined. Using splines, 
we confirmed that tertiles best represented the risk associated with alcohol intake.  
The primary tobacco exposure covariate selected was continuous duration of 
cigarette smoking rounded to whole years. Dichotomous variables representing additional 
potential tobacco confounders were: ever use of non-cigarette tobacco products, ever 
exposed to environmental tobacco smoke (ETS) at work, and ever exposed to ETS at home.  
SNPs. For this project, 75 SNPs (69 tag SNPs and 6 candidate SNPs found in prior 
studies to be associated with cancer incidence or survival, or alcohol dependence) were 
selected in 12 genes that are part of two metabolic pathways: ADH1B, ADH1C, ADH4, 
ADH7, ALDH2, and CYP2E1 in the alcohol metabolism pathway in the upper aerodigestive 
tract; and CAT, SOD1, SOD2, GPX1, GPX2, and GPX4 in the oxidative stress metabolic 
pathway. Tag SNPs, chosen to represent the genetic variation within each of the 12 
candidate genes (gene and 2000 bp upstream and downstream) were selected using the 
Genome Variation Server (223), using SNPs that were polymorphic in either CEU or YRI 
HapMap Release 2 (unrelated only), and with the following parameters: allele frequency 
cutoff 10%, 0.8 R2 threshold minimum for variations to belong to the same cluster, 85% 
minimum data coverage for tag SNPs, 70% minimal data coverage for a variation to be 
potentially clustered with others.  
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To control for potential population stratification, we selected 157 ancestry informative 
markers (AIMs) to maximize (1) the difference in allele frequencies (delta) between 
European and African populations in the HapMap data (CEU versus YRI), and (2) the 
Fisher’s information criterion (FIC). AIMs were prioritized based on having the highest delta 
and FIC values in the following order: 90% European/10% African, 10% European/90% 
African, and 50% European/50% African. This allowed AIMs to represent the entire 
expected ancestral distribution of the study population. Individual estimates of percentage 
African ancestry were calculated from 145 successfully genotyped AIMs using maximum 
likelihood estimation (MLE) methods previously described (184, 189, 224). AIMs were 
chosen to differentiate only between African and European ancestry, so we derived 
individual ancestry estimates for the two groups that summed to 1.0.  
DNA was extracted from blood or buccal samples collected at time of interview. 
Genotyping was done by the University of North Carolina at Chapel Hill, Mammalian 
Genotyping Core Facility, using the Illumina GoldenGate genotyping assay with Sentrix 
Array matrix and 96-well standard microtiter plates.  
Haplotypes using the study data were constructed separately for African-Americans 
and whites using default D’ blocks in Haploview 4.2. The algorithm (217) constructs 95% 
confidence limits on D’ and each comparison is defined as either “strong LD”, “inconclusive” 
or “strong recombination”. A block is created if 95% of informative comparisons are in 
“strong LD”. The method ignores markers with minor allele frequency less than 5%. 
Assignment of most likely haplotype for individuals with ambiguous haplotype was done 
using an EM algorithm in haplo.stats (205), with minimum counts set to 10. Estimation of 
odds ratios and confidence intervals was accomplished using unconditional logistic 
regression implemented in haplo.stats 1.4.4. 
SES, oral health: Dichotomous variables representing additional potential 
confounders were: covered by health insurance on reference date, ever had a routine dental 
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visit, ever had a loose permanent tooth due to disease, ever used mouthwash, family history 
of SCCHN, household poverty as defined by federal guidelines for both income and number 
of persons supported, and highest attained education level.  
3.3.3 Statistical analysis 
Odds ratios for the independent effects of SNPs and alcohol, and their interactive 
effects, were computed using conditional logistic regression methods implemented in SAS® 
9.2. Odds ratios for the main effects of haplotypes were computed using unconditional 
logistic regression methods implemented in haplo.stats 1.4.4. 
A dominant genetic model (at least one minor allele versus referent of no minor 
alleles) was used for SNPs instead of the general model because for many of the SNPs, the 
number of subjects homozygous for the minor allele was too small to permit estimation of 
precise effect estimates.  
Potential covariates were eliminated using step-wise backwards elimination, 
comparing each reduced model to the full model that included all covariates listed in Table 
14. Note that no collinearity was noted between any variables in the full model, with one 
exception as described below. If a covariate did not change the ln(OR) for any SNP by a 
difference of at least 0.10, it was eliminated from all models. The final models contained the 
genetic variant (single SNP or haplotype), coded for a dominant genetic model for SNPs, 
additive genetic model for haplotypes; categorized lifetime drinking variable; continuous 
smoking duration variable; and the SNP*drinking interaction term (for SNP genetic variants, 
but not for haplotypes). The conditional logistic regression used for SNPs by definition takes 
into account the matching variables of age category, sex, and race. The unconditional 
logistic regression models used for haplotypes (for each race separately) included, as 
covariates, sex, age, and their 2-way interaction. Ancestry was not important for the genetic 
variants studied, probably because self-reported race was already included (as a matching 
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variable). The ancestry variable also showed evidence of collinearity with race, so for these 
reasons and for parsimony’s sake, ancestry was not included in final models.  
A Bonferroni correction was used to adjust p-values to control for Type 1 error 
introduced by multiple statistical testing, for either 64 tests (for 64 SNPs) or for 12 or 13 tests 
(for haplotypes).  
Departures from additive interaction were evaluated by computing interaction 
contrast ratios (ICRs) and Bonferroni-corrected confidence intervals for 64 statistical tests. 
ICRs were calculated using cancer odds ratios of subjects in three categories: (1) the 
highest drinking category and no minor allele (i.e., those singly exposed to drinking only – 
OR01); (2) never-drinkers with at least one minor allele (i.e., those singly exposed to only the 
variant allele – OR10); and (3) subjects in the highest drinking category and at least one 
minor allele (i.e., those doubly exposed to both alcohol and the variant allele – OR11), 
compared to never-drinkers homozygous for the major allele (i.e., the referent group that 
was not exposed to either the variant allele or to drinking – OR00 = 1.0). ICR is calculated as 
follows: ICR=OR11 - OR01 - OR10 + 1. ICRs significantly different from zero indicate 
departure from additive interaction.  
3.4 RESULTS 
3.4.1 Description of study population 
Although controls were somewhat older and more likely to be female and white than 
cases (Table 14), the percentages of cases versus controls in each of the 28 age-sex-race 
cross-categories, as a proportion of the entire study population, differed by less than 2%. 
Compared to controls, cases smoked and drank more, and were poorer, less likely to have 
completed high school or have health insurance, less likely to have ever had a routine 
dental visit, and more likely to have lost a permanent tooth to disease. Cases were also 
more likely to have been exposed to ETS at home and work. Mean proportion of African 
ancestry was slightly higher in cases than controls.  
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The SNPs in Table 16 that were analyzed for this study were genotyped as part of a 
larger panel of 1,536 SNPs. Assay intensity data and genotype cluster images for all SNPs 
were individually reviewed; as a result, 9 tag/candidate SNPs and 12 AIMs (9% of SNPs) 
were excluded due to inadequate signal or inability to distinguish genotype clusters. Blind 
duplicates of 109 samples were genotyped to verify call reliability; none of the calls for SNPs 
analyzed in this study were discrepant. Two tag SNPs, judged to be out of HWE (SAS® 
PROC ALLELE) in both black and white controls due to an exact p-value <0.001, were 
eliminated from analysis.   
There were no large differences in allele frequencies between cases and controls, 
when stratified by race (Appendix C). However there are large allele frequency differences 
between African-Americans and whites.  
3.4.2 Cancer risk from alcohol consumption 
The odds of developing SCCHN increase monotonically as lifetime alcohol 
consumption increases (Table 15). Subjects with the lowest level of consumption (up to 
133,294 ml) experienced reduced SCCHN odds compared to non-drinkers (OR=0.8, 95% 
CI=0.6-1.0), a reduction which was driven by laryngeal and oral cavity tumors (OR=0.7, 95% 
CI=0.4-1.1 and OR=0.4, 95% CI=0.2-0.9, respectively).  
Successively higher levels of alcohol consumption were associated with increasing 
odds. The middle tertile of lifetime consumption (133,294 to 757,550 ml) was associated 
with 30% higher odds than never-drinkers (OR=1.3, 95% CI=1.0-1.8). The highest lifetime 
consumption (>=757,550 ml) was associated with tripled odds of SCCHN (OR=3.2, 95% 
CI=2.3-4.5). In the highest drinking category, all sub-sites were associated with significantly 
increased odds: doubled odds of laryngeal cancer, and tripled or greater odds for 
oropharyngeal, oral-cavity-oropharyngeal-hypopharyngeal-NOS cancers, and oral cavity 
tumors.  
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3.4.3 Cancer risk from genetic variants 
None of the SNP associations with SCCHN or any of the sub-site cancers had a 
significant Bonferroni-corrected p-value, although five SNPs in ADH1B, ALDH2, and SOD2 
showed evidence of reduced or increased cancer odds ratios overall and in oral cavity, 
laryngeal, and hypopharyngeal sub-sites (Table 16; remaining sub-site effects in Appendix 
D). In ADH1B, the rs1229984 A allele was associated with decreased SCCHN odds 
(OR=0.7, 95% CI=0.6-0.9), and the rs17028834 C allele with increased odds of laryngeal 
tumors (OR=1.5, 95% CI=1.1-2.0). In ALDH2, the rs2238151 C allele showed evidence of 
association with increased odds of SCCHN (OR=1.1, 95% CI=1.0-1.2), driven largely by an 
association with laryngeal tumors (OR=1.2, 95% CI=1.1-1.4). In SOD2, the rs4342445 A 
allele was associated with increased odds for oral cavity tumors (OR=1.3, 95% CI=1.1-1.6), 
and the rs5746134 T allele with odds for hypopharyngeal cancer (OR=2.1, 95% CI=1.2-3.7).  
Four haplotypes in ALDH2, CYP2E1, GPX2, and SOD1 were associated with 
SCCHN, either in whites or African-Americans, or both (Table 17). One GPX2 haplotype 
was significantly associated with decreased odds of SCCHN in whites (OR=0.7, 95% 
CI=0.5-0.9). Reduced SCCHN odds were found for an ALDH2 haplotype (OR=0.5, 95% 
CI=0.3-0.8) in African-Americans and a CYP2E1 haplotype in whites (OR=0.7, 95% CI=0.6-
0.9). The SOD1 AGGC haplotype was associated with increased odds in whites and 
reduced odds in African-Americans.  
3.4.4 Cancer risk from alcohol interaction with SNPs 
Four SNPs showed evidence of possible additive interaction with alcohol 
consumption (Table 18). All met the following two characteristics: (1) statistically significant 
or near-significant Bonferroni-corrected p-value (for 64 tests; p<0.0008) for departure from 
additive interaction, and (2) at least 10 cases and 10 controls in each of the three 
comparison groups OR01, OR10, OR11. For example, rs2238151 in ALDH2 showed 
statistically significant evidence of synergistic additive interaction (increased odds for 
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drinkers with the C allele). Also the T allele at rs1159918 in ADH1B, the A allele at 
rs1154460 in ADH7, and the T allele at rs2249695 in CYP2E1 showed some evidence for 
greater than additive interaction between alcohol consumption and SNP. (Evaluations of 
additive interaction with alcohol for remaining SNPs can be found in Appendix E.) 
No interactions with alcohol were detected for anatomic sub-sites.  
3.4.5 SNP effects by race 
SNP effect estimates were similar in whites and African-Americans, with the 
exception of two SNPs in SOD1 (rs10432782, rs2070424) that were associated with 
decreased odds of getting SCCHN in African-Americans and increased odds in whites. 
These SNPs were part of the SOD1 haplotype that we found to be associated with different 
direction of effect in African-Americans and whites. Direction of effect for carrying the minor 
allele of individual SNPs was consistent with the haplotype: OR (95% CI) for rs10432782 
was 0.65 (0.42-1.00) in African-Americans, 1.35 (1.07-1.71) in whites; OR (95% CI) for 
rs2070424 was 0.52 (0.33-0.83) in African-Americans, 1.47 (1.10-1.97) in whites. The 
magnitude of the joint effect for the four SNPs found to interact additively with alcohol 
exposure did not differ between races (data not shown).   
3.5 DISCUSSION 
Alcohol consumption. Most studies report a strong dose-response relationship 
between higher levels of drinking, both in lifetime frequency of drinking (e.g. drinks per day) 
and lifetime alcohol intake (e.g. milliliters of ethanol), and increased cancer risk. However, 
the type of alcohol beverage associated with cancer risk varies substantially by study. For 
example, some studies suggest that the most common alcoholic beverage in the study’s 
geographic region studied produces the highest cancer risk (58). There is some evidence 
that moderate levels of wine consumption produce lower risk than beer and liquor 
(comparing 16-30 ethanol-standardized drinks per week of each type), but above 30 drinks 
per week, all types are associated with increased risk (58).  
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We found a general pattern of association with alcohol intake that is consistent with 
previous studies (52), with monotonically increasing cancer risk as lifetime consumption 
increases. Beer and liquor accounted for about 90% of lifetime alcohol consumption in our 
study population, and those beverages were associated with higher cancer risk than wine 
consumption (data not shown). This is consistent with the hypothesis that the most 
commonly drunk alcoholic beverages are associated with the highest risk. We found 
suggestive evidence of reduced odds of SCCHN for drinkers in the lowest tertile compared 
to non-drinkers. 
Alcohol metabolism genes. Variant ADH and ALDH alleles coding for either 
superactive or inactive subunits of ADH and ALDH isozymes are common. Numerous 
studies in Asian populations have reported an association between several presumably 
functional variants in ADH1B, ADH1C, ADH4, ADH7, and ALDH2 and SCCHN incidence 
(105, 106, 111, 113, 114, 127, 130, 131). However, these studies lacked sufficient power to 
consistently detect interaction between gene and alcohol drinking. In recent years, these 
variants and others were investigated in larger studies of Europeans, Latin-Americans, and 
Indians with similar findings (103, 104, 107, 115, 121, 123-126, 128). However, only a few 
smaller studies examined risk in whites and African-Americans (109, 122, 150, 152, 153), 
and those included very small numbers of African-Americans.  
We discovered an association between rs1229984 in ADH1B and SCCHN odds 
(ORAA+AGvsGG=0.7, 95% CI=0.6-0.9). It is the same direction of effect for the A allele as 
reported in a Japanese study (105)(ORGG+GAvsAA=2.20, 95% CI=1.46-3.32) and in European 
Caucasians and Latin-Americans (104) (ORAA+GAvsGG=0.56, 95% CI=0.47-0.66), but is the 
reverse of the effect reported in a few other studies (103, 106, 123) (e.g. (103): 
ORGG+GAvsAA=0.36, 95% CI=0.17-0.77). A recent INHANCE GWAS (149) reported a 
replicated association of 5 SNPs with upper aerodigestive tract (UADT) cancer (i.e. SCCHN 
and esophageal cancer), including rs1229984, for which the A allele under a log-additive 
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genetic model was associated with reduced odds in both the discovery (OR=0.52, 95% 
CI=0.43-0.64) and the replication phases (OR=0.68, 95% CI=0.60-0.78). The GWAS 
replication sample included 2,027 CHANCE subjects as 10% of the replication sample.  
We found no effect on SCCHN risk of the rs1693482 “slow” allele in ADH1C 
(ORTT+TCvsCC=1.05, 95% CI=0.95-1.15). The two largest studies to date of this SNP and 
SCCHN in European-Caucasians (103) and European-Caucasians and Latin-Americans 
(104) found increased odds associated with this allele (OR=1.49, 95% CI=1.08-2.05; 
OR=1.20, 95% CI=1.08-1.32); respectively). Also, all four studies of rs698 “slow” or G allele 
in Brazilian, Japanese, European-American and Latin-American populations (103-105, 123) 
reported evidence of 16-38% increased odds. In CHANCE, rs1631460 is in high LD 
(r2=0.95) with rs698 in both CEU and YRI HapMap populations, but we found no association 
between it and SCCHN odds (OR=1.04, 95% CI=0.95-1.14).   
No ADH4 and ADH7 SNPs were associated with SCCHN, including the rs1573496 C 
allele in ADH7 (OR=1.0, 95% CI=0.9-1.1). This is in contrast to the one study that 
investigated this allele and found it to be associated with reduced odds in Europeans and 
Latin-Americans (OR=0.7, 95% CI=0.6-0.8) (104).  
No ALDH2 SNPs were associated with SCCHN, and a possible haplotype 
association was present only in African-Americans (OR=0.5, 95% CI=0.3-0.8). Previous 
studies of rs886205, a SNP that is polymorphic in Europeans, found conflicting results of no 
association and increased association for the G allele (103, 115).   
Gene interaction with alcohol. We discovered evidence of additive interaction with 
alcohol of several SNPs in alcohol metabolism pathway genes, although the SNPs we 
identified were different from those previously reported in the literature. Specifically, we 
found two SNPs in ADH1B and ADH7 – rs1159918 and rs1154460, respectively – that 
appear to interact with alcohol. We also found one previously unstudied ALDH2 SNP, 
rs2238151, that showed evidence of additive interaction (OR11actual=3.3 versus 
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OR11expected=1.4). Whereas previous studies reported that rs1229984 in ADH1B, rs4148887 
in ADH4, rs1573496 in ADH7, and rs886205, rs441 (both in high LD with our SNP 
rs4767939), and rs440 in ALDH2 interacted with alcohol drinking (103, 104, 106, 113, 123), 
we did not find evidence for an interaction with these SNPs, probably because we measured 
alcohol consumption using lifetime alcohol intake instead of drinking frequency.  
We also found evidence for greater than additive interaction for CYP2E1 rs2249695 
with alcohol. A recent linkage and association study (225) identified that SNP, among 
others, to be associated with “tipsiness,” or quick response to alcohol challenge. In 
CHANCE, the T allele (Table 18, last row) appeared to be protective in never-drinkers 
(OR10=0.6, 95% CI=0.4-0.9) but in the heaviest drinkers the odds of cancer for those with 
the T allele are 70% higher than expected.  
Oxidative stress genes. We found two previously unstudied SNPs in SOD2 to be 
associated with specific tumor sites: rs4342445 with oral cavity tumors, and rs5746134 with 
hypopharynx tumors. One SOD1 haplotype was associated with SCCHN risk in both races, 
albeit in different directions, likely related to the effect of three individual SNP effects that 
differed by race in that gene. Finally, we found a GPX2 haplotype to be associated with 
reduced SCCHN risk in whites only. This may indicate that the haplotype is in high LD with 
an unmeasured causal polymorphism in whites but not in African-Americans.  
Only one previous study examined effects on SCCHN incidence of any SNPs in 
oxidative stress pathways (115); it reported that rs2758346 in SOD2 (which we did not 
study) was not associated with SCCHN (ORAAvsGG=0.98, 95% CI=0.78-1.22).  
We found no evidence of interaction with alcohol consumption for any oxidative 
stress SNP.  
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3.6 CONCLUSIONS 
CHANCE is one of the largest studies of head and neck cancer conducted in both 
African-Americans and whites. This study examined genetic polymorphisms in genes in the 
alcohol metabolism and oxidative stress biological pathways, and estimated main effects of 
these polymorphisms along with their interaction with alcohol. We selected tag SNPs to 
capture most of the variation in the 12 genes studied, rather than studying only missense 
SNPs within the coding regions.  
An inherent limitation of genotyping common tag SNPs, as we did, is that the method 
is likely to miss rare variants. A second limitation is that, due to small numbers, we could not 
precisely estimate the interaction between SNPs and alcohol intake for allele frequencies 
<30% or in relation to anatomic site of tumor. 
Our study confirms findings of previous studies that the effects of many 
polymorphisms in alcohol metabolism pathways are modified by alcohol intake. However, 
most genetic variants in ALDH2 and CYP2E1 have been understudied and warrant 
additional investigation in light of the new associations that we report.  
Our analysis of tag SNPs in GPX2, SOD1, and SOD2 has identified several that are 
associated with SCCHN, hypopharyngeal, and oral cavity tumors. Confirmation of these 
findings in a variety of populations is warranted.  
  
Variable na (col %) na (col %)
Age (years)
20-49 239 19.5% 151 11.4% <0.0001
50-54 189 15.4% 156 11.8%
55-59 207 16.9% 199 15.0%
60-64 205 16.7% 202 15.2%
65-69 168 13.7% 237 17.9%
70-74 135 11.0% 216 16.3%
75-80 84 6.8% 164 12.4%
Sex
Male 938 76.4% 924 69.7% 0.0001
Female 289 23.6% 401 30.3%
Race
White 922 75.1% 1074 81.1% 0.0003
African-American 305 24.9% 251 18.9%
Drinking (lifetime ethanol intake in ml) <0.0001
never drinkers 117 9.5% 280 21.1%
>0 to <134,699 210 17.1% 467 35.2%
134,699 to 757,550 318 25.9% 360 27.2%
757,550+ 505 41.2% 173 13.1%
missing 77 6.3% 45 3.4%
Smoking (duration in years) <0.0001
0 160 13.0% 497 37.5%
1-19 104 8.5% 266 20.1%
20-39 435 35.5% 314 23.7%
40-49 295 24.0% 131 9.9%
50+ 155 12.6% 71 5.4%
Missing 78 6.4% 46 3.5%
Poverty group (at or above, or below, federal poverty guideline) <0.0001
>= poverty guideline 816 66.5% 1088 82.1%
<poverty guideline 356 29.0% 187 14.1%
Had a routine dental visit in past 10 years? <0.0001
Yes 781 63.7% 1115 84.2%
No 438 35.7% 210 15.8%
Drank alcoholic beverages in prior 20 years? 0.8851
No 24 2.0% 27 2.0%
Yes 1202 98.0% 1298 98.0%
Ever exposed to environmental tobacco smoke at work 0.0024
No 316 25.8% 414 31.2%
Yes 909 74.1% 911 68.8%
Ever exposed to environmental tobacco smoke at home <0.0001
No 399 32.5% 592 44.7%
Yes 827 67.4% 732 55.2%
Ever used non-cigarette tobacco products 0.1165
No 754 61.5% 854 64.5%
Yes 473 38.5% 471 35.5%
Had health insurance at reference date <0.0001
Yes 1068 87.0% 1250 94.3%
No 154 12.6% 74 5.6%
Highest education level attained <0.0001
>=high school 828 67.5% 1123 84.8%
<high school 399 32.5% 202 15.2%
Ever had loose permanent tooth due to disease <0.0001
No 765 62.3% 1018 76.8%
Yes 455 37.1% 305 23.0%
Ever regularly used mouthwash 0.8572
No 502 40.9% 549 41.4%
Yes 719 58.6% 775 58.5%
Family history of SCCHN among 1st degree relatives 0.3848
No 1206 98.3% 1296 97.8%
Yes 21 1.7% 29 2.2%
Mean % African ancestry 0.0008
23.8% 19.7%
Chi-square or t-
test, 
unadjusted p-
value
a Frequencies for all variables may not sum to the total number of cases and controls, due 
to missing values
Table 14. Distribution of non-genetic variables in cases and controls 
Cases (n=1227) Controls (n=1325)
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Table 17. Selected haplotype main effects on SCCHN risk, additive genetic model
Gene (haplotype definition) haplotype Race
prevalence 
(%) OR (95% CI)b
ACAGCT 26% 1.0 (ref)
ATGGCT 11% 0.5 (0.3-0.8)
GCCC White 65% 1.0 (ref)
GCCT 10% 0.7 (0.6-0.9) 
GGC White 70% 1.0 (ref)
GCT 9% 0.7 (0.5-0.9)
GTAC White 58% 1.0 (ref)
AGGC 6% 1.4 (1.1-1.9) 
GTAC 52% 1.0 (ref)
AGGC 6% 0.6 (0.4-0.9)
b Unconditional logistic regression models adjusted for matching variables sex, race, age category, and their interactions; and for 
continuous smoking duration rounded to whole years. The referent group for each OR was the most common haplotype.
a Criterion for selecting haplotypes for this table: ORs were statistically significant, or nearly so, after Bonferroni correction for multiple 
testing (13 for White, 12 for African-American). Statistically significant ORs are highlighted in bold.
ALDH2 
(rs4767939, rs2238151, rs7312055, rs2158029, rs16941667, rs16941669) 
CYP2E1 
(rs915908, rs7092584, rs743535, rs2249695) 
GPX2 
(rs11623705, rs2412065, rs2737844) 
SOD1 
(rs4998557, rs10432782, rs2070424, rs1041740)
African-
American
African-
American
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Table 18. Additive interactive effects of alcohol with selected SNPsa
Gene, SNP, major/minor alleles      
     lifetime ethanol (ml)
# cases/
controls
Adjusted OR 
(95% CI)b
# cases/
controls
Adjusted OR 
(95% CI)b
ICRc 
(Bonferroni-
corrected CI)
ALDH2 , rs2238151, T/C
    never-drinkers 50/95 1.0 (ref) 67/184 0.7 (0.4-1.1) 1.9 (0.1-3.80)
    >0 to <134,699 75/173 0.5 (0.3-0.9) 133/293 0.6 (0.4-1.0) 
    134,699 to <757,550 97/138 0.8 (0.5-1.3) 220/222 1.2 (0.8-1.9) 
     757,550+ 122/65 1.7 (1.0-2.8) 381/106 3.3 (2.0-5.3) 
ADH1B , rs1159918, G/T 
     never-drinkers 49/101 1.0 (ref) 68/179 0.9 (0.6-1.5) 1.0 (-0.9, 3.0)
    >0 to <134,699 80/168 0.7 (0.4-1.1) 129/298 0.7 (0.5-1.1)
    134,699 to <757,550 107/129 1.1 (0.7-1.8) 211/231 1.3 (0.8-2.0)
     757,550+ 140/58 2.4 (1.4-4.1) 365/115 3.3 (2.1-5.4) 
ADH7 , rs1154460, G/A 
     never-drinkers 35/65 1.0 (ref) 81/215 0.6 (0.4-1.1) 0.9 (-0.6, 2.4)
    >0 to <134,699 57/131 0.5 (0.3-0.9) 152/334 0.6 (0.3-0.9)
    134,699 to <757,550 88/111 0.8 (0.5-1.4) 229/249 1.0 (0.6-1.6)
     757,550+ 133/54 1.9 (1.1-3.5) 371/119 2.5 (1.5-4.2)
CYP2E1 , rs2249695, C/T 
     never-drinkers 73/136 1.0 (ref) 44/144 0.6 (0.4-0.9) 1.2 (-0.6, 3.0)
    >0 to <134,699 127/253 0.6 (0.4-0.9) 82/213 0.5 (0.3-0.8)
    134,699 to <757,550 160/178 1.1 (0.7-1.6) 158/181 1.0 (0.6-1.4)
     757,550+ 218/92 2.1 (1.4-3.3) 286/81 2.9 (1.8-4.6) 
homozygous for major 
allele
one or two copies of 
minor allele
b Conditional logistic regression models conditioned on sex, race, and age category, and adjusted for continuous smoking 
duration rounded to whole years
c ICRs were calculated using odds ratios that are highlighted in bold. Bonferroni correction of ICR confidence interval for 64 
statistical tests.
a Selected SNPs have (1) ICR confidence intervals that either don't include 0 or nearly so, after Bonferroni correction, and (2) 
genotype information on sufficient numbers of cases and controls (at least 10 each) for calculating each of the three ORs 
highlighted in bold for that SNP. If ICR confidence interval appeared significant but numbers of cases and controls were too 
sparse, SNP was judged to have insufficient evidence of interaction with alcohol, and was not included in this table.
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CHAPTER 4   
 
EFFECTS OF POLYMORPHISMS IN ALCOHOL METABOLISM AND OXIDATIVE  
STRESS GENES ON SURVIVAL FROM HEAD AND NECK CANCER 
 
4.1 ABSTRACT 
Heavy drinking of alcoholic beverages increases risk of developing squamous cell 
carcinoma of the head and neck (SCCHN). While the mechanisms of alcohol-induced 
carcinogenesis are complex, alcohol metabolism leads to generation of cytotoxic and 
mutagenic intermediates including acetaldehyde and reactive oxygen species (ROS). Single 
nucleotide polymorphisms (SNPs) in alcohol metabolism genes have been associated with 
SCCHN incidence, and genetic variation in the antioxidant pathways may impact ROS 
metabolism. We hypothesized that the genes involved in these pathways may influence 
survival after SCCHN diagnosis.  
 Interview and SNP genotyping data were obtained from 1227 white and African-
American cases from the Carolina Head and Neck Cancer Epidemiology study, a 
population-based case-control study of head and neck cancer conducted in North Carolina 
from 2002-2006. Vital status and date and cause of death through 2008 were obtained from 
the National Death Index. To identify survival differences between alleles of each SNP, we 
performed Kaplan-Meier log-rank tests and estimated both unadjusted and adjusted hazard 
ratios and 95% confidence intervals. 
 Minor alleles of two SNPs in CYP2E1 – the ‘C’ allele of both rs3813865 and 
rs8192772 – were associated with increased hazard of cancer-specific death in both 
adjusted and unadjusted analyses (HRadjusted, 95% CI = 2.09, 1.38-3.18; 1.71, 1.23-2.37), 
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respectively). Four additional SNPs in CYP2E1 and four in GPx1, SOD1, and SOD2 
displayed suggestive differences in allele hazards for all-cause and/or cancer death. No 
consistent associations with survival were found for SNPs in ADH1B, ADH1C, ADH4, ADH7, 
ALDH2, GPx2, GPx4, and CAT.  
 Polymorphisms in alcohol metabolism and ROS-detoxification genes influence 
survival in subjects with SCCHN. Previously unreported associations of SNPs in CYP2E1 
warrant further investigation, especially with regard to interaction with type of 
chemotherapeutic agent used for treatment.  
4.2 INTRODUCTION 
Head and neck cancers typically include cancers of the oral cavity, pharynx, larynx, 
nose, nasal cavity and sinuses, and esophagus. There were 49,260 new cases and 11,480 
deaths from oropharyngeal and laryngeal cancer in the U.S. in 2010 (219). Globally in 2008, 
oral cavity tumors were among the top 10 incident cancers in men world-wide, and among 
the top 10 fatal cancers in men in developing countries (220). Five-year relative survival for 
laryngeal and oropharyngeal cancer patients averages about 80% for localized cases, 50% 
for regional cases, and 33% for metastatic cases, with somewhat lower survival for laryngeal 
compared to oropharyngeal cancers (226). 
It is estimated that 75% of new cases of SCCHN in the United States are caused by 
tobacco use, especially cigarette smoking, and/or drinking of alcoholic beverages (56). In 
the past few decades the proportional incidence of oropharyngeal tumors associated with 
carcinogenic human papillomavirus sub-types has risen; such tumors appear to have better 
prognosis than non-HPV oropharyngeal tumors (227). Multiple studies have reported 
associations between SCCHN incidence and polymorphisms in alcohol metabolism genes, 
especially ADH1B, ADH1C, ADH4, ADH7, ALDH2, and CYP2E1 ((104, 105, 115, 121-127)). 
The primary biological mechanism responsible for this effect is hypothesized to be high 
levels of toxic and mutagenic acetaldehyde, the metabolic intermediate between ethanol 
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and acetate. Acetaldehyde, when associated with consumption of alcoholic beverages, is 
classified as a known human carcinogen by the International Agency for Research on 
Cancer (70). Also, alcohol metabolism through CYP2E1 is known to result in production of 
excess levels of reactive oxygen species (ROS) (228). The resulting DNA damage from 
these metabolic pathways may also influence cancer progression and, moreover, variation 
in pathway genes may modify progression and survival. Therefore, it is also of interest to 
know whether polymorphisms in genes encoding enzymes protective against oxidative 
stress (SOD, GPx, CAT) are associated with altered survival in SCCHN patients.  
In contrast to the multiple studies on genetic associations with SCCHN incidence, 
there have been few investigations of the effect of gene polymorphisms in alcohol 
metabolism and oxidative stress genes on survival of subjects with SCCHN. For example, 
only two studies investigated whether selected ADH1C and CYP2E1 polymorphisms 
influence prognosis, and they reported evidence of an association with advanced clinical 
stages or higher recurrence (124, 150). Further, no studies have examined the influence on 
post-diagnosis survival of genetic variation in the oxidative stress pathways.  
We examined the effect on survival of SNPs in genes in the alcohol metabolism and 
oxidative stress pathways, using exposure, genetic, clinical, and outcome data from cases 
included in a large North Carolina (NC) population-based case-control study of SCCHN.  
4.3 METHODS 
4.3.1 Study population 
Cases for this analysis were obtained from the Carolina Head and Neck Cancer 
Epidemiology study (CHANCE), a population-based case-control study (222). 
All cases of squamous cell carcinoma of the oral cavity, pharynx, and larynx 
diagnosed in 46 N.C. counties between January 1, 2002 and February 28, 2006 were 
eligible for enrollment. Rapid identification of cases was conducted by the N.C. Central 
Cancer Registry. CHANCE cases included ICD-O-3 topography codes C0.00 to C14.8, and 
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C32.0 to C32.9, excluding salivary gland tumors (C07.9, C08.0 to C08.9), nasopharynx 
(C11.0 to C11.9), nasal cavity (C30.0), and nasal sinuses (C31.0 to C31.9). ICD-O-3 
morphology codes included were 8010/3, 8051/3, 8083/3, 8071/3, 8072/3, 8073/3, 8074/3, 
and 8076/3. Benign tumors, carcinomas in situ, papillary carcinomas, and adenoid 
carcinomas were excluded. This analysis further excluded 21 lip cancers (C00.3-C00.9, 
C14.2), 26 cases of “other” race, and 115 without genotyping data, producing a study 
composition of 1227 cases, of which 922 were white/European-American and 305 were 
black/African-American.  
Case tumors were classified into anatomic sub-site according to the following 5 ICD-
O  categories that are also used by the International Head and Neck Cancer Epidemiology 
(INHANCE) Consortium (52): (1) oral cavity: C02.0-C02.3, C03.0, C03.1, C03.9, C04.0, 
C04.1, C04.8, C04.9, C05.0, C06.0-C06.2, C06.8, and C06.9; (2) oropharynx: C01.9, C02.4, 
C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0-C10.4, C10.8, and C10.9; (3) oral cavity-
oropharynx-hypopharynx NOS: C02.8, C02.9, C05.8, C05.9, C14.0, C14.2, and C14.8; (4) 
hypopharynx: C12.9, C13.0-C13.2, C13.8, and C13.9; and (5) larynx: C32.0-C32.3, and 
C32.8-C32.9.  
Written informed consent was obtained from all subjects. The study was approved by 
the Biomedical Institutional Review Board at the University of North Carolina at Chapel Hill.  
4.3.2 Outcome assessment 
We determined whether death had occurred in study participants by December 31, 
2008, and, if so, the date and cause, through linkage with the National Death Index (NDI). 
The NDI is a national file of identified death record information compiled from computer files 
submitted by State vital statistics offices. CHANCE collected multiple matching data: social 
security number (SSN), date of birth (DOB), sex, race, state of residence, and name. 
Therefore there was a high proportion (76% for 2008 deaths) of perfect/very close to perfect 
matches on SSN, DOB, and sex. A small number of partial matches (e.g. a few SSN digits, 
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parts of DOB) were examined and a determination was made whether to accept or not. If 
the initial three digits of the first-listed cause of death code were C01-C06, C09, C10, C12-
C14, or C32, the cause of death was classified as head and neck cancer.  
4.3.3 SNP Selection and Genotyping 
Blood samples were obtained at the time of questionnaire administration by nurse-
interviewers trained in phlebotomy. If the subject was not willing or able to consent to the 
blood draw, they were asked to contribute a buccal cell sample via mouthrinse.  
For this project, 75 SNPs (69 tag SNPs and 6 candidate SNPs found in prior studies 
to be associated with cancer incidence or survival, or alcohol dependence) were selected in 
12 genes that are part of two metabolic pathways: ADH1B, ADH1C, ADH4, ADH7, ALDH2, 
and CYP2E1 in the alcohol metabolism pathway in the upper aerodigestive tract; and CAT, 
SOD1, SOD2, GPx1, GPx2, and GPx4 in the oxidative stress metabolic pathway. Tag 
SNPs, chosen to represent the genetic variation within each of the 12 candidate genes 
(gene and 2000 bp upstream and downstream) were selected using the Genome Variation 
Server (223), using SNPs that were polymorphic in either CEU or YRI HapMap Release 2 
(unrelated only), and with the following parameters: allele frequency cutoff 10%, 0.8 R2 
threshold minimum for variations to belong to the same cluster, 85% minimum data 
coverage for tag SNPs, 70% minimal data coverage for a variation to be potentially 
clustered with others. 
To control for potential population stratification, we selected 157 Ancestry Informative 
Markers (AIMs) to maximize (1) the difference in allele frequencies (delta) between 
European and African populations in the HapMap data (CEU versus YRI), and (2) the 
Fisher’s information criterion (FIC). AIMs were prioritized based on having the highest delta 
and FIC values in the following order: 90% European/10% African, 10% European/90% 
African, and 50% European/50% African. This allowed AIMs to represent the entire 
expected ancestral distribution of the study population. Individual estimates of percentage 
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African ancestry were calculated from 145 successfully genotyped AIMs using maximum 
likelihood estimation (MLE) methods previously described (184, 189, 224). AIMs were 
chosen to differentiate only between African and European ancestry, so we derived 
individual ancestry estimates for the two groups that summed to 1.0.  
Genotyping was done by the Mammalian Genotyping Core Facility, University of 
North Carolina at Chapel Hill, using the Illumina GoldenGate genotyping assay with Sentrix 
Array matrix and 96-well standard microtiter plates. Technicians were blinded to case/control 
status of samples, and samples from both cases and controls were tested on each plate, 
along with DNA controls and random sample duplicates. Assay intensity data and genotype 
cluster images for all SNPs were individually reviewed to identify those with inadequate 
signal intensity or indistinguishable genotype clusters. Blind duplicates of 109 samples were 
genotyped to verify reliability of genotype calls. Tests of Hardy-Weinberg equilibrium (HWE) 
were conducted in controls stratified by race, and those SNPs for which the p-value was 
<0.001 were judged to be out of HWE.  
4.3.4 Covariate measurement  
Trained nurse-interviewers conducted an in-person interview with each subject. For 
this analysis only self-reported, non-proxy data were included. Questions were asked about 
demographics (age, sex, race-ethnicity, education, income, health insurance), cigarette 
smoking, drinking of alcoholic beverages, diet, oral health, medical history, family history of 
cancer, and textual information on co-morbid conditions.  
We made an initial selection of covariates based on a priori knowledge regarding 
their potential association with survival. Covariates obtained from the interview included age, 
sex, race; duration of cigarette smoking; ever-use of non-cigarette tobacco products, ever 
exposure to environmental tobacco smoke (ETS) at work, ever exposure to ETS at home; 
whether the subject was covered by health insurance on diagnosis date, ever had a routine 
dental visit, ever had a loose permanent tooth due to disease, ever used mouthwash; family 
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history of SCCHN; household poverty as defined by federal guidelines for both income and 
number of persons supported, highest attained education level; and presence of selected 
co-morbid diseases: liver disease including hepatitis, cardiovascular and/or lung disease, 
renal disease and/or diabetes, and other cancers. Alcohol consumption, although measured, 
was not included in analyses because it may be an intermediate in the causal pathway 
between the SNPs and survival.  
Clinical information about the tumor and its treatment were abstracted from the 
subjects’ medical record. Pathology reports were reviewed by the study pathologist (WF) 
and a head and neck cancer surgeon (MW). Tumor and treatment characteristics obtained 
included TNM and summary stages, margin status, angiolymphatic invasion status, and 
cancer treatment (surgery, radiation, and/or chemotherapy).  
4.3.5 Statistical analysis 
For all-cause death, months of survival were calculated by subtracting the date of 
diagnosis from the date of death, and subjects who were still alive on 12/31/2008 were 
censored on that date. For head-and-neck-cancer-specific death (hereafter referred to as 
cancer death or cancer-specific death), months of survival were calculated by subtracting 
the date of diagnosis from the date of cancer death, while subjects who died of another 
cause were censored as of the date of death; subjects who were still alive on 12/31/2008 
were censored on that date. Kaplan-Meier survival plots, and hazard ratios for the 
independent effects of SNPs from Cox proportional hazards regression models, were 
implemented in SAS® 9.2.  
Kaplan-Meier plots and log-rank tests for all-cause and cancer-specific survival were 
constructed for the two alleles of each SNP. Kaplan-Meier plots and log-rank tests were also 
constructed for all-cause and cancer specific survival for the two races, for all head-and-
neck cancers combined as well as separately for each anatomic sub-site.  
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A dominant genetic model (at least one minor allele versus referent of no minor 
alleles) was implemented because, for many of the SNPs, the number of subjects 
homozygous for the minor allele was too small to permit estimation of precise effect 
estimates.  
Potential covariates were selected using a step-wise backwards elimination from a 
full model (which contained demographic, socioeconomic status (SES), tumor, clinical, co-
morbid diseases, oral health, and tobacco exposure variables, as listed in Table 20) and 
comparison of each reduced model to the full model. There was no collinearity between any 
of the explanatory variables except possibly between race and ancestry. If eliminating a set 
of covariates did not change the ln(HR) for any SNP by a difference of at least 0.10, those 
covariates were eliminated from subsequent models. The final Cox models for all-cause and 
cancer-specific death included the demographic, SES, tumor, clinical, co-morbid diseases, 
oral health, and tobacco exposure variables listed in Table 21 footnotes. With self-reported 
race included in the model the ancestry variable was not important to all-cause or cancer-
specific death for the genetic variants studied, so for parsimony, and because ancestry and 
race showed evidence of collinearity, ancestry was not included in final models.  
For head and neck cancer, clinicians consider local-regional-distant stage 
classification to be inadequate for predicting survival; for example, advanced nodal (N) 
stage is a worse prognosticator than advanced loci disease (229, 230). Therefore, recent 
studies of survival in head and neck cancer patients most often control for cancer stage in 
Cox regression models by including separate variables representing tumor (T), node (N), 
and metastasis (M) stages. In CHANCE, comparison of two sets of hazard ratios and 
confidence intervals from Cox regression models that included summary stage, versus 
models that included separate variables for T, N, and M stages, revealed similar estimates 
from both methods. Therefore I decided to control for stage using three separate variables. 
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The angiolymphatic invasion variable was missing in 13.5% of subjects and that, 
along with a small percent missing in other covariates, resulted in 18% of records being 
excluded from complete-case analyses. In order to include available information from all 
cases, and because the data were not missing in a monotone pattern, we used the Markov 
Chain Monte Carlo method implemented in SAS® 9.2 PROC MI and information about non-
missing values from all variables in full models to impute missing values for variables 
included in final models. This method imputes missing values for binary variables (such as 
angiolymphatic invasion) as continuous values from a normal distribution, which we did not 
round to 0 or 1 because the continuous values are less biased. Hazard ratios reported from 
those analyses are summaries of HRs from Cox regressions using 25 imputed datasets, 
calculated using SAS® 9.2 PROC MIANALYZE.  
Bonferroni correction for 64 statistical tests was used to adjust p-values to control for 
Type 1 error introduced by multiple statistical testing.  
4.4 RESULTS 
Mean survival in subjects with SCCHN was 45.5 months (Table 19). Mean/median 
survival for those with hypopharynx tumors was lower (35/30 months) than for those with 
other tumor sites (43-47/45-48 months). For subjects who died during the follow-up period, 
mean/median survival for all-cause death was 26.2/22.4 months, and for cancer-specific 
death, 22.3/18.7 months.   
Genotyping. DNA samples from 1266 CHANCE SCCHN cases of white or African-
American race were genotyped. Of these, 38 failed to genotype, and 1 was gender 
discrepant, leaving 1227 cases with genotyping data. Of the 75 tag and candidate SNPs for 
which genotyping was attempted, 8 tag SNPs and 1 candidate SNP were excluded from 
analyses due to inadequate signal intensity or inability to distinguish genotype clusters, and 
2 tag SNPs were excluded due to genotypes being out of HWE at the p<0.001 level, leaving 
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64 tag and candidate SNPs available for analyses. Genotype calls for blind duplicates were 
concordant for all SNPs. All 1227 cases had less than 4% missing SNP results. 
Descriptive analyses. Table 20 presents the frequency distributions and hazard 
ratios for the initial set of covariates within the study population. Eighty percent of the 
subjects were 50 years of age or older upon diagnosis, three-quarters were male, and 25% 
were African-American.  
For both all-cause and cancer-specific survival, more subjects with oropharynx 
cancer survived compared to those with oral cavity and hypopharynx tumors (Table 20). 
Increased survival was also associated with: lower Tumor and Node stages, absence of 
angiolymphatic invasion, having had surgical cancer treatment, absence of cardiovascular 
and lung disease, and shorter duration of smoking. In addition, having survived was also 
associated with being younger, richer, and more educated; absence of cardiovascular or 
lung disease; having had at least one routine dental visit in the last 10 years, and not having 
been exposed to environmental tobacco smoke (ETS) at home. Surprisingly, race was 
associated with all-cause death but not cancer-specific death in univariate analysis. 
Examination of univariate hazard ratios for all-cause and cancer-specific death 
calculated for each potential covariate in separate Cox regression models (without SNPs) 
(Table 20), indicates that, with only a few exceptions, the same variables that are associated 
with vital status (yes/no) are also associated with length of all-cause and cancer-specific 
survival.  
SNP hazard ratios and survival plots. Backwards elimination of potential covariates, 
from 64 full models each containing one SNP (of the 64 studied) and all covariates listed in 
Table 20, produced a Cox regression model for all-cause death containing the following 
covariates: SNP being analyzed (one per model), anatomic subsite, T stage, N stage, M 
stage, angiolymphatic invasion status, treatment (surgery, chemotherapy), co-morbid 
cardiovascular or lung disease, duration of cigarette smoking, and routine dental care. The 
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final Cox regression model for cancer death contained all those variables, plus radiation 
treatment, co-morbid liver disease, sex, race, age category, federal poverty group, exposure 
to ETS at work, and tooth mobility due to disease. 
In unadjusted analyses, most SNPs were not associated with significantly increased 
hazard of all-cause or cancer death (Table 21). However, two SNPs in CYP2E1 – 
rs3813865 and rs8192772 – were statistically associated with increased hazard of cancer 
death after adjustment for confounders in complete-case analysis and Bonferroni correction 
of p-values, with a similar pattern noted after adjustment for confounders in multiple 
imputation analysis (Table 21). Carrying ‘C’ minor allele of rs3813865 was associated with 
more than double the hazard of cancer death compared to the ‘G’ allele. Similarly, carrying 
‘C’ allele of rs8192772 was associated with about 80% increased cancer death hazard 
compared to the ‘T’ allele. A non-significant increase in hazard of all-cause death was also 
noted for these SNPs. Separate analysis of deaths due to head and neck cancer versus 
deaths due to other causes indicates that there was no association of these SNPs with non-
cancer deaths, and the non-significant increase in hazard of all-cause death was caused by 
cancer deaths (data not shown). Figure 9 presents the Kaplan-Meier survival curves for 
these SNPs.  
There were no statistically significant differences in hazard ratios by race, because 
imprecise effect estimates precluded detailed study of this question. For example, carrying 
the CYP2E1 rs3813865 minor ‘C’ allele, present in 26% of African-Americans and 5% of 
whites, conferred an increased HR (95% CI) in all subjects of 2.1 (1.4-3.2), which was 2.8 
(1.5-5.2) in African-Americans, and 1.4 (0.7-2.9) in whites. Carrying the minor ‘C’ allele of 
rs8192772, present in 22% of African-Americans and 14% of whites, conferred similar 
increased risks in blacks and whites, with a HR (95% CI) of 1.7 (1.2-2.4) in all subjects, 2.1 
(1.1-4.3) in African-Americans, and 1.5 (1.0-2.3) in whites. Although no other SNP HRs 
achieved statistical significance in the adjusted Cox models, four additional SNPs in 
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CYP2E1 (rs7092584, rs743535, rs2249695, rs28969387), and four SNPs in the oxidative 
stress pathway (rs11623705 and rs2412065 in GPx2, rs2070424 in SOD1, and rs2842980 
in SOD2) displayed suggestive differences in allele hazards for either or both all-cause and 
cancer death from Kaplan-Meier and log-rank analysis (Table 22). 
To investigate the effect of including alcohol consumption and percent African 
ancestry variables to the final reduced models, hazard ratios were re-calculated with those 
variables included. Effect estimates changed very little, if at all (data not shown).  
 
4.5 DISCUSSION 
In this study we evaluated the association of SNPs in genes in alcohol metabolism 
and oxidative stress pathways with survival after SCCHN diagnosis. We found that the minor 
alleles of several SNPs in CYP2E1 were significantly associated with increased hazard for 
death from head and neck cancer.  
CYP2E1 is a member of the cytochrome P450 oxidative system that is involved in 
metabolism of xenobiotics, ethanol, and drugs (231). Although CYP2E1 enzymatically 
inactivates some substrates, it has also been shown to bioactivate many compounds that 
are possibly carcinogenic; for example, the tobacco carcinogen N-nitrosamines, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (232). Indeed, the induction of alcohol 
metabolism, especially the CYP2E1 pathway, has been suggested as one of the key modes 
of alcohol-induced cancer (233). Laboratory studies have demonstrated that the most 
common chemotherapy drugs used to treat SCCHN – i.e., platinum-containing 
chemotherapeutic agents – increase in vivo CYP2E1 activity in mice, and in vitro CYP2E1 
activity in renal and liver cells and liver microsomes (234-237). Moreover, numerous studies 
report that increased CYP2E1 activity is cytotoxic to liver cells in vitro and in mouse models, 
and decreased activity is protective against liver damage (238). Thus it is plausible that 
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CYP2E1 polymorphisms may differentially affect CYP2E1 activity when exposed to 
platinum-containing chemotherapy drugs.  
The genes for Class I CYPs are highly conserved. Some polymorphisms have been 
found to be associated with cancer risk and survival. For example RsaI/rs2031920 and a 96-
bp insertion polymorphism have been associated with colorectal and esophageal cancer 
(232). It is thought that these effects are produced by CYP2E1 inducibility rather than 
enzyme function. One study suggested that CYP2E1 polymorphisms play a role in the 
metabolism of drugs used to treat non-Hodgkin lymphoma, with one allele of rs2070673 
associated with longer survival (239), and another reported a significant association 
between CYP2E1 rs2031920 wild-type C allele and improved survival from non-small cell 
lung cancer (240).  
Our findings provide evidence that CYP2E1 gene polymorphisms are associated with 
survival from head and neck cancer. Similar to other studies reporting that apparently non-
functional CYP2E1 SNPs influence cancer risk, the two SNPs we identified are also in 
typically non-coding regions of the genome – rs3813865 in the 5’ region near the gene, and 
rs8192772 in intron 2. Interestingly, some studies have suggested that upstream 5’ 
mutations in CYP2E1 may affect gene expression and inducibility by ethanol (241). If these 
SNPs are not causal, they may instead be in linkage disequilibrium with a causal 
polymorphism.  
Stratified analysis identified little difference in HR for the minor ‘C’ allele of 
rs3813865 in those who received chemotherapy (HR=2.0, 95% CI=1.0-3.8) and those who 
didn’t (HR=2.2, 95% CI=1.3-3.9), but there was a large difference in HR for rs8192772 for 
those who received chemotherapy (HR=1.2, 95% CI=0.7-2.0) versus those who didn’t 
(HR=2.1, 95% CI=1.4-3.2), indicating that some of the survival effects of CYP2E1 
polymorphisms may be mediated through either the differential effect of SNP alleles on the 
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metabolism of the chemotherapeutic agent and/or the differential effect of the 
chemotherapeutic agent on CYP2E1 activity.  
Although one previous study reported an association of CYP2E1 rs2031920 with 
advanced T stage SCCHN (124), ours is the first study to report the association of SNPs in 
CYP2E1 with survival after SCCHN diagnosis. Our results are compatible with the 
hypothesis that genetic predisposition affects cancer-specific survival after diagnosis, and 
that at least some of this effect may be mediated by interaction of chemotherapeutic agents 
with CYP2E1 polymorphisms. We did not, however, find any other SNPs in the alcohol 
metabolism pathway, or in the oxidative stress pathway, to be associated with survival, 
either cancer-specific or overall. We also did not have detailed information on the specific 
chemotherapeutic agents administered to our subjects; some drugs may interact with 
CYP2E1 to affect survival and others may not, which would confound our results.  
In conclusion, our study found multiple SNPs in CYP2E1 to be associated with 
cancer-specific survival. Some had different effects in those who received chemotherapy 
versus those who didn’t, while others had the same effect in both groups. Future genetic 
survival analyses of head and neck cancer should confirm the association with these SNPs 
and investigate potentially causal loci. Such research would improve understanding of 
differential treatment effects on head and neck tumor progression and metastasis.  
  
Table 19. Survival1 within study population
Variable Categories n (col %)
Vital status
Alive 744 60.6%
Dead 483 39.4%
Cause of death head and neck cancer?
No (other cause) 268 21.8%
Yes 215 17.5%
N/A (alive) 744 60.6%
n Mean Median Std dev
All subjects 1227 45.5 46.0 21.8
Oral cavity 172 43.0 44.7 22.6
Oropharynx 333 47.0 46.7 21.5
Hypopharynx 55 35.0 30.0 22.3
224 44.0 45.8 22.5
Larynx 443 47.3 47.7 20.7
Subjects who died of any cause 483 26.2 22.4 17.0
Subjects who died of head and neck cancer 215 22.3 18.7 14.1
1 Vital status as of 12/31/2008, as determined from NDI
Cases (n=1227)
Survival (months)
Oral cavity - oropharynx - hypopharynx NOS
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Table 20. Descriptives and univariate hazard ratios for non-SNP variables -- one explanatory variable per model
(complete case analysis)
Potential covariate (type) Covariate values
# (%) of total 
cases
# died/
# survived HR1 (95% CI)
 unadjusted p-
value (BOLD 
if <0.05)
# died/
# survived HR1 (95% CI)
 unadjusted p-
value (BOLD 
if <0.05)
DEMOGRAPHICS
Age category (ordinal) 20-49 years 239 (19.5%) 80/159 1.08 (1.03-1.13) 0.002 40/199 1.06 (0.99-1.14) 0.097
50-54 years 189 (15.4%) 75/114 30/159
55-59 years 207 (16.9%) 70/137 33/174
60-64 years 205 (16.7%) 79/126 36/169
65-69 years 168 (13.7%) 78/90 29/139
70-74 years 135 (11.0%) 58/77 26/109
75-80 years 84 (6.8%) 43/41 21/63
Sex (categorical) Female 289 (23.6%) 111/178 1.00 (ref) 57/232 1.00 (ref)
Male 938 (76.4%) 372/566 1.05 (0.85-1.30) 0.644 158/780 0.87 (0.64-1.18) 0.363
Race (categorical) White/European-American 922 (75.1%) 339/583 1.00 (ref) 160/762 1.00 (ref)
Black/African-American 305 (24.9%) 144/161 1.41 (1.16-1.72) 0.000 55/250 1.13 (0.83-1.54) 0.427
1227 1.63 (1.25-2.12) 0.000 1.18 (0.78-1.79) 0.435
TUMOR/TREATMENT CHARACTERISTICS
Anatomic subsite (categorical) oral cavity (referent) 172 (14.0%) 83/89 1.00 (ref) 38/134 1.00 (ref)
hypopharynx 55 (4.5%) 35/20 1.59 (1.07-2.36) 0.021 15/40 1.44 (0.79-2.62) 0.231
larynx 443 (36.1%) 169/274 0.71 (0.55-0.93) 0.012 70/373 0.65 (0.44-0.97) 0.033
oral cavity-oropharynx-
hypopharynx NOS 224 (18.3%) 83/141 0.75 (0.55-1.02) 0.065 41/183 0.81 (0.52-1.26) 0.359
oropharynx 333 (27.1%) 113/220 0.64 (0.48-0.85) 0.002 51/282 0.64 (0.42-0.97) 0.037
T stage (ordinal) T1, T1a, T1b 392 (31.9%) 105/287 1.43 (1.32-1.55) 0.000 31/361 1.64 (1.45-1.85) 0.000
T2 409 (33.3%) 151/258 69/340
T3 218 (17.8%) 108/110 53/165
T4, T4a, T4b 208 (17.0%) 119/89 62/146
N stage (ordinal) N0 657 (53.5%) 223/434 1.31 (1.20-1.43) 0.000 84/573 1.50 (1.31-1.71) 0.000
N1 156 (12.7%) 59/97 31/125
N2, N2a, N2b, N2c 366 (29.8%) 170/196 79/287
N3 48 (3.9%) 31/17 21/27
M stage (categorical) M0 1219 (99.3%) 476/743 1.00 (ref) 210/1009 1.00 (ref)
M1 8 (0.7%) 7/1 7.63 (3.60-16.17) 0.000 5/3 10.79 (4.41-26.40) 0.000
Margin status (categorical) Negative 396 (32.3%) 151/245 1.00 (ref) 64/332 1.00 (ref)
Positive 691 (56.3%) 284/407 1.13 (0.93-1.38) 0.225 128/563 1.19 (0.88-1.60) 0.263
Missing 140 (11.4%) 48/92 23/117
Angiolymphatic invasion Absent 954 (77.8%) 371/583 1.00 (ref) 162/792 1.00 (ref)
(categorical) Present 107 (8.7%) 52/55 1.47 (1.10-1.96) 0.010 26/81 1.64 (1.08-2.48) 0.020
Missing 166 (13.5%) 60/106 27/139
Surgical treatment (categorical) No 537 (43.8%) 243/294 1.00 (ref) 114/423 1.00 (ref)
Yes 690 (56.2%) 240/450 0.69 (0.58-0.83) 0.000 101/589 0.63 (0.48-0.83) 0.001
Radiation treatment (categorical) No 282 (23.0%) 92/190 1.00 (ref) 36/246 1.00 (ref)
Yes 945 (77.0%) 391/554 1.36 (1.08-1.71) 0.008 179/766 1.57 (1.10-2.24) 0.014
Chemotherapy treatment No 754 (61.5%) 287/467 1.00 (ref) 125/629 1.00 (ref)
(categorical) Yes 473 (38.5%) 196/277 1.17 (0.98-1.41) 0.088 90/383 1.22 (0.93-1.60) 0.157
COMORBID DISEASES
Comorbid liver disease and/or No 1113 (90.7%) 420/693 1.00 (ref) 187/926 1.00 (ref)
hepatitis (categorical) Yes 105 (8.6%) 57/48 1.63 (1.23-2.15) 0.001 24/81 1.49 (0.97-2.27) 0.068
Missing 9 (0.7%) 6/3 4/5
Comorbid cardiovascular and/or No 887 (72.3%) 302/585 1.00 (ref) 145/742 1.00 (ref)
lung disease (categorical) Yes 336 (27.4%) 158/178 1.45 (1.20-1.74) 0.000 68/268 1.29 (0.97-1.72) 0.085
Missing 4 (0.3%) 2/2 2/2
Comorbid renal disease and/or No 1053 (85.8%) 403/650 1.00 (ref) 186/867 1.00 (ref)
diabetes (categorical) Yes 167 (13.6%) 74/93 1.23 (0.96-1.58) 0.098 26/141 0.94 (0.62-1.42) 0.772
Missing 7 (0.6%) 6/1 3/4
Comorbid disease: other cancer No 1019 (83.0%) 395/624 1.00 (ref) 177/842 1.00 (ref)
(categorical) Yes 204 (16.6%) 85/119 1.08 (0.85-1.37) 0.521 35/169 0.98 (0.68-1.41) 0.918
Missing 4 (0.3%) 3/1 3/1
# comorbid conditions (continuous) (mean # in those who died) 1227 1.21 (1.11-1.32) 0.000 1.13 (0.99-1.28) 0.074
OTHER POTENTIAL CONFOUNDERS
1227 1.02 (1.02-1.03) 0.000 1.02 (1.01-1.03) 0.000
1.36 (1.23-1.52) 0.000 1.24 (1.07-1.44) 0.005
Federal poverty guideline At or above 816 (66.5%) 271/545 1.00 (ref) 126/690 1.00 (ref)
(categorical) Below 356 (29.0%) 188/168 1.87 (1.55-2.25) 0.000 76/280 1.59 (1.19-2.11) 0.002
Missing 55 (4.5%) 24/31 13/42
Routine dental visit in last 10 Yes 781 (63.7%) 240/541 1.00 (ref) 118/663 1.00 (ref)
years (categorical) No 438 (35.7%) 238/200 2.06 (1.72-2.46) 0.000 94/344 1.63 (1.24-2.14) 0.000
Missing 8 (0.7%) 5/3 3/5
Environmental tobacco smoke No 399 (32.5%) 128/271 1.00 (ref) 59/340 1.00 (ref)
exposure at home (categorical) Yes 827 (67.4%) 354/473 1.38 (1.13-1.69) 0.002 155/672 1.31 (0.97-1.76) 0.081
Missing 1 (0.1%) 1/0 1/0
Environmental tobacco smoke No 316 (25.8%) 134/182 1.00 (ref) 58/258 1.00 (ref)
exposure at work (categorical) Yes 909 (74.1%) 348/561 0.87 (0.71-1.06) 0.154 155/754 0.90 (0.66-1.21) 0.478
Missing 2 (0.2%) 1/1 1/1
Proportion African ancestry (continuous) (mean % in those who 
died)
Smoking duration, rounded to nearest whole year (continuous) 
(mean # years in those who died)
DEATH FROM ALL CAUSES 
(n=483)
DEATH FROM HEAD & NECK 
CANCER
(n=215)
Alcoholic beverages, lifetime consumption of ethanol in ml, 
never-users and tertiles of drinking (ordinal)
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Table 20. Descriptives and univariate hazard ratios for non-SNP variables -- one explanatory variable per model
(complete case analysis)
Potential covariate (type) Covariate values
# (%) of total 
cases
# died/
# survived HR1 (95% CI)
 unadjusted p-
value (BOLD 
if <0.05)
# died/
# survived HR1 (95% CI)
 unadjusted p-
value (BOLD 
if <0.05)
DEATH FROM ALL CAUSES 
(n=483)
DEATH FROM HEAD & NECK 
CANCER
(n=215)
Ever used non-cigarette tobacco No 754 (61.5%) 292/462 1.00 (ref)
129/625
1.00 (ref)
product (categorical) Yes 473 (38.5%) 191/282 1.06 (0.88-1.27) 0.552 86/387 1.08 (0.82-1.42) 0.590
Had health insurance on Yes 1068 (87.0%) 403/665 1.00 (ref) 177/891 1.00 (ref)
reference date (categorical) No 154 (12.6%) 76/78 1.50 (1.17-1.92) 0.001 36/118 1.58 (1.11-2.27) 0.012
Missing 5 (0.4%) 1/1 2/3
Highest education level attained High school or more 828 (67.5%) 286/542 1.00 (ref) 133/695 1.00 (ref)
(categorical) Less than high school 399 (32.5%) 197/202 1.57 (1.31-1.89) 0.000 82/317 1.39 (1.06-1.83) 0.019
Ever had loose permanent tooth No 765 (62.3%) 276/489 1.00 (ref) 138/627 1.00 (ref)
due to disease (categorical) Yes 455 (37.1%) 202/253 1.29 (1.08-1.55) 0.005 74/381 0.93 (0.70-1.24) 0.638
Missing 7 (0.6%) 5/2 3/4
Ever regularly used mouthwash No 502 (40.9%) 191/311 1.00 (ref) 82/420 1.00 (ref)
(categorical) Yes 719 (58.6%) 287/432 1.06 (0.89-1.28) 0.501 131/588 1.14 (0.86-1.50) 0.369
Missing 6 (0.5%) 5/1 2/4
Family history of H&N cancer in No 1206 (98.3%) 474/732 1.00 (ref) 210/996 1.00 (ref)
1st degree relatives (categorical) Yes 21 (1.7%) 9/12 1.13 (0.58-2.18) 0.722 5/16 1.39 (0.57-3.37) 0.466
1 For categorical variables, HRs are in comparison to referent category. For continuous and ordinal variables, HRs are per unit of measurement and are 
cumulative (e.g. HR per year of age, HR per each additional comorbid disease, HR per each higher stage category)
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Table 22. Hazard differences between alleles of selected SNPs
gene snp
major/
minor 
allele
 Adjusted HR1 
(95% CI) Unadjusted
Bonferroni-
corrected 
(64 tests)
 Adjusted HR2 
(95% CI) Unadjusted
Bonferroni-
corrected 
(64 tests)
CYP2E1 rs3813865 G/C 1.47 (1.12-1.92) 0.002 0.099 2.09 (1.38-3.18) 0.008 0.505
rs8192772 T/C 1.40 (1.12-1.76) 0.002 0.146 1.71 (1.23-2.37) 0.004 0.276
rs7092584 C/T 1.26 (1.02-1.55) 0.009 0.600 1.37 (1.01-1.86) 0.042 1.000
rs743535 C/T 1.23 (1.00-1.52) 0.006 0.390 1.55 (1.13-2.11) 0.005 0.309
rs2249695 C/T 1.07 (0.89-1.28) 0.002 0.159 1.33 (0.98-1.81) 0.021 1.000
rs28969387 A/T 1.12 (0.66-1.89) 0.031 1.000 1.43 (0.67-3.06) 0.035 1.000
GPX2 rs11623705 G/T 0.98 (0.77-1.24) 0.681 1.000 1.41 (1.02-1.97) 0.030 1.000
rs2412065 G/C 1.04 (0.87-1.25) 0.044 1.000 1.27 (0.96-1.69) 0.025 1.000
SOD1 rs2070424 A/G 1.12 (0.89-1.40) 0.036 1.000 1.31 (0.93-1.82) 0.040 1.000
SOD2 rs2842980 A/T 1.16 (0.97-1.39) 0.040 1.000 1.47 (1.11-1.94) 0.005 0.331
3 Kaplan-Meier log-rank test for differences between the survival curves for the two alleles of each SNP
2 Cox models used to calculate hazard ratios for cancer-specific death included snp coded for dominant model (any minor allele versus 
homozygous major allele) and all covariates listed above for all-cause death models, plus the following additional variables: radiation 
treatment, presence of comorbid liver disease or hepatitis, sex, race, age, federal poverty level, ever exposure to environmental tobacco 
smoke at work, ever loss of a tooth due to disease. 25 datasets were imputed, and results were summarized as a single HR.
1 Cox models used to calculate hazard ratios for all-cause death included snp coded for dominant model (any minor allele versus 
homozygous major allele), anatomical site, T stage, N stage, M stage, angiolymphatic invasion status, treatment (surgery, chemotherapy), 
presence of comorbid cardiovascular or lung disease, duration of smoking cigarettes (years), reception of at least one routine dental visit in 
past 10 years. 25 datasets were imputed, and results were summarized as a single HR.
ALL-CAUSE DEATH CANCER DEATH
p-values from Kaplan-
Meier log-rank tests3
p-values from Kaplan-
Meier log-rank tests3
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Figure 9. Kaplan-Meier survival plots for CYP2E1 rs3813865 and rs8192772 alleles 
 
  
 
 
CHAPTER 5   
 
SUMMARY AND CONCLUSIONS 
5.1 SPECIFIC AIMS 
This dissertation research investigating the association of genetic variation in the 
alcohol and oxidative stress metabolism pathways with head and neck cancer accomplished 
the following aims: to measure (1) main effects of genetic variation on risk of developing 
cancer; (2) interaction of genetic variations with ethanol consumption from alcoholic 
beverages; and (3) main effects of genetic variation on survival after cancer diagnosis. 
5.2 STUDY POPULATION AND DATA COLLECTION 
To accomplish these aims, data from a single study population, the Carolina Head 
and Neck Cancer Epidemiology study (CHANCE), were analyzed. CHANCE was a large 
population-based case-control study of squamous cell carcinoma of the head and neck 
conducted in North Carolina (United States) from 2002-2006. It included both white and 
African-American cases and controls, with controls being frequency matched to cases on 
sex, race, and age category. Rapid ascertainment techniques were used to identify cases in 
an effort to capture cases while they were still capable of personally answering the 
questionnaire and providing a biological sample.   
Nurse-administered questionnaires were used to gather self-report information. This 
study analyzed questionnaire data regarding demographics (sex, age, and race); duration, 
frequency, size, and type of alcoholic beverages consumed; duration and frequency of 
cigarette smoking; exposure to environmental tobacco smoke and non-cigarette tobacco 
products; socioeconomic variables of education, income, and health insurance; oral health; 
co-morbid disease; and family history of cancer.  
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Many previous case-control studies measured odds ratios for functional or presumed 
functional non-synonymous polymorphisms in candidate genes. Because synonymous 
SNPs and variations in introns and up- and down-stream regions can also affect enzyme 
function, I wanted to study greater genetic variation across each candidate gene (six genes 
in each pathway) rather than only non-synonymous SNPs. Therefore, for each gene, tag 
SNPs were selected that were in high linkage disequilibrium with other SNPs in the same 
gene, including an additional 2000 bp both up- and down-stream, with the goal of capturing 
80% of the genetic variation within and near each gene. This would allow us to also examine 
the effect of haplotypes on cancer risk. In addition to tag SNPs, six candidate SNPs 
examined in previous studies of head and neck or other cancers were also genotyped. DNA 
extracted from blood and buccal samples was genotyped for each SNP; the laboratory 
successfully genotyped 64 of 75 SNPs (85%), including 59 tag and 5 candidate SNPs.  
Because the study population included both whites and African-Americans, it was 
possible that population stratification could bias effect measure estimates. Self-reported 
race, which does not take admixture into account, might have been inadequate for purposes 
of controlling for population stratification in regression analyses. Therefore CHANCE 
investigators also genotyped ancestry informative markers (AIMs, 157 SNPs) that were 
selected to be highly divergent between African and European-American HapMap 
populations (YRI and CEU, respectively) for purposes of constructing an estimate of 
proportion of African ancestry. The laboratory successfully genotyped 145 of 157 AIMs 
(92%).  
For Aim 3, CHANCE physician investigators abstracted clinical information from 
subjects’ medical records about tumor location, stage, treatment, and other prognostic 
factors such as presence of angiolymphatic invasion and surgical margin status. Vital status 
and date and cause of death were obtained from linkage with the National Death Index as of 
12/31/2008. 
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5.3 FINDINGS 
5.3.1 Aim 1 
The minor allele of two SNPs was associated with altered SCCHN risk: the ‘A’ allele 
of ADH1B rs1229984 was associated with decreased odds and the ‘C’ allele of ALDH2 
rs2238151 with increased odds. In addition, minor alleles of three SNPs were associated 
with increased cancer odds in anatomic sub-sites: the ‘C’ allele of ADH1B rs17028834 with 
laryngeal cancer, the ‘A’ allele of SOD2 rs4342445 with oral cavity tumors, and the ‘T’ allele 
of SOD2 rs5746134 with hypopharyngeal cancer. Previous studies, including a recent 
genome-wide association study spearheaded by IARC, have also found decreased risk 
associated with the A allele of ADH1B rs1229984, but have not reported the associations I 
found between ADH1B rs17028834 and laryngeal cancer, or between ALDH2 rs2238151 
and SCCHN. No other studies have examined SNPs in SOD2 in regard to risk of SCCHN or 
any of its anatomic sub-sites. 
Most SNPs studied (59 of 64, or 92%) were not associated with altered cancer risk. 
No SNPs in ADH1C, ADH4, ADH7, CYP2E1, CAT, GPx1, GPx2, GPx4, and SOD1 were 
associated with risk of developing head and neck cancer. Though other studies have 
investigated SNPs in ADH1C, ADH4, ADH7, and CYP2E1, this is the first study to 
investigate the association of CAT, GPx1, GPx2, GPX4, and SOD1 with SCCHN.  
Because alcohol may be in the causal pathway between SNPs in these genes and 
SCCHN, I did not adjust for alcohol consumption when estimating odds ratios for SNPs. 
Sex, race, and age category were included in conditional logistic regression models 
because controls were frequency matched to cases on these variables. Although I included 
13 potential covariates in initial models, including measurements of tobacco exposure, 
socioeconomic status, health history, and percent African ancestry, the only variable that 
materially affected odds ratios was years of cigarette smoking. The fact that adjusting for 
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African ancestry did not change effect estimates provides evidence that self-reported race 
sufficiently controlled for population stratification in the CHANCE study population.  
5.3.2 Aim 2 
Many studies have investigated interaction between alcohol metabolism genes and 
alcoholic beverage consumption. The strongest associations were found in Asian 
populations, in which the highly prevalent null (non-functional) and 10% functional 
genotypes of ALDH2 are markedly associated with increased SCCHN risk in drinkers. 
Although the prevalence of the null ALDH2 genotype is very low (<5%) or non-existent in 
non-Asian populations, including CHANCE, studies in other populations have reported that a 
common polymorphism of another gene, ADH1B, in the alcohol metabolism pathway is 
associated with risk. The “slow” form of ADH1B, which is about 40 times slower at 
metabolizing ethanol than the fast form – is associated with reduced risk of SCCHN overall, 
and synergistically interacts with lifetime alcohol consumption. Conversely, the majority of 
studies of the fast versus slow form of ADH1C reported no main effect on SCCHN 
incidence, but some evidence of increased risk in drinkers. It is important to note that the 
ADH1C fast form is only 2 ½ times faster at processing ethanol than the slow form, which 
may explain why fewer effects on cancer incidence are noted for ADH1C compared to 
ADH1B. Although my findings were consistent with the literature for the slow form of ADH1B 
being associated with reduced SCCHN risk, in contrast to many other studies I found no 
evidence of its interaction with alcohol consumption. Consistent with most studies of the 
ADH1C fast allele, I found no main effect or interaction with alcohol for that polymorphism.   
This study found four tag SNPs in alcohol metabolism genes that showed evidence 
of additive interaction with the level of alcohol consumption, in the entire population and 
suggestively among whites and African-Americans separately: ADH1B rs1159918, ADH7 
rs1154460, ALDH2 rs2238151, and CYP2E1 rs2249695. These SNPs are different from 
those reported by previous studies of alcohol interaction and SCCHN incidence. The body of 
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literature supports the hypothesis that polymorphisms of ADH and ALDH genes produce 
enzymes that interact differentially with alcohol to affect SCCHN incidence, so it is not 
surprising that my tag SNPs, due to linkage disequilibrium with causal alleles, would also 
pick up signals of genetic interaction with alcohol. Evidence of CYP2E1 interaction with 
alcohol had been less compelling. However, a 2011 linkage study reported that, consistent 
with my finding, rs2249695 is associated with “tipsiness” and is a predictor of alcoholism 
risk.   
This is the only study to report having examined interactions of alcohol with SNPs in 
oxidative stress genes. I found no evidence of interaction for these genes and alcohol. 
Alcohol metabolism genes interact with alcohol by causing direct DNA damage via 
acetaldehyde and ROS, as well as discomfort or tipsiness mechanisms that influence the 
individual’s level of drinking. Discomfort mechanisms are unlikely to occur due to the action 
of oxidative stress genes, which are not known to affect how individuals feel upon drinking, 
so the effects of these genes on cancer incidence are likely due to direct DNA damage. 
5.3.3 Aim 3 
With the exception of one study examining a single SNP in SOD2, this is the only 
study to have examined survival associations of polymorphisms in the alcohol metabolism 
and oxidative stress pathways. 
Carrying the C allele for either of two SNPs in CYP2E1 is associated with increased 
hazard of head-and-neck-cancer-specific death in both adjusted and unadjusted analyses. 
Four additional SNPs in CYP2E1 and four in GPx1, SOD1, and SOD2 displayed suggestive 
differences in allele hazards for all-cause and/or cancer death. No consistent associations 
with survival were found for SNPs in ADH1B, ADH1C, ADH4, ADH7, ALDH2, GPx2, GPx4, 
and CAT.  
  143 
Adjusting for self-reported race was sufficient to control for confounding by race in 
Cox proportional hazards models, and including percent African ancestry in models did not 
change hazard ratio estimates.  
Alcohol was excluded from main effects models because it may be in the causal 
pathway between SNPs and survival. In addition to the potential confounders tested for 
inclusion in the logistic regression models for odds of developing cancer, initial Cox models 
for survival included variables representing presence of selected co-morbid diseases (liver, 
cardiovascular/lung, renal/diabetes, other cancers), TNM stage, margin status, presence of 
angiolymphatic invasion, and treatment (surgery, radiation, and/or chemotherapy). As 
expected, both overall and cancer-specific survival were affected by smoking and many 
other factors, including TNM stage, angiolymphatic invasion, surgical cancer treatment, and 
co-morbid cardiovascular/lung disease, although margin status, believed to be clinically 
important, was not associated with survival in either univariate or adjusted analyses. 
Socioeconomic, health, and other variables that were not important to cancer incidence 
became important for survival after diagnosis, including income, education level, co-morbid 
cardiovascular/lung disease, exposure to environmental tobacco smoke at home, and 
whether or not the subject had at least one routine dental visit in the past 10 years. I find it 
very interesting that having had a routine dental visit is strongly associated with improved 
all-cause and cancer-specific survival. Is this a marker for having received preventive health 
care in general, or for oral health as an independent factor influencing survival? Having had 
routine dental care is partially correlated (Pearson’s correlation coefficients ranging from 
0.14 to 0.35) with race, lifetime alcohol drinking, duration of cigarette smoking, poverty level, 
highest attained education, having had tooth mobility due to disease,  and whether the 
person had health insurance at the time of diagnosis. It is therefore difficult to rule out 
residual confounding from socioeconomic factors as the source of oral health care’s 
importance in regression models.  
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Because CYP2E1 metabolizes the platinum-containing chemotherapeutic agents 
often used to treat SCCHN, and its metabolism of alcohol and xenobiotics is associated with 
liver damage and cancer in animal models, it is biologically plausible that polymorphisms in 
this gene might affect enzyme function, treatment efficacy, and thus survival. The two 
CYP2E1 SNPs most associated with cancer-specific survival in this study are located in the 
5’ region near the gene and in intron 2, three suggestively associated SNPs were in introns, 
and only one suggestively associated SNP was a missense variant. Although it is possible 
that some of the SNPs I investigated were functional, it is more likely that they are simply 
markers of other variants that are the true causal polymorphisms.  
Suggestive survival effects of SNPs in GPx1, SOD1 and SOD2 need to be 
investigated in other and larger studies, as my findings are not statistically significant.  
5.3.4 Across specific aims 
Polymorphisms in ADH1B, ALDH2, CYP2E1, and SOD2 were found to have multiple 
associations with incidence or survival, across more than one specific aim. These 
associations are summarized below.  
Carriers of the minor allele of two SNPs in ADH1B were found to have higher odds of 
developing SCCHN and laryngeal tumors (Aim 1), and a third SNP in this gene interacted 
with ethanol consumption to increase risk in heavy drinkers (Aim 2). However, no SNPs in 
ADH1B were associated with survival.  
Carriers of the minor allele of rs2238151 in ALDH2 had higher odds of developing 
SCCHN cancer, primarily due to increased risk of laryngeal tumors (Aim 1), and experienced 
increased risk if they were heavy drinkers (Aim 2). But this SNP had no effect on survival.   
CYP2E1, with its dual roles in both alcohol and drug metabolism, had a haplotype 
that was associated with reduced odds of developing SCCHN (Aim 1) and that included a 
SNP which interacted with alcohol to increase risk in heavier drinkers carrying the minor 
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allele (Aim 2). The minor alleles of several CYP2E1 SNPs were also associated with worse 
cancer-specific survival (Aim 3). 
SOD2 contains two SNPs for which the minor allele was suggestively associated 
with higher odds of oral cavity and hypopharyngeal (Aim 1), and one SNP whose minor 
allele was associated with increased hazard of death (Aim 3). 
5.4 STRENGTHS AND LIMITATIONS 
5.4.1 For all study aims 
CHANCE is one of the largest studies of head and neck cancer conducted in the 
United States. Its population is drawn from a state with a large African-American population, 
and as a result it has the largest number of African-Americans ever enrolled in a molecular 
epidemiologic study of head and neck cancer. Even though population ancestry was 
determined to be unnecessary in regression models once self-reported race was included, it 
is an advantage of this study to be able to confirm that residual confounding due to ancestry 
admixture is probably not confounding the results.  
Because I studied mostly tag SNPs, I was able to study polymorphism associations 
with cancer with greater coverage across the gene. However, because they are selected to 
capture information about other SNPs with a minor allele frequency of at least 10%, they are 
likely to miss rare variants. This study was limited by the fact that 11 of the 75 tag SNPs 
were not successfully genotyped, thereby preventing effect estimation for the gene sections 
tagged by the missing SNPs. Genotyping failure most affected coverage in ADH1C (3 of 9 
SNPs failed), ADH1B (3 of 11), and CYP2E1 (3 of 13), and to a lesser extent ADH4 (1 of 8) 
and SOD2 (1 of 6), but did not affect coverage of the ADH7, ALDH2, SOD1, GPx family, and 
CAT genes. The laboratory was not able to genotype one of the six candidate (non-tag) 
SNPs, a missense SNP in ADH1C (rs698), because of its low Illumina design score, so I 
was not able to compare its effects in the CHANCE population to those reported in the 
literature.  
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There were a number of cases who died very soon after qualifying for enrollment in 
CHANCE, and who thereby neither personally responded to the questionnaire nor provided 
a biological sample. These cases were excluded from this study. If incidence and survival 
effects due to SNP polymorphisms are more pronounced in subjects with rapidly-fatal 
disease, this selection bias would tend to skew effect estimates toward the null. However, I 
found no evidence of SNP associations with T, N, or summary stage in our data. CHANCE 
also gathered no information on infection with carcinogenic types of human papillomavirus, 
an important cause of SCCHN especially in the oropharynx. This could alter effect estimates 
in similar fashion to what would happen if cigarette smoking, a significant cause of SCCHN, 
were excluded from models.  
As with all questionnaire-based studies, CHANCE was dependent on accuracy of 
subject recall for socially sensitive questionnaire variables such as smoking and drinking 
habits. Researchers investigating self-report of addictive behaviors have concluded that its 
validity varies with the sensitivity of the information desired, methodologic sophistication of 
the questionnaire and of the interviewer (including task characteristics), and personal 
characteristics of the subject, with the latter believed to be of relatively less importance than 
other factors (214, 215), The literature suggests that in the U.S., African-Americans under-
report all types of substance use, but these findings may not be generalizable (212, 242). It 
may be related to reduced trust, some of which is ameliorated by in-person interviews 
versus a more distance telephone interview (243). It is also believed that recall error is 
minimized when the recall period is sufficiently long (216). Many studies in a variety of 
populations have compared self-report smoking behavior with serum cotinine levels, with the 
consensus that self-reported smoking levels are highly correlated with biological 
assessment. CHANCE used trained nurse interviewers to ask, in person, a standardized 
script of questions about legal behaviors (smoking and drinking) over a long period of time 
(lifetime). For this reason and because we detected alcohol and tobacco associations with 
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SCCHN similar to those observed in other studies, I believe CHANCE measures of smoking 
and drinking are acceptable for my broad classifications of tertiles of lifetime alcoholic 
beverage consumption as a primary exposure, and lifetime duration of smoking as a 
confounder.  
Fruit and vegetable intake, in servings per day, was also measured by questionnaire. 
In addition to subjects who were truly missing this information, many cases reported such 
high caloric intake that they were considered outliers according to accepted nutrition 
research practice. Their fruit and vegetable intake variables were also set to missing. As a 
result, due to truly missing data and suspect outlier data, I felt that the CHANCE fruit and 
vegetable intake variables were missing in too many subjects, and not-at-random, such that 
including them in regression models would bias results in unpredictable ways. Therefore I 
did not include them in my logistic regression models. Because the oxidative stress 
metabolism genes I studied may well interact with the anti-oxidants in fruits and vegetables 
consumed, I may have residual confounding and biased effect estimates as a result.  
5.4.2 Aim 1 
The number of subjects was sufficient to detect SCCHN incidence odds ratios 
greater than about 1.3. I had sufficient power to detect larger associations with anatomic 
sub-site tumors, except for hypharyngeal tumors due to the small number of cases. Power to 
detect main effects in African-American participants was insufficient to detect main effects 
except when the prevalence of the minor allele was greater than 20% (which was true for 
78% of this study’s SNPs in African-Americans) and the OR was greater than 1.8; i.e. two-
fold effects or greater.  
5.4.3 Aim 2 
The wording of alcohol consumption questions on the questionnaire precluded 
construction of a drinking frequency variable that integrated all three beverage types. 
Instead, I used a lifetime consumption variable that combined information on both frequency 
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and duration of alcoholic beverage consumption. Based on results from numerous studies, 
IARC has concluded that drinking frequency is highly associated with SCCHN incidence 
while duration is only weakly associated; these conclusions were also borne out in CHANCE 
data. Beer and liquor accounted for 88% of lifetime volume of ethanol consumed by 
CHANCE subjects, and correlations between each beverage’s frequency variable and 
lifetime ethanol intake in milliliters (summed over all types) are relatively high (0.81 for liquor, 
0.64 for beer). Correlation between wine drinking frequency and lifetime ethanol intake is 
lower (0.53) but wine represented only 12% of average lifetime ethanol intake, making this a 
proportionally small source of error. Thus the metric available in CHANCE – overall lifetime 
ethanol intake – is highly correlated with the preferred metric of drink frequency.  
This study had low power to detect additive interactions except when the additive 
effect was quite large. Therefore I did not examine gene-gene interactions and may well 
have missed gene-alcohol interactions of moderate effect size. Due to even smaller 
numbers of cases within each of the five sub-sites, I could not assess interaction between 
SNPs and alcohol intake in relation to anatomic site of tumor.  
5.4.4 Aim 3 
CHANCE collected excellent information for matching participant records to the 
National Death Index (NDI), including first and last names, middle initial, social security 
number, and date of birth. The result was that about three-quarters of identified deaths 
matched perfectly with a single NDI record. By the end of 2008, 39.4% of cases had died of 
any cause and 17.5% had died of head and neck cancer. For polymorphisms present in at 
least 10% of subjects – which includes 36 of 45 SNPs studied in the alcohol metabolism 
pathway (including 6 of 10 CYP2E1 SNPs) and 16 of 19 SNPS studied in the oxidative 
stress pathway – I had at least 80% power to detect hazard ratios of 1.3 or greater for all-
cause death and 1.5 or greater for cancer-specific death.  
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A limitation of my study was that CHANCE collected no data on recurrence (relapse-
free survival) or second primary tumors, or on use of alcohol and tobacco after diagnosis. I 
found that drinking and smoking prior to diagnosis affect all-cause but not head-and-neck-
cancer-specific survival (244), and there is extensive literature associating continued 
smoking post-diagnosis with worse all-cause survival and increased number of second 
primary head and neck tumors. In contrast, there are very few studies examining whether 
continuing to drink after diagnosis affects all-cause and cancer-specific survival. Existing 
studies are small and examined all-cause survival (not head-and-neck-cancer-specific 
survival) or occurrence of second primary tumors, with conflicting results (245). In any case, 
lacking data on post-diagnosis drinking and smoking behavior, I was not able to address the 
question of whether quitting smoking or drinking improves cancer-specific survival.  
I had information on whether the subject received chemotherapy as treatment for 
their cancer, but not on the specific type of agent used. CYP2E1 is known to bio-activate 
platinum-containing agents, which are commonly used to treat head and neck cancers, but 
there are differences in CYP2E1 metabolism for different platinum-containing agents, and I 
could not investigate those.  
5.5  IMPLICATIONS AND CONCLUSIONS 
This study replicated, in a study population of mixed white and African-American 
ancestry, previous studies’ findings for Asian, European, Indian, and Latin American 
populations that some polymorphisms in the alcohol metabolism pathway interact with 
alcohol consumption to affect risk of head and neck cancer. This is the first study to report 
associations of polymorphisms in oxidative stress genes with SCCHN incidence, and that 
polymorphisms in CYP2E1 are associated with cancer-specific survival. Some associations 
may be causal, but most are probably due to linkage disequilibrium between the measured 
SNP and the causal polymorphism.  
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Elucidation of carcinogenesis pathways for head and neck cancers is not 
immediately useful for public health purposes, but may eventually lead to specific preventive 
measures and recommendations, and more effective ways of treating cancer patients. In 
particular, studies designed to explore possible genetic reasons for high incidence rates of 
laryngeal cancer in African-American men could result in targeted intervention in that 
population.   
Alcohol metabolism genes should continue to be studied in relation to head and neck 
cancer, in an effort to pinpoint the functional or regulatory polymorphisms that are 
responsible for observed effects on cancer incidence. Questions asking about alcohol 
consumption should be worded so that summary measures of drinking frequency (including 
all beverage types) can be computed. Measuring gene-alcohol interaction and effects of 
rarer variants will require the statistical power of large consortia and pooling studies such as 
INHANCE, which combine subjects from multiple smaller studies using similar design and 
protocols. This will eventually involve gene sequencing as well as enzyme expression and 
functionality studies, and will facilitate understanding of how these mechanisms influence 
carcinogenesis.  
As part of these investigations, CYP2E1 variation and its interaction with 
chemotherapy treatments should be investigated for effects on cancer-specific survival, to 
replicate my findings and to pinpoint the responsible polymorphisms. This line of 
investigation may eventually lead to improved treatments. Also, in light of the associations 
this study found in oxidative stress genes, I suggest that future genetic studies on SCCHN 
and other cancers include polymorphisms in these genes, to replicate my findings, to 
explore possible interaction with fruit and vegetable intake, and to further illuminate 
mechanisms of carcinogenesis.  
Finally, future studies of head and neck cancer should measure post-diagnosis 
drinking behavior, updated at specified intervals, as well as timing of recurrence and second 
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primary tumors, in order to address the public health question of whether reducing or 
eliminating drinking after diagnosis will improve all-cause and cancer-specific survival.  
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Appendix A 
 
List of 157 SNPs genotyped as ancestry informative markers (AIMs)  
by the method of C. Tian et al., 2006 (alphabetically ordered) 
 
rs100280571  
rs10041728  
rs10056388  
rs1011643  
rs10124991  
rs10195705  
rs10202705  
rs10254729  
rs10255169  
rs1043809  
rs10806263  
rs10842753  
rs109083121  
rs10952147  
rs109626121 
rs11000419  
rs11150219  
rs1117382  
rs11223503  
rs11252171  
rs11264110  
rs11607932  
rs11652805  
rs11901793  
rs12094678  
rs12129648  
rs1256197  
rs1257010  
rs12594483  
rs12612040  
rs12640848  
rs12676654  
rs12692701  
rs12900262  
rs12900552  
rs12926237  
rs12945601  
rs12997060  
rs1303629  
rs130803531  
rs13169284  
rs13173738  
rs13178470  
rs13261248  
rs13318432  
rs1335826  
rs1372115  
rs1372894  
rs1380014  
rs1412521  
rs1415723  
rs14266541  
rs1462309  
rs1470608  
rs1477921  
rs1490728  
rs1508061  
rs1554091  
rs16891982  
rs17049450  
rs17261772  
rs17269594  
rs1733731  
rs17520733  
rs1862819  
rs1870571  
rs18851671  
rs1911999  
rs1917028  
rs1982235  
rs1991818  
rs2075902  
rs2184033  
rs222674  
rs2246695  
rs228768  
rs2416791  
rs2426515  
rs2451563  
rs2488465  
rs2593595  
rs2596793  
rs2660769  
rs2687427  
rs2777804  
rs316598  
rs328744  
rs33957  
rs344454  
rs3755446  
rs3759171  
rs3791896  
rs385194  
rs3861709  
rs4143633  
rs4149436  
rs4350528  
rs4489979  
rs4506877  
rs4529792  
rs4602918  
rs4619931  
rs4659762  
rs4789070  
rs4792105  
rs4793237  
rs48116511  
rs4823460  
rs4859147  
rs4885162  
rs48967801  
rs4923940  
rs503677  
rs567357  
rs6023376  
rs6414248  
rs645510  
rs6491743  
rs6494466  
rs6535244  
rs6556352  
rs6666101  
rs6765491  
rs6820509  
rs6937164  
rs7021690  
rs7086  
rs710052  
rs7107482  
rs7111814  
rs7134682  
rs71611  
rs7187359  
rs7189172  
rs735480  
rs7424137  
rs7512316  
rs75751471  
rs7689609  
rs7788641  
rs7810554  
rs798443  
rs8113143  
rs833282  
rs857440  
rs870272  
rs897351  
rs9297712  
rs9306906  
rs9416026  
rs9416972  
rs9525462  
rs9530646  
rs9543532  
rs9806307  
rs9849733  
rs9923864 
 
1Genotyping 
failed 
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Appendix B 
Alcohol questions on nurse-administered questionnaire 
CHANCE study (p. 1 of 5) 
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Appendix B 
Alcohol questions on nurse-administered questionnaire 
CHANCE study (p. 2 of 5) 
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Appendix B 
Alcohol questions on nurse-administered questionnaire 
CHANCE study (p. 3 of 5) 
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Appendix B 
Alcohol questions on nurse-administered questionnaire 
CHANCE study (p. 4 of 5) 
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Appendix B 
Alcohol questions on nurse-administered questionnaire 
CHANCE study (p. 5 of 5) 
 
 
Gene SNP
Major/minor 
allele Genotype n (col %) n (col %) n (col %) n (col %)
ALCOHOL METABOLISM GENES
ADH1B rs12507573 C/A AA 188 20.4% 234 21.8% 56 18.4% 40 15.9%
AC 462 50.1% 536 49.9% 149 48.9% 127 50.6%
CC 272 29.5% 304 28.3% 100 32.8% 83 33.1%
missing 0 0.0% 0 0.0% 0 0.0% 1 0.4%
rs1042026 A/G GG 73 7.9% 81 7.5% 3 1.0% 5 2.0%
GA 382 41.4% 457 42.6% 54 17.7% 36 14.3%
AA 467 50.7% 536 49.9% 248 81.3% 210 83.7%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs7673353 C/T TT 0 0.0% 0 0.0% 7 2.3% 12 4.8%
TC 3 0.3% 6 0.6% 89 29.2% 65 25.9%
CC 919 99.7% 1068 99.4% 209 68.5% 174 69.3%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs17028834 T/C CC 1 0.1% 0 0.0% 2 0.7% 5 2.0%
CT 3 0.3% 2 0.2% 80 26.2% 50 19.9%
TT 918 99.6% 1072 99.8% 223 73.1% 196 78.1%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1693457 T/C CC 27 2.9% 27 2.5% 9 3.0% 16 6.4%
CT 297 32.2% 333 31.0% 88 28.9% 86 34.3%
TT 597 64.8% 714 66.5% 208 68.2% 148 59.0%
missing 1 0.1% 0 0.0% 0 0.0% 1 0.4%
rs1229984 G/A AA 0 0.0% 3 0.3% 0 0.0% 0 0.0%
AG 30 3.3% 71 6.6% 1 0.3% 5 2.0%
GG 892 96.7% 1000 93.1% 304 99.7% 246 98.0%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1159918 G/T TT 129 14.0% 138 12.8% 161 52.8% 140 55.8%
TG 419 45.4% 485 45.2% 116 38.0% 93 37.1%
GG 374 40.6% 451 42.0% 28 9.2% 18 7.2%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1229982 G/T TT 30 3.3% 45 4.2% 69 22.6% 51 20.3%
TG 282 30.6% 327 30.4% 146 47.9% 125 49.8%
GG 610 66.2% 702 65.4% 90 29.5% 75 29.9%
missing 0.0% 0 0.0% 0 0.0% 0 0.0% 0.0%
ADH1C rs2298753 T/C CC 15 1.6% 15 1.4% 0 0.0% 0 0.0%
CT 186 20.2% 177 16.5% 20 6.6% 14 5.6%
TT 721 78.2% 882 82.1% 285 93.4% 237 94.4%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1614972 C/T TT 73 7.9% 96 8.9% 67 22.0% 67 26.7%
TC 403 43.7% 446 41.5% 144 47.2% 129 51.4%
CC 446 48.4% 532 49.5% 94 30.8% 55 21.9%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1391088 C/A AA 3 0.3% 4 0.4% 2 0.7% 2 0.8%
AC 118 12.8% 161 15.0% 55 18.0% 36 14.3%
CC 801 86.9% 909 84.6% 248 81.3% 213 84.9%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1693482 C/T TT 158 17.1% 172 16.0% 6 2.0% 4 1.6%
TC 437 47.4% 497 46.3% 94 30.8% 64 25.5%
CC 325 35.2% 403 37.5% 205 67.2% 183 72.9%
missing 2 0.2% 2 0.2% 0 0.0% 0 0.0%
rs1631460 C/G GG 160 17.4% 173 16.1% 6 2.0% 4 1.6%
GC 443 48.0% 508 47.3% 95 31.1% 65 25.9%
CC 318 34.5% 393 36.6% 204 66.9% 182 72.5%
missing 1 0.1% 0 0.0% 0 0.0% 0 0.0%
rs11936869 C/G GG 64 6.9% 69 6.4% 53 17.4% 56 22.3%
GC 354 38.4% 430 40.0% 143 46.9% 122 48.6%
CC 504 54.7% 575 53.5% 109 35.7% 72 28.7%
missing 0 0.0% 0 0.0% 0 0.0% 1 0.4%
ADH4 rs29001227 A/T TT 1 0.1% 1 0.1% 8 2.6% 8 3.2%
TA 4 0.4% 1 0.1% 92 30.2% 59 23.5%
AA 917 99.5% 1072 99.8% 205 67.2% 184 73.3%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1126672 C/T TT 53 5.7% 82 7.6% 6 2.0% 2 0.8%
TC 386 41.9% 434 40.4% 60 19.7% 46 18.3%
CC 483 52.4% 558 52.0% 239 78.4% 203 80.9%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs4699710 T/C CC 70 7.6% 98 9.1% 13 4.3% 5 2.0%
CT 412 44.7% 458 42.6% 90 29.5% 78 31.1%
APPENDIX C Distribution of SNP genotypes in cases and controls, by race
Whites African-Americans
Cases (n=922) Controls (n=1074) Cases (n=305) Controls (n=251)
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Gene SNP
Major/minor 
allele Genotype n (col %) n (col %) n (col %) n (col %)
APPENDIX C Distribution of SNP genotypes in cases and controls, by race
Whites African-Americans
Cases (n=922) Controls (n=1074) Cases (n=305) Controls (n=251)
TT 440 47.7% 518 48.2% 202 66.2% 168 66.9%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs10017466 T/C CC 72 7.8% 99 9.2% 40 13.1% 32 12.7%
CT 414 44.9% 459 42.7% 143 46.9% 101 40.2%
TT 436 47.3% 516 48.0% 121 39.7% 118 47.0%
missing 0 0.0% 0 0.0% 1 0.3% 0 0.0%
rs1800759 C/A AA 114 12.4% 150 14.0% 171 56.1% 152 60.6%
AC 472 51.2% 527 49.1% 113 37.0% 83 33.1%
CC 336 36.4% 397 37.0% 21 6.9% 16 6.4%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1800761 G/A AA 31 3.4% 28 2.6% 26 8.5% 22 8.8%
AG 293 31.8% 343 31.9% 124 40.7% 100 39.8%
GG 598 64.9% 703 65.5% 155 50.8% 129 51.4%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs3762894 T/C CC 25 2.7% 20 1.9% 14 4.6% 17 6.8%
CT 247 26.8% 306 28.5% 99 32.5% 73 29.1%
TT 650 70.5% 748 69.6% 192 63.0% 161 64.1%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
ADH7 rs284787 C/T TT 61 6.6% 58 5.4% 6 2.0% 6 2.4%
TC 339 36.8% 384 35.8% 78 25.6% 57 22.7%
CC 522 56.6% 632 58.8% 221 72.5% 188 74.9%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs894369 C/G GG 32 3.5% 43 4.0% 7 2.3% 6 2.4%
GC 275 29.8% 356 33.1% 77 25.2% 68 27.1%
CC 615 66.7% 675 62.8% 221 72.5% 176 70.1%
missing 0 0.0% 0 0.0% 0 0.0% 1 0.4%
rs17588403 T/A AA 44 4.8% 31 2.9% 4 1.3% 3 1.2%
AT 274 29.7% 344 32.0% 66 21.6% 58 23.1%
TT 604 65.5% 699 65.1% 235 77.0% 190 75.7%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1154454 T/C CC 24 2.6% 31 2.9% 49 16.1% 48 19.1%
CT 250 27.1% 309 28.8% 146 47.9% 128 51.0%
TT 648 70.3% 734 68.3% 110 36.1% 75 29.9%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1154456 T/C CC 116 12.6% 127 11.8% 7 2.3% 7 2.8%
CT 438 47.5% 494 46.0% 87 28.5% 68 27.1%
TT 368 39.9% 453 42.2% 211 69.2% 176 70.1%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1154460 G/A AA 194 21.0% 218 20.3% 66 21.6% 58 23.1%
AG 466 50.5% 544 50.7% 169 55.4% 127 50.6%
GG 259 28.1% 312 29.1% 70 23.0% 65 25.9%
missing 3 0.3% 0 0.0% 0 0.0% 1 0.4%
rs971074 G/A AA 7 0.8% 10 0.9% 8 2.6% 5 2.0%
AG 165 17.9% 210 19.6% 101 33.1% 70 27.9%
GG 750 81.3% 854 79.5% 196 64.3% 176 70.1%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1573496 C/G GG 5 0.5% 9 0.8% 0 0.0% 0 0.0%
GC 154 16.7% 190 17.7% 7 2.3% 6 2.4%
CC 762 82.6% 875 81.5% 298 97.7% 245 97.6%
missing 1 0.1% 0 0.0% 0 0.0% 0 0.0%
ALDH2 rs4767939 A/G GG 35 3.8% 39 3.6% 52 17.0% 38 15.1%
GA 297 32.2% 315 29.3% 145 47.5% 125 49.8%
AA 589 63.9% 720 67.0% 108 35.4% 88 35.1%
missing 1 0.1% 0 0.0% 0 0.0% 0 0.0%
rs2238151 T/C CC 119 12.9% 125 11.6% 257 84.3% 179 71.3%
CT 436 47.3% 464 43.2% 46 15.1% 71 28.3%
TT 363 39.4% 482 44.9% 2 0.7% 1 0.4%
missing 4 0.4% 3 0.3% 0 0.0% 0 0.0%
rs7312055 G/A AA 0 0.0% 0 0.0% 28 9.2% 12 4.8%
AG 5 0.5% 8 0.7% 111 36.4% 101 40.2%
GG 917 99.5% 1066 99.3% 166 54.4% 138 55.0%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs2158029 G/A AA 0 0.0% 0 0.0% 6 2.0% 1 0.4%
AG 6 0.7% 11 1.0% 45 14.8% 41 16.3%
GG 916 99.3% 1063 99.0% 254 83.3% 209 83.3%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs16941667 C/T TT 6 0.7% 5 0.5% 6 2.0% 4 1.6%
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Major/minor 
allele Genotype n (col %) n (col %) n (col %) n (col %)
APPENDIX C Distribution of SNP genotypes in cases and controls, by race
Whites African-Americans
Cases (n=922) Controls (n=1074) Cases (n=305) Controls (n=251)
TC 153 16.6% 158 14.7% 74 24.3% 58 23.1%
CC 763 82.8% 911 84.8% 225 73.8% 188 74.9%
missing 0 0.0% 0 0.0% 0 0.0% 1 0.4%
rs16941669 T/G GG 14 1.5% 11 1.0% 2 0.7% 0 0.0%
GT 174 18.9% 190 17.7% 50 16.4% 36 14.3%
TT 734 79.6% 872 81.2% 253 83.0% 214 85.3%
missing 0 0.0% 1 0.1% 0 0.0% 1 0.4%
CYP2E1 rs3813865 G/C CC 0 0.0% 1 0.1% 4 1.3% 3 1.2%
CG 45 4.9% 49 4.6% 76 24.9% 53 21.1%
GG 877 95.1% 1023 95.3% 225 73.8% 195 77.7%
missing 0 0.0% 1 0.1% 0 0.0% 0 0.0%
rs3813867 G/C CC 1 0.1% 0 0.0% 1 0.3% 1 0.4%
CG 51 5.5% 58 5.4% 30 9.8% 25 10.0%
GG 870 94.4% 1016 94.6% 273 89.5% 224 89.2%
missing 0 0.0% 0 0.0% 1 0.3% 1 0.4%
rs8192772 T/C CC 6 0.7% 7 0.7% 3 1.0% 2 0.8%
CT 127 13.8% 146 13.6% 64 21.0% 53 21.1%
TT 789 85.6% 921 85.8% 237 77.7% 196 78.1%
missing 0 0.0% 0 0.0% 1 0.3% 0 0.0%
rs915908 G/A AA 21 2.3% 27 2.5% 0 0.0% 1 0.4%
AG 211 22.9% 266 24.8% 18 5.9% 22 8.8%
GG 690 74.8% 781 72.7% 287 94.1% 228 90.8%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs915909 C/T TT 0 0.0% 0 0.0% 5 1.6% 2 0.8%
TC 1 0.1% 4 0.4% 53 17.4% 40 15.9%
CC 921 99.9% 1070 99.6% 246 80.7% 204 81.3%
missing 0 0.0% 0 0.0% 1 0.3% 5 2.0%
rs7092584 C/T TT 11 1.2% 9 0.8% 4 1.3% 5 2.0%
TC 168 18.2% 197 18.3% 80 26.2% 58 23.1%
CC 743 80.6% 868 80.8% 219 71.8% 187 74.5%
missing 0 0.0% 0 0.0% 2 0.7% 1 0.4%
rs743535 C/T TT 11 1.2% 6 0.6% 7 2.3% 4 1.6%
CT 149 16.2% 176 16.4% 82 26.9% 57 22.7%
CC 757 82.1% 886 82.5% 212 69.5% 188 74.9%
missing 5 0.5% 6 0.6% 4 1.3% 2 0.8%
rs2249695 C/T TT 34 3.7% 41 3.8% 28 9.2% 23 9.2%
"tipsy" SNP TC 292 31.7% 372 34.6% 124 40.7% 103 41.0%
CC 595 64.5% 661 61.5% 153 50.2% 124 49.4%
missing 1 0.1% 0 0.0% 0 0.0% 1 0.4%
rs28969387 A/T TT 0 0.0% 0 0.0% 0 0.0% 0 0.0%
TA 2 0.2% 0 0.0% 23 7.5% 20 8.0%
AA 920 99.8% 1074 100.0% 282 92.5% 231 92.0%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs11101812 T/C CC 0 0.0% 0 0.0% 2 0.7% 1 0.4%
CT 2 0.2% 1 0.1% 22 7.2% 18 7.2%
TT 919 99.7% 1073 99.9% 279 91.5% 230 91.6%
missing 1 0.1% 0 0.0% 2 0.7% 2 0.8%
OXIDATIVE STRESS METABOLISM GENES
CAT rs1049982 C/T TT 95 10.3% 106 9.9% 92 30.2% 76 30.3%
TC 396 43.0% 449 41.8% 147 48.2% 123 49.0%
CC 429 46.5% 514 47.9% 65 21.3% 50 19.9%
missing 2 0.2% 5 0.5% 1 0.3% 2 0.8%
GPX1 rs8179172 T/A AA 0 0.0% 0 0.0% 0 0.0% 1 0.4%
AT 1 0.1% 2 0.2% 50 16.4% 48 19.1%
TT 921 99.9% 1072 99.8% 255 83.6% 202 80.5%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1800668 C/T TT 77 8.4% 101 9.4% 15 4.9% 19 7.6%
TC 381 41.3% 437 40.7% 115 37.7% 91 36.3%
CC 464 50.3% 533 49.6% 174 57.0% 140 55.8%
missing 0 0.0% 3 0.3% 1 0.3% 1 0.4%
rs3811699 A/G GG 79 8.6% 100 9.3% 23 7.5% 28 11.2%
GA 379 41.1% 442 41.2% 133 43.6% 105 41.8%
AA 464 50.3% 532 49.5% 149 48.9% 118 47.0%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs3448 C/T TT 84 9.1% 83 7.7% 29 9.5% 17 6.8%
TC 350 38.0% 397 37.0% 115 37.7% 96 38.2%
CC 488 52.9% 594 55.3% 161 52.8% 138 55.0%
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Whites African-Americans
Cases (n=922) Controls (n=1074) Cases (n=305) Controls (n=251)
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
GPX2 rs11623705 G/T TT 13 1.4% 15 1.4% 0 0.0% 0 0.0%
TG 199 21.6% 220 20.5% 15 4.9% 19 7.6%
GG 710 77.0% 839 78.1% 290 95.1% 232 92.4%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs2412065 G/C CC 37 4.0% 55 5.1% 48 15.7% 47 18.7%
CG 290 31.5% 369 34.4% 154 50.5% 119 47.4%
GG 595 64.5% 650 60.5% 103 33.8% 85 33.9%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs2737844 C/T TT 76 8.2% 109 10.1% 209 68.5% 162 64.5%
TC 361 39.2% 462 43.0% 82 26.9% 75 29.9%
CC 481 52.2% 498 46.4% 13 4.3% 14 5.6%
missing 4 0.4% 5 0.5% 1 0.3% 0 0.0%
GPX4 rs757229 G/C CC 192 20.8% 233 21.7% 104 34.1% 86 34.3%
CG 484 52.5% 522 48.6% 145 47.5% 123 49.0%
GG 246 26.7% 318 29.6% 55 18.0% 42 16.7%
missing 0 0.0% 1 0.1% 1 0.3% 0 0.0%
SOD1 rs11910115 A/C CC 0 0.0% 0 0.0% 2 0.7% 5 2.0%
CA 1 0.1% 1 0.1% 59 19.3% 59 23.5%
AA 921 99.9% 1073 99.9% 244 80.0% 187 74.5%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs4998557 G/A AA 12 1.3% 14 1.3% 41 13.4% 40 15.9%
AG 205 22.2% 195 18.2% 137 44.9% 111 44.2%
GG 704 76.4% 862 80.3% 127 41.6% 100 39.8%
missing 1 0.1% 3 0.3% 0 0.0% 0 0.0%
rs10432782 T/G GG 12 1.3% 14 1.3% 20 6.6% 20 8.0%
GT 205 22.2% 194 18.1% 113 37.0% 101 40.2%
TT 704 76.4% 865 80.5% 172 56.4% 130 51.8%
missing 1 0.1% 1 0.1% 0 0.0% 0 0.0%
rs2070424 A/G GG 6 0.7% 5 0.5% 6 2.0% 7 2.8%
AG 127 13.8% 113 10.5% 83 27.2% 77 30.7%
AA 789 85.6% 956 89.0% 216 70.8% 167 66.5%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs1041740 C/T TT 88 9.5% 101 9.4% 6 2.0% 3 1.2%
TC 387 42.0% 473 44.0% 62 20.3% 43 17.1%
CC 447 48.5% 500 46.6% 237 77.7% 205 81.7%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
SOD2 rs4342445 G/A AA 57 6.2% 56 5.2% 5 1.6% 4 1.6%
AG 340 36.9% 355 33.1% 71 23.3% 59 23.5%
GG 525 56.9% 663 61.7% 229 75.1% 188 74.9%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs2842980 A/T TT 42 4.6% 61 5.7% 30 9.8% 24 9.6%
TA 299 32.4% 338 31.5% 139 45.6% 92 36.7%
AA 581 63.0% 675 62.8% 136 44.6% 135 53.8%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs8031 T/A AA 206 22.3% 267 24.9% 31 10.2% 35 13.9%
AT 467 50.7% 534 49.7% 134 43.9% 107 42.6%
TT 249 27.0% 273 25.4% 140 45.9% 109 43.4%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs5746134 C/T TT 0 0.0% 0 0.0% 7 2.3% 3 1.2%
TC 0 0.0% 4 0.4% 93 30.5% 58 23.1%
CC 922 100.0% 1070 99.6% 205 67.2% 190 75.7%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
rs2758331 C/A AA 204 22.1% 264 24.6% 18 5.9% 18 7.2%
AC 468 50.8% 537 50.0% 113 37.0% 87 34.7%
CC 250 27.1% 273 25.4% 174 57.0% 146 58.2%
missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
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ALCOHOL METABOLISM GENES
ADH1B rs12507573 C/A 71/386 152/935 0.94 (0.80-1.11) 1.00 91/386 241/935 1.02 (0.88-1.17) 1.00
rs1042026 A/G 125/744 98/578 1.04 (0.89-1.22) 1.00 193/744 139/578 0.97 (0.84-1.11) 1.00
rs7673353 C/T 204/1239 19/83 1.09 (0.79-1.50) 1.00 309/1239 23/83 0.97 (0.72-1.29) 1.00
rs17028834 T/C 211/1265 12/57 1.05 (0.72-1.53) 1.00 312/1265 20/57 1.29 (0.94-1.77) 1.00
rs1693457 T/C 136/860 86/461 1.13 (0.97-1.32) 1.00 223/860 109/461 1.02 (0.89-1.18) 1.00
rs1229984 G/A 219/1243 4/79 0.60 (0.36-1.01) 1.00 322/1243 10/79 0.74 (0.52-1.06) 1.00
rs1159918 G/T 65/468 158/854 1.16 (0.98-1.37) 1.00 109/468 223/854 1.12 (0.97-1.29) 1.00
rs1229982 G/T 129/775 94/547 0.99 (0.84-1.16) 1.00 197/775 135/547 0.98 (0.85-1.12) 1.00
ADH1C rs2298753 T/C 180/1117 43/205 1.18 (0.97-1.44) 1.00 270/1117 62/205 1.19 (1.00-1.41) 1.00
rs1614972 C/T 95/585 128/737 1.02 (0.87-1.19) 1.00 141/585 191/737 1.02 (0.89-1.16) 1.00
rs1391088 C/A 192/1119 31/203 0.98 (0.79-1.22) 1.00 280/1119 52/203 1.03 (0.86-1.24) 1.00
rs1693482 C/T 97/585 125/735 1.03 (0.88-1.20) 1.00 145/585 186/735 1.03 (0.90-1.18) 1.00
rs1631460 C/G 93/574 130/748 1.05 (0.90-1.23) 1.00 144/574 188/748 1.02 (0.89-1.17) 1.00
rs11936869 C/G 111/645 112/676 0.96 (0.83-1.12) 1.00 161/645 171/676 0.99 (0.87-1.13) 1.00
ADH4 rs29001227 A/T 208/1253 15/69 1.00 (0.70-1.42) 1.00 305/1253 27/69 1.33 (0.99-1.79) 1.00
rs1126672 C/T 131/758 92/564 1.02 (0.87-1.19) 1.00 201/758 131/564 0.96 (0.83-1.10) 1.00
rs4699710 T/C 120/684 103/638 0.98 (0.84-1.13) 1.00 179/684 153/638 0.96 (0.84-1.10) 1.00
rs10017466 T/C 106/632 117/690 1.00 (0.87-1.16) 1.00 157/632 174/690 1.02 (0.89-1.16) 1.00
rs1800759 C/A 75/412 148/910 0.93 (0.79-1.10) 1.00 101/412 231/910 1.00 (0.87-1.16) 1.00
rs1800761 G/A 134/830 89/492 1.01 (0.87-1.18) 1.00 193/830 139/492 1.07 (0.94-1.22) 1.00
rs3762894 T/C 150/906 73/416 1.00 (0.86-1.18) 1.00 218/906 114/416 1.04 (0.91-1.20) 1.00
ADH7 rs284787 C/T 126/817 97/505 1.14 (0.98-1.33) 1.00 208/817 124/505 1.01 (0.88-1.16) 1.00
rs894369 C/G 153/849 70/472 0.93 (0.80-1.09) 1.00 217/849 115/472 0.96 (0.84-1.10) 1.00
rs17588403 T/A 157/887 66/435 0.92 (0.78-1.08) 1.00 230/887 102/435 0.94 (0.81-1.08) 1.00
rs1154454 T/C 134/808 89/514 0.95 (0.81-1.11) 1.00 208/808 124/514 0.94 (0.82-1.09) 1.00
rs1154456 T/C 108/629 115/693 0.98 (0.84-1.14) 1.00 150/629 182/693 1.08 (0.94-1.24) 1.00
rs1154460 G/A 61/377 161/944 1.01 (0.86-1.20) 1.00 88/377 244/944 1.06 (0.91-1.23) 1.00
rs971074 G/A 168/1027 55/295 1.07 (0.90-1.27) 1.00 257/1027 75/295 0.95 (0.81-1.12) 1.00
rs1573496 C/G 186/1117 36/205 1.08 (0.88-1.33) 1.00 292/1117 40/205 0.84 (0.69-1.02) 1.00
ALDH2 rs4767939 A/G 135/806 88/516 0.99 (0.85-1.16) 1.00 191/806 140/516 1.08 (0.94-1.23) 1.00
rs2238151 T/C 66/482 156/837 1.13 (0.95-1.34) 1.00 114/482 217/837 1.02 (0.88-1.18) 1.00
rs7312055 G/A 196/1201 27/121 0.88 (0.65-1.20) 1.00 301/1201 31/121 0.83 (0.64-1.09) 1.00
rs2158029 G/A 216/1269 7/53 0.74 (0.47-1.14) 1.00 316/1269 16/53 1.06 (0.76-1.47) 1.00
rs16941667 C/T 189/1097 34/224 0.96 (0.78-1.18) 1.00 266/1097 66/224 1.11 (0.94-1.31) 1.00
rs16941669 T/G 175/1084 48/236 1.14 (0.95-1.37) 1.00 272/1084 60/236 0.98 (0.83-1.16) 1.00
CYP2E1 rs3813865 G/C 204/1215 19/106 1.02 (0.77-1.36) 1.00 298/1215 34/106 1.11 (0.88-1.40) 1.00
rs3813867 G/C 207/1237 16/84 1.02 (0.76-1.37) 1.00 316/1237 16/84 0.81 (0.60-1.09) 1.00
rs8192772 T/C 195/1114 28/208 0.92 (0.73-1.15) 1.00 279/1114 53/208 1.07 (0.90-1.28) 1.00
rs915908 G/A 164/1006 59/316 1.11 (0.93-1.32) 1.00 263/1006 69/316 0.89 (0.75-1.04) 1.00
rs915909 C/T 212/1271 11/46 1.11 (0.75-1.62) 1.00 317/1271 15/46 1.02 (0.72-1.45) 1.00
rs7092584 C/T 181/1052 42/269 0.98 (0.81-1.19) 1.00 262/1052 70/269 1.05 (0.89-1.23) 1.00
rs743535 C/T 182/1071 41/243 0.99 (0.82-1.20) 1.00 268/1071 60/243 1.00 (0.85-1.19) 1.00
rs2249695 C/T 108/682 115/639 1.01 (0.86-1.19) 1.00 180/682 152/639 0.90 (0.78-1.04) 1.00
rs28969387 A/T 219/1302 4/20 1.06 (0.59-1.90) 1.00 326/1302 6/20 0.93 (0.56-1.53) 1.00
rs11101812 T/C 219/1300 3/20 0.98 (0.52-1.85) 1.00 327/1300 4/20 0.92 (0.52-1.63) 1.00
OXIDATIVE STRESS METABOLISM GENES
CAT rs1049982 C/T 100/589 123/726 0.97 (0.831.13) 1.00 134/589 197/726 1.07 (0.94-1.22) 1.00
GPX1 rs8179172 T/A 212/1271 11/51 0.97 (0.661.44) 1.00 320/1271 12/51 0.90 (0.62-1.29) 1.00
rs1800668 C/T 113/672 110/646 1.06 (0.911.23) 1.00 172/672 160/646 1.02 (0.89-1.16) 1.00
rs3811699 A/G 109/649 114/673 1.06 (0.911.23) 1.00 167/649 165/673 1.01 (0.89-1.15) 1.00
rs3448 C/T 113/729 110/593 1.12 (0.971.31) 1.00 190/729 142/593 0.98 (0.86-1.12) 1.00
GPX2 rs11623705 G/T 185/1069 38/253 0.94 (0.771.14) 1.00 268/1069 64/253 1.02 (0.86-1.21) 1.00
rs2412065 G/C 122/733 101/589 0.98 (0.841.15) 1.00 193/733 139/589 0.94 (0.82-1.08) 1.00
rs2737844 C/T 88/511 134/806 0.95 (0.811.12) 1.00 136/511 194/806 0.93 (0.81-1.08) 1.00
GPX4 rs757229 G/C 60/358 162/963 0.98 (0.831.16) 1.00 85/358 247/963 1.02 (0.88-1.18) 1.00
SOD1 rs11910115 A/C 208/1257 15/65 1.01 (0.701.45) 1.00 319/1257 13/65 0.86 (0.60-1.22) 1.00
rs4998557 G/A 155/959 68/360 1.00 (0.841.20) 1.00 232/959 99/360 1.07 (0.92-1.25) 1.00
rs10432782 T/G 163/992 60/329 0.98 (0.821.17) 1.00 240/992 91/329 1.07 (0.92-1.25) 1.00
rs2070424 A/G 187/1120 36/202 0.95 (0.761.17) 1.00 274/1120 58/202 1.05 (0.88-1.26) 1.00
rs1041740 C/T 127/705 96/617 0.94 (0.801.10) 1.00 174/705 158/617 0.99 (0.87-1.14) 1.00
SOD2 rs4342445 G/A 145/850 78/472 1.01 (0.861.18) 1.00 202/850 130/472 1.08 (0.95-1.24) 1.00
rs2842980 A/T 129/807 94/515 1.06 (0.911.23) 1.00 189/807 143/515 1.09 (0.96-1.25) 1.00
rs8031 T/A 77/382 146/940 0.91 (0.771.07) 1.00 102/382 230/940 0.99 (0.86-1.14) 1.00
rs5746134 C/T 207/1257 16/65 1.20 (0.851.68) 1.00 304/1257 28/65 1.41 (1.05-1.89) 1.00
rs2758331 C/A 86/419 137/903 0.90 (0.771.06) 1.00 108/419 224/903 1.02 (0.88-1.17) 1.00
c Bonferroni-corrected for 64 statistical tests
APPENDIX D. SNP effects on odds of developing cancer (dominant genetic model)
b Conditional logistic regression models conditioned on sex, race, and age category, and adjusted for continuous duration of smoking in years (rounded to whole years). Odds 
ratios are for those with one or more copies of the minor allele versus the referent group of those homozygous for the major allele (dominant genetic model). 
Oropharyngeal cancerOral cavity, oropharyngeal, hypopharyngeal cancer NOS
n cases/controls n cases/controls
a Cases and controls do not sum to 1227 and 1325, respectively, because 4 cases and 3 controls are missing information on duration of cigarette smoking, and because a few 
subjects lack genotype information for some SNPs
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ALCOHOL METABOLISM GENES
ADH1B rs12507573 C/A never drinkers 40 / 72 1.00 (ref) 77 / 208 0.64 ( 0.39 - 1.06 ) -0.19
>0 to <134,699 68 / 142 0.62 ( 0.37 - 1.05 ) 141 / 323 0.52 ( 0.32 - 0.85 )
134,699 to <757,550 84 / 118 0.74 ( 0.44 - 1.27 ) 234 / 242 1.05 ( 0.65 - 1.69 )
757,550+ 160 / 47 2.75 ( 1.56 - 4.86 ) 345 / 126 2.21 ( 1.34 - 3.65 )
rs1042026 A/G never drinkers 59 / 157 1.00 (ref) 58 / 123 1.20 ( 0.75 - 1.93 ) -0.75
>0 to <134,699 112 / 253 0.80 ( 0.53 - 1.20 ) 97 / 213 0.85 ( 0.56 - 1.30 )
134,699 to <757,550 188 / 206 1.48 ( 0.99 - 2.22 ) 130 / 154 1.31 ( 0.86 - 2.01 )
757,550+ 312 / 98 3.75 ( 2.42 - 5.81 ) 193 / 75 3.20 ( 2.02 - 5.08 )
rs7673353 C/T never drinkers 115 / 261 1.00 (ref) 2 / 19 0.29 ( 0.06 - 1.35 ) 1.06
>0 to <134,699 199 / 438 0.72 ( 0.53 - 0.98 ) 10 / 28 0.71 ( 0.31 - 1.62 )
134,699 to <757,550 289 / 346 1.17 ( 0.85 - 1.60 ) 29 / 14 3.14 ( 1.44 - 6.84 )
757,550+ 453 / 159 3.10 ( 2.19 - 4.39 ) 52 / 14 3.44 ( 1.66 - 7.15 )
rs17028834 T/C never drinkers 113 / 272 1.00 (ref) 4 / 8 1.13 ( 0.28 - 4.49 ) 3.55
>0 to <134,699 201 / 447 0.75 ( 0.55 - 1.01 ) 8 / 19 1.01 ( 0.40 - 2.54 )
134,699 to <757,550 303 / 342 1.29 ( 0.95 - 1.77 ) 15 / 18 1.39 ( 0.61 - 3.16 )
757,550+ 453 / 163 3.06 ( 2.16 - 4.32 ) 52 / 10 6.73 ( 3.06 - 14.81 )
rs1693457 T/C never drinkers 78 / 177 1.00 (ref) 38 / 103 0.86 ( 0.52 - 1.41 ) 1.02
>0 to <134,699 146 / 295 0.77 ( 0.54 - 1.11 ) 63 / 170 0.64 ( 0.42 - 0.98 )
134,699 to <757,550 201 / 234 1.21 ( 0.84 - 1.75 ) 117 / 126 1.31 ( 0.87 - 1.98 )
757,550+ 327 / 122 2.85 ( 1.92 - 4.24 ) 178 / 51 3.72 ( 2.34 - 5.93 )
rs1229984 G/A never drinkers 109 / 268 1.00 (ref) 8 / 12 1.60 ( 0.59 - 4.32 ) -1.85
previously studied >0 to <134,699 206 / 427 0.83 ( 0.61 - 1.13 ) 3 / 39 0.15 ( 0.04 - 0.50 )
134,699 to <757,550 305 / 339 1.35 ( 0.98 - 1.85 ) 13 / 21 1.07 ( 0.48 - 2.37 )
757,550+ 499 / 169 3.36 ( 2.38 - 4.75 ) 6 / 4 2.11 ( 0.49 - 9.10 )
rs1159918 G/T never drinkers 49 / 101 1.00 (ref) 68 / 179 0.90 ( 0.55 - 1.46 ) 1.03
>0 to <134,699 80 / 168 0.67 ( 0.41 - 1.07 ) 129 / 298 0.73 ( 0.47 - 1.14 )
134,699 to <757,550 107 / 129 1.11 ( 0.68 - 1.80 ) 211 / 231 1.26 ( 0.81 - 1.97 )
757,550+ 140 / 58 2.42 ( 1.43 - 4.08 ) 365 / 115 3.34 ( 2.08 - 5.36 )
rs1229982 G/T never drinkers 72 / 168 1.00 (ref) 45 / 112 0.91 ( 0.56 - 1.47 ) 0.52
>0 to <134,699 131 / 270 0.79 ( 0.54 - 1.16 ) 78 / 196 0.64 ( 0.42 - 0.97 )
134,699 to <757,550 180 / 211 1.21 ( 0.83 - 1.79 ) 138 / 149 1.28 ( 0.85 - 1.93 )
757,550+ 274 / 98 2.91 ( 1.91 - 4.43 ) 231 / 75 3.34 ( 2.14 - 5.21 )
ADH1C rs2298753 T/C never drinkers 97 / 238 1.00 (ref) 20 / 42 1.19 ( 0.63 - 2.27 ) -0.56
>0 to <134,699 169 / 392 0.74 ( 0.53 - 1.03 ) 40 / 74 0.96 ( 0.59 - 1.57 )
134,699 to <757,550 246 / 303 1.22 ( 0.87 - 1.71 ) 72 / 57 1.84 ( 1.16 - 2.93 )
757,550+ 429 / 144 3.34 ( 2.32 - 4.81 ) 76 / 29 2.97 ( 1.71 - 5.16 )
rs1614972 C/T never drinkers 56 / 123 1.00 (ref) 61 / 157 0.84 ( 0.53 - 1.34 ) 0.02
>0 to <134,699 81 / 219 0.52 ( 0.33 - 0.82 ) 128 / 247 0.84 ( 0.55 - 1.28 )
134,699 to <757,550 155 / 152 1.33 ( 0.86 - 2.06 ) 163 / 208 1.05 ( 0.68 - 1.61 )
757,550+ 216 / 75 2.99 ( 1.86 - 4.79 ) 289 / 98 2.85 ( 1.80 - 4.50 )
rs1391088 C/A never drinkers 100 / 235 1.00 (ref) 17 / 45 0.95 ( 0.50 - 1.82 ) 0.12
>0 to <134,699 181 / 392 0.76 ( 0.55 - 1.06 ) 28 / 74 0.66 ( 0.39 - 1.12 )
134,699 to <757,550 270 / 315 1.24 ( 0.89 - 1.72 ) 48 / 45 1.59 ( 0.95 - 2.67 )
757,550+ 427 / 145 3.18 ( 2.21 - 4.57 ) 78 / 28 3.24 ( 1.87 - 5.62 )
rs1693482 C/T never drinkers 44 / 123 1.00 (ref) 73 / 157 1.24 ( 0.77 - 2.01 ) -0.24
previously studied >0 to <134,699 84 / 199 0.87 ( 0.54 - 1.38 ) 124 / 265 0.85 ( 0.55 - 1.33 )
134,699 to <757,550 135 / 164 1.37 ( 0.86 - 2.18 ) 182 / 196 1.54 ( 0.98 - 2.41 )
757,550+ 234 / 77 3.64 ( 2.22 - 5.96 ) 271 / 96 3.65 ( 2.26 - 5.88 )
rs1631460 C/G never drinkers 43 / 119 1.00 (ref) 74 / 161 1.23 ( 0.76 - 1.99 ) -0.17
>0 to <134,699 81 / 195 0.86 ( 0.53 - 1.37 ) 128 / 271 0.86 ( 0.55 - 1.34 )
134,699 to <757,550 134 / 162 1.38 ( 0.87 - 2.22 ) 184 / 198 1.53 ( 0.97 - 2.41 )
757,550+ 231 / 76 3.61 ( 2.19 - 5.93 ) 273 / 97 3.66 ( 2.26 - 5.93 )
rs11936869 C/G never drinkers 61 / 135 1.00 (ref) 56 / 145 0.90 ( 0.56 - 1.43 ) -0.17
>0 to <134,699 102 / 237 0.64 ( 0.42 - 0.98 ) 107 / 228 0.79 ( 0.52 - 1.20 )
134,699 to <757,550 170 / 174 1.37 ( 0.90 - 2.08 ) 148 / 186 1.08 ( 0.71 - 1.65 )
757,550+ 242 / 78 3.17 ( 2.00 - 5.02 ) 263 / 95 2.90 ( 1.85 - 4.54 )
ADH4 rs29001227 A/T never drinkers 113 / 271 1.00 (ref) 4 / 9 1.04 ( 0.27 - 4.02 ) 4.55
>0 to <134,699 199 / 445 0.74 ( 0.55 - 1.01 ) 10 / 21 0.98 ( 0.41 - 2.31 )
134,699 to <757,550 294 / 334 1.28 ( 0.94 - 1.76 ) 24 / 26 1.47 ( 0.74 - 2.93 )
757,550+ 445 / 163 3.02 ( 2.13 - 4.27 ) 60 / 10 7.61 ( 3.46 - 16.75 )
rs1126672 C/T never drinkers 58 / 152 1.00 (ref) 59 / 128 1.19 ( 0.74 - 1.92 ) -0.14
>0 to <134,699 120 / 263 0.84 ( 0.56 - 1.27 ) 89 / 203 0.79 ( 0.51 - 1.22 )
134,699 to <757,550 186 / 214 1.37 ( 0.91 - 2.06 ) 132 / 146 1.46 ( 0.95 - 2.24 )
757,550+ 310 / 107 3.47 ( 2.24 - 5.37 ) 195 / 66 3.53 ( 2.21 - 5.63 )
rs4699710 T/C never drinkers 49 / 142 1.00 (ref) 68 / 138 1.45 ( 0.90 - 2.32 ) 0.09
>0 to <134,699 108 / 239 0.93 ( 0.61 - 1.44 ) 101 / 227 0.91 ( 0.58 - 1.41 )
134,699 to <757,550 172 / 183 1.70 ( 1.10 - 2.63 ) 146 / 177 1.45 ( 0.93 - 2.24 )
757,550+ 272 / 100 3.69 ( 2.33 - 5.85 ) 233 / 73 4.23 ( 2.63 - 6.80 )
rs10017466 T/C never drinkers 45 / 134 1.00 (ref) 72 / 146 1.46 ( 0.91 - 2.35 ) 1.08
>0 to <134,699 100 / 224 0.93 ( 0.60 - 1.46 ) 109 / 242 0.93 ( 0.60 - 1.45 )
134,699 to <757,550 154 / 163 1.73 ( 1.11 - 2.72 ) 164 / 197 1.49 ( 0.96 - 2.31 )
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757,550+ 223 / 93 3.26 ( 2.03 - 5.24 ) 281 / 80 4.80 ( 2.98 - 7.72 )
rs1800759 C/A never drinkers 35 / 93 1.00 (ref) 82 / 187 1.17 ( 0.70 - 1.95 ) 0.66
>0 to <134,699 70 / 153 0.80 ( 0.47 - 1.36 ) 139 / 313 0.86 ( 0.53 - 1.39 )
134,699 to <757,550 101 / 104 1.61 ( 0.95 - 2.73 ) 217 / 256 1.37 ( 0.85 - 2.22 )
757,550+ 132 / 55 3.02 ( 1.72 - 5.31 ) 373 / 118 3.85 ( 2.32 - 6.41 )
rs1800761 G/A never drinkers 68 / 167 1.00 (ref) 49 / 113 1.13 ( 0.70 - 1.81 ) -0.63
>0 to <134,699 121 / 300 0.70 ( 0.48 - 1.04 ) 88 / 166 0.95 ( 0.63 - 1.44 )
134,699 to <757,550 208 / 235 1.39 ( 0.95 - 2.04 ) 110 / 125 1.29 ( 0.84 - 1.98 )
757,550+ 310 / 101 3.57 ( 2.35 - 5.45 ) 195 / 72 3.07 ( 1.95 - 4.83 )
rs3762894 T/C never drinkers 82 / 178 1.00 (ref) 35 / 102 0.75 ( 0.45 - 1.23 ) -0.74
>0 to <134,699 135 / 328 0.62 ( 0.43 - 0.89 ) 74 / 138 0.83 ( 0.55 - 1.27 )
134,699 to <757,550 226 / 263 1.15 ( 0.80 - 1.65 ) 92 / 97 1.22 ( 0.79 - 1.88 )
757,550+ 348 / 108 3.28 ( 2.19 - 4.89 ) 157 / 65 2.29 ( 1.45 - 3.60 )
ADH7 rs284787 C/T never drinkers 67 / 166 1.00 (ref) 50 / 114 1.05 ( 0.65 - 1.68 ) 0.45
>0 to <134,699 127 / 299 0.74 ( 0.50 - 1.08 ) 82 / 167 0.83 ( 0.54 - 1.27 )
134,699 to <757,550 195 / 210 1.36 ( 0.92 - 2.01 ) 123 / 150 1.26 ( 0.83 - 1.92 )
757,550+ 308 / 112 3.11 ( 2.05 - 4.72 ) 197 / 61 3.61 ( 2.26 - 5.74 )
rs894369 C/G never drinkers 84 / 181 1.00 (ref) 33 / 99 0.71 ( 0.42 - 1.17 ) 0.80
>0 to <134,699 140 / 303 0.70 ( 0.48 - 1.00 ) 69 / 162 0.63 ( 0.42 - 0.96 )
134,699 to <757,550 207 / 214 1.26 ( 0.87 - 1.83 ) 111 / 146 1.00 ( 0.67 - 1.50 )
757,550+ 350 / 125 2.75 ( 1.85 - 4.07 ) 155 / 48 3.25 ( 2.02 - 5.22 )
rs17588403 T/A never drinkers 71 / 190 1.00 (ref) 46 / 90 1.35 ( 0.83 - 2.19 ) -1.33
>0 to <134,699 142 / 307 0.87 ( 0.60 - 1.25 ) 67 / 159 0.78 ( 0.51 - 1.21 )
134,699 to <757,550 226 / 251 1.49 ( 1.03 - 2.16 ) 92 / 109 1.32 ( 0.85 - 2.05 )
757,550+ 347 / 108 3.96 ( 2.63 - 5.96 ) 158 / 65 2.97 ( 1.88 - 4.69 )
rs1154454 T/C never drinkers 76 / 175 1.00 (ref) 41 / 105 0.85 ( 0.52 - 1.39 ) 0.13
>0 to <134,699 143 / 276 0.82 ( 0.57 - 1.19 ) 66 / 190 0.55 ( 0.36 - 0.84 )
134,699 to <757,550 191 / 227 1.16 ( 0.80 - 1.70 ) 127 / 133 1.31 ( 0.86 - 1.98 )
757,550+ 306 / 106 3.04 ( 2.02 - 4.58 ) 199 / 67 3.02 ( 1.91 - 4.77 )
rs1154456 T/C never drinkers 54 / 125 1.00 (ref) 63 / 155 0.77 ( 0.48 - 1.22 ) -0.03
>0 to <134,699 91 / 218 0.62 ( 0.40 - 0.96 ) 118 / 248 0.68 ( 0.44 - 1.04 )
134,699 to <757,550 149 / 181 1.03 ( 0.67 - 1.59 ) 169 / 179 1.20 ( 0.78 - 1.85 )
757,550+ 256 / 81 2.91 ( 1.82 - 4.65 ) 249 / 92 2.65 ( 1.67 - 4.20 )
rs1154460 G/A never drinkers 35 / 65 1.00 (ref) 81 / 215 0.63 ( 0.37 - 1.07 ) 0.92
>0 to <134,699 57 / 131 0.53 ( 0.30 - 0.92 ) 152 / 334 0.55 ( 0.34 - 0.90 )
134,699 to <757,550 88 / 111 0.83 ( 0.48 - 1.45 ) 229 / 249 0.97 ( 0.59 - 1.60 )
757,550+ 133 / 54 1.93 ( 1.07 - 3.46 ) 371 / 119 2.48 ( 1.47 - 4.20 )
rs971074 G/A never drinkers 91 / 219 1.00 (ref) 26 / 61 1.15 ( 0.65 - 2.03 ) 0.86
>0 to <134,699 166 / 357 0.79 ( 0.56 - 1.11 ) 43 / 109 0.73 ( 0.46 - 1.17 )
134,699 to <757,550 247 / 275 1.34 ( 0.95 - 1.89 ) 71 / 85 1.31 ( 0.84 - 2.05 )
757,550+ 380 / 140 3.13 ( 2.15 - 4.55 ) 125 / 33 4.14 ( 2.47 - 6.94 )
rs1573496 C/G never drinkers 98 / 236 1.00 (ref) 19 / 44 1.08 ( 0.57 - 2.05 ) 0.46
previously studied >0 to <134,699 175 / 386 0.76 ( 0.55 - 1.06 ) 34 / 80 0.76 ( 0.46 - 1.27 )
134,699 to <757,550 272 / 301 1.31 ( 0.94 - 1.83 ) 46 / 59 1.29 ( 0.78 - 2.13 )
757,550+ 446 / 155 3.20 ( 2.23 - 4.59 ) 58 / 18 3.73 ( 1.98 - 7.05 )
ALDH2 rs4767939 A/G never drinkers 76 / 174 1.00 (ref) 41 / 106 0.88 ( 0.54 - 1.44 ) 1.09
>0 to <134,699 120 / 289 0.65 ( 0.44 - 0.94 ) 89 / 177 0.84 ( 0.56 - 1.27 )
134,699 to <757,550 194 / 218 1.21 ( 0.83 - 1.77 ) 124 / 142 1.28 ( 0.85 - 1.93 )
757,550+ 261 / 103 2.69 ( 1.78 - 4.07 ) 243 / 70 3.66 ( 2.35 - 5.71 )
rs2238151 T/C never drinkers 50 / 95 1.00 (ref) 67 / 184 0.70 ( 0.43 - 1.14 ) 1.91
>0 to <134,699 75 / 173 0.54 ( 0.34 - 0.88 ) 133 / 293 0.64 ( 0.41 - 0.99 )
134,699 to <757,550 97 / 138 0.81 ( 0.50 - 1.31 ) 220 / 222 1.19 ( 0.76 - 1.86 )
757,550+ 122 / 65 1.66 ( 0.99 - 2.80 ) 381 / 106 3.27 ( 2.02 - 5.28 )
rs7312055 G/A never drinkers 111 / 254 1.00 (ref) 6 / 26 0.41 ( 0.15 - 1.12 ) 0.97
>0 to <134,699 201 / 427 0.74 ( 0.54 - 1.01 ) 8 / 39 0.32 ( 0.13 - 0.78 )
134,699 to <757,550 282 / 328 1.19 ( 0.87 - 1.64 ) 36 / 32 1.30 ( 0.69 - 2.46 )
757,550+ 422 / 152 2.93 ( 2.06 - 4.17 ) 83 / 21 3.31 ( 1.76 - 6.23 )
rs2158029 G/A never drinkers 116 / 270 1.00 (ref) 1 / 10 0.28 ( 0.03 - 2.30 ) 2.73
>0 to <134,699 207 / 443 0.77 ( 0.57 - 1.04 ) 2 / 23 0.13 ( 0.03 - 0.60 )
134,699 to <757,550 302 / 349 1.25 ( 0.91 - 1.70 ) 16 / 11 1.79 ( 0.72 - 4.45 )
757,550+ 470 / 166 3.09 ( 2.19 - 4.35 ) 35 / 7 5.10 ( 2.04 - 12.73 )
rs16941667 C/T never drinkers 98 / 233 1.00 (ref) 19 / 47 1.06 ( 0.57 - 1.99 ) 0.99
>0 to <134,699 163 / 390 0.70 ( 0.50 - 0.98 ) 46 / 75 1.11 ( 0.69 - 1.79 )
134,699 to <757,550 259 / 294 1.29 ( 0.92 - 1.80 ) 59 / 66 1.42 ( 0.89 - 2.29 )
757,550+ 405 / 148 3.12 ( 2.17 - 4.49 ) 100 / 25 4.17 ( 2.39 - 7.28 )
rs16941669 T/G never drinkers 97 / 218 1.00 (ref) 20 / 61 0.74 ( 0.41 - 1.34 ) 1.45
>0 to <134,699 162 / 380 0.67 ( 0.48 - 0.94 ) 47 / 86 0.88 ( 0.55 - 1.39 )
134,699 to <757,550 254 / 302 1.17 ( 0.84 - 1.64 ) 64 / 58 1.46 ( 0.90 - 2.35 )
757,550+ 415 / 149 2.90 ( 2.01 - 4.18 ) 90 / 23 4.09 ( 2.30 - 7.26 )
CYP2E1 rs3813865 G/C never drinkers 108 / 259 1.00 (ref) 9 / 20 1.24 ( 0.51 - 3.00 ) 1.95
>0 to <134,699 196 / 432 0.76 ( 0.56 - 1.04 ) 13 / 34 0.75 ( 0.37 - 1.54 )
134,699 to <757,550 289 / 324 1.32 ( 0.96 - 1.82 ) 29 / 36 1.27 ( 0.69 - 2.31 )
757,550+ 437 / 160 3.11 ( 2.19 - 4.42 ) 68 / 13 5.31 ( 2.65 - 10.65 )
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rs3813867 G/C never drinkers 110 / 263 1.00 (ref) 7 / 16 0.94 ( 0.35 - 2.47 ) 3.88
>0 to <134,699 197 / 441 0.74 ( 0.54 - 1.01 ) 12 / 25 0.80 ( 0.37 - 1.76 )
134,699 to <757,550 301 / 329 1.35 ( 0.98 - 1.85 ) 17 / 31 0.65 ( 0.33 - 1.28 )
757,550+ 460 / 165 3.00 ( 2.11 - 4.25 ) 44 / 8 6.82 ( 2.90 - 16.02 )
rs8192772 T/C never drinkers 99 / 237 1.00 (ref) 18 / 43 1.07 ( 0.55 - 2.05 ) 1.89
>0 to <134,699 179 / 394 0.75 ( 0.54 - 1.03 ) 30 / 72 0.84 ( 0.50 - 1.41 )
134,699 to <757,550 264 / 294 1.30 ( 0.94 - 1.81 ) 53 / 66 1.29 ( 0.80 - 2.08 )
757,550+ 413 / 152 3.02 ( 2.11 - 4.33 ) 92 / 21 4.97 ( 2.78 - 8.91 )
rs915908 G/A never drinkers 93 / 216 1.00 (ref) 24 / 64 1.04 ( 0.59 - 1.85 ) -1.29
>0 to <134,699 152 / 352 0.74 ( 0.53 - 1.04 ) 57 / 114 0.80 ( 0.52 - 1.24 )
134,699 to <757,550 254 / 277 1.35 ( 0.96 - 1.91 ) 64 / 83 1.12 ( 0.71 - 1.77 )
757,550+ 417 / 131 3.56 ( 2.45 - 5.17 ) 88 / 42 2.31 ( 1.39 - 3.82 )
rs915909 C/T never drinkers 115 / 270 1.00 (ref) 2 / 9 0.62 ( 0.12 - 3.24 ) 0.80
>0 to <134,699 206 / 449 0.76 ( 0.56 - 1.03 ) 3 / 15 0.35 ( 0.09 - 1.30 )
134,699 to <757,550 302 / 348 1.26 ( 0.92 - 1.71 ) 16 / 12 1.74 ( 0.71 - 4.24 )
757,550+ 468 / 163 3.15 ( 2.23 - 4.44 ) 36 / 9 3.56 ( 1.56 - 8.17 )
rs7092584 C/T never drinkers 92 / 223 1.00 (ref) 25 / 57 1.17 ( 0.66 - 2.07 ) 1.06
>0 to <134,699 167 / 375 0.75 ( 0.54 - 1.05 ) 42 / 91 0.89 ( 0.56 - 1.44 )
134,699 to <757,550 252 / 279 1.36 ( 0.97 - 1.92 ) 65 / 80 1.24 ( 0.79 - 1.94 )
757,550+ 384 / 142 3.10 ( 2.14 - 4.49 ) 120 / 31 4.33 ( 2.58 - 7.26 )
rs743535 C/T never drinkers 95 / 223 1.00 (ref) 22 / 53 0.93 ( 0.51 - 1.69 ) 2.26
>0 to <134,699 169 / 386 0.70 ( 0.50 - 0.98 ) 40 / 78 0.91 ( 0.56 - 1.49 )
134,699 to <757,550 252 / 279 1.29 ( 0.92 - 1.81 ) 60 / 80 1.04 ( 0.66 - 1.65 )
757,550+ 386 / 147 2.79 ( 1.93 - 4.04 ) 116 / 26 4.98 ( 2.89 - 8.59 )
rs2249695 C/T never drinkers 73 / 136 1.00 (ref) 44 / 144 0.56 ( 0.35 - 0.91 ) 1.21
"tipsy" SNP >0 to <134,699 127 / 253 0.63 ( 0.43 - 0.94 ) 82 / 213 0.52 ( 0.34 - 0.80 )
134,699 to <757,550 160 / 178 1.06 ( 0.71 - 1.59 ) 158 / 181 0.95 ( 0.63 - 1.43 )
757,550+ 218 / 92 2.12 ( 1.37 - 3.28 ) 286 / 81 2.89 ( 1.83 - 4.55 )
rs28969387 A/T never drinkers 115 / 275 1.00 (ref) 2 / 5 1.03 ( 0.16 - 6.58 ) 0.05
>0 to <134,699 206 / 464 0.75 ( 0.55 - 1.01 ) 3 / 2 2.25 ( 0.33 - 15.13 )
134,699 to <757,550 311 / 353 1.30 ( 0.95 - 1.77 ) 7 / 7 1.06 ( 0.33 - 3.38 )
757,550+ 493 / 170 3.22 ( 2.29 - 4.54 ) 12 / 3 3.30 ( 0.88 - 12.40 )
rs11101812 T/C never drinkers 115 / 275 1.00 (ref) 1 / 5 0.41 ( 0.04 - 3.90 ) 19.34
>0 to <134,699 205 / 463 0.74 ( 0.55 - 1.00 ) 4 / 3 2.70 ( 0.52 - 14.05 )
134,699 to <757,550 312 / 348 1.31 ( 0.96 - 1.79 ) 5 / 10 0.67 ( 0.20 - 2.23 )
757,550+ 489 / 172 3.10 ( 2.20 - 4.36 ) 15 / 1 21.85 ( 2.60 ##### )
OXIDATIVE STRESS METABOLISM GENES
CAT rs1049982 C/T never drinkers 60 / 137 1.00 (ref) 57 / 140 1.10 ( 0.69 - 1.77 ) -0.15
>0 to <134,699 95 / 216 0.75 ( 0.49 - 1.15 ) 114 / 247 0.81 ( 0.54 - 1.22 )
134,699 to <757,550 135 / 150 1.41 ( 0.92 - 2.16 ) 183 / 209 1.29 ( 0.85 - 1.94 )
757,550+ 200 / 71 3.33 ( 2.10 - 5.28 ) 303 / 102 3.28 ( 2.12 - 5.07 )
GPX1 rs8179172 T/A never drinkers 116 / 270 1.00 (ref) 1 / 10 0.14 ( 0.02 - 1.25 ) 0.16
>0 to <134,699 205 / 450 0.73 ( 0.54 - 0.99 ) 4 / 16 0.44 ( 0.13 - 1.46 )
134,699 to <757,550 305 / 349 1.21 ( 0.88 - 1.65 ) 13 / 11 2.15 ( 0.85 - 5.44 )
757,550+ 475 / 160 3.10 ( 2.19 - 4.38 ) 30 / 13 2.40 ( 1.10 - 5.27 )
rs1800668 C/T never drinkers 56 / 146 1.00 (ref) 61 / 132 1.16 ( 0.73 - 1.85 ) 0.37
>0 to <134,699 97 / 222 0.76 ( 0.50 - 1.16 ) 112 / 243 0.85 ( 0.56 - 1.29 )
134,699 to <757,550 178 / 185 1.43 ( 0.94 - 2.16 ) 140 / 175 1.33 ( 0.87 - 2.04 )
757,550+ 272 / 95 3.23 ( 2.07 - 5.05 ) 233 / 77 3.75 ( 2.37 - 5.95 )
rs3811699 A/G never drinkers 55 / 142 1.00 (ref) 62 / 138 1.14 ( 0.72 - 1.82 ) 0.37
>0 to <134,699 95 / 216 0.76 ( 0.50 - 1.17 ) 114 / 250 0.85 ( 0.56 - 1.29 )
134,699 to <757,550 171 / 176 1.45 ( 0.95 - 2.21 ) 147 / 184 1.31 ( 0.86 - 2.01 )
757,550+ 258 / 91 3.21 ( 2.04 - 5.04 ) 247 / 82 3.71 ( 2.35 - 5.88 )
rs3448 C/T never drinkers 60 / 158 1.00 (ref) 57 / 122 1.27 ( 0.80 - 2.03 ) 0.32
>0 to <134,699 116 / 256 0.84 ( 0.56 - 1.26 ) 93 / 210 0.84 ( 0.55 - 1.28 )
134,699 to <757,550 157 / 192 1.35 ( 0.89 - 2.03 ) 161 / 168 1.55 ( 1.03 - 2.34 )
757,550+ 273 / 105 3.34 ( 2.17 - 5.14 ) 232 / 68 3.93 ( 2.49 - 6.22 )
GPX2 rs11623705 G/T never drinkers 86 / 232 1.00 (ref) 31 / 48 1.58 ( 0.90 - 2.77 ) -0.76
>0 to <134,699 166 / 367 0.83 ( 0.59 - 1.17 ) 43 / 99 0.83 ( 0.52 - 1.32 )
134,699 to <757,550 263 / 292 1.47 ( 1.05 - 2.08 ) 55 / 68 1.24 ( 0.77 - 2.01 )
757,550+ 421 / 142 3.60 ( 2.47 - 5.24 ) 84 / 31 3.41 ( 2.00 - 5.84 )
rs2412065 G/C never drinkers 67 / 158 1.00 (ref) 50 / 122 1.00 ( 0.62 - 1.60 ) 0.06
>0 to <134,699 126 / 251 0.85 ( 0.57 - 1.26 ) 83 / 215 0.65 ( 0.43 - 0.99 )
134,699 to <757,550 186 / 204 1.32 ( 0.89 - 1.96 ) 132 / 156 1.25 ( 0.82 - 1.90 )
757,550+ 278 / 99 3.18 ( 2.07 - 4.88 ) 227 / 74 3.24 ( 2.06 - 5.10 )
rs2737844 C/T never drinkers 58 / 117 1.00 (ref) 59 / 161 0.76 ( 0.48 - 1.22 ) 0.03
>0 to <134,699 100 / 173 0.84 ( 0.54 - 1.30 ) 108 / 292 0.54 ( 0.35 - 0.82 )
134,699 to <757,550 129 / 147 1.09 ( 0.70 - 1.70 ) 188 / 211 1.12 ( 0.73 - 1.72 )
757,550+ 180 / 62 2.84 ( 1.73 - 4.65 ) 322 / 111 2.63 ( 1.66 - 4.16 )
GPX4 rs757229 G/C never drinkers 35 / 83 1.00 (ref) 82 / 197 0.92 ( 0.55 - 1.52 ) 0.09
>0 to <134,699 58 / 114 0.74 ( 0.43 - 1.28 ) 150 / 352 0.69 ( 0.43 - 1.12 )
134,699 to <757,550 67 / 109 0.90 ( 0.52 - 1.56 ) 251 / 251 1.34 ( 0.83 - 2.17 )
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APPENDIX E. Odds ratios for developing SCCHN for SNP genotypes, at varying levels of lifetime alcohol consumption
Odds ratios in comparison to common referent groupa
homozygous major allele at least one minor allele
n 
(cases/
controls)b
Adjusted odds ratio (95% CI)
n 
(cases/
controls)b
Adjusted odds ratio (95% CI)
757,550+ 116 / 40 3.05 ( 1.68 - 5.54 ) 389 / 132 3.05 ( 1.84 - 5.06 )
SOD1 rs11910115 A/C never drinkers 116 / 271 1.00 (ref) 1 / 9 0.31 ( 0.03 - 2.91 ) 2.22
>0 to <134,699 205 / 441 0.76 ( 0.56 - 1.04 ) 4 / 25 0.27 ( 0.08 - 0.92 )
134,699 to <757,550 299 / 340 1.27 ( 0.93 - 1.73 ) 19 / 20 1.33 ( 0.62 - 2.85 )
757,550+ 469 / 165 3.09 ( 2.19 - 4.35 ) 36 / 8 4.63 ( 1.94 - 11.06 )
rs4998557 G/A never drinkers 85 / 202 1.00 (ref) 32 / 78 0.91 ( 0.54 - 1.53 ) 1.51
>0 to <134,699 157 / 341 0.75 ( 0.53 - 1.07 ) 52 / 122 0.69 ( 0.44 - 1.09 )
134,699 to <757,550 208 / 258 1.15 ( 0.80 - 1.64 ) 110 / 102 1.53 ( 1.00 - 2.34 )
757,550+ 328 / 124 2.76 ( 1.87 - 4.08 ) 176 / 49 4.18 ( 2.60 - 6.72 )
rs10432782 T/G never drinkers 86 / 208 1.00 (ref) 31 / 72 0.95 ( 0.56 - 1.61 ) 1.15
>0 to <134,699 162 / 351 0.77 ( 0.55 - 1.09 ) 47 / 115 0.65 ( 0.41 - 1.04 )
134,699 to <757,550 222 / 267 1.20 ( 0.84 - 1.70 ) 96 / 93 1.48 ( 0.96 - 2.27 )
757,550+ 350 / 128 2.91 ( 1.98 - 4.27 ) 154 / 44 4.00 ( 2.48 - 6.46 )
rs2070424 A/G never drinkers 95 / 238 1.00 (ref) 22 / 42 1.17 ( 0.63 - 2.17 ) 0.01
>0 to <134,699 181 / 402 0.78 ( 0.56 - 1.08 ) 28 / 64 0.76 ( 0.44 - 1.30 )
134,699 to <757,550 260 / 302 1.31 ( 0.94 - 1.83 ) 58 / 58 1.41 ( 0.87 - 2.30 )
757,550+ 407 139 3.27 ( 2.27 - 4.72 ) 98 / 34 3.45 ( 2.06 - 5.79 )
rs1041740 C/T never drinkers 56 / 156 1.00 (ref) 61 / 124 1.43 ( 0.89 - 2.28 ) -1.09
>0 to <134,699 104 / 239 0.89 ( 0.59 - 1.35 ) 105 / 227 0.90 ( 0.59 - 1.37 )
134,699 to <757,550 193 / 191 1.71 ( 1.13 - 2.59 ) 125 / 169 1.33 ( 0.86 - 2.05 )
757,550+ 291 / 94 4.15 ( 2.65 - 6.49 ) 214 / 79 3.49 ( 2.21 - 5.52 )
SOD2 rs4342445 G/A never drinkers 55 / 177 1.00 (ref) 62 / 103 2.14 ( 1.33 - 3.44 ) 0.27
>0 to <134,699 135 / 296 1.10 ( 0.74 - 1.63 ) 74 / 170 0.96 ( 0.62 - 1.49 )
134,699 to <757,550 184 / 227 1.61 ( 1.07 - 2.40 ) 134 / 133 2.11 ( 1.38 - 3.24 )
757,550+ 331 / 123 4.04 ( 2.65 - 6.17 ) 174 / 50 5.45 ( 3.33 - 8.90 )
rs2842980 A/T never drinkers 74 / 169 1.00 (ref) 43 / 111 0.87 ( 0.54 - 1.41 ) 0.89
>0 to <134,699 121 / 282 0.69 ( 0.47 - 1.01 ) 88 / 184 0.76 ( 0.50 - 1.14 )
134,699 to <757,550 196 / 222 1.27 ( 0.87 - 1.87 ) 122 / 138 1.15 ( 0.76 - 1.74 )
757,550+ 291 / 108 2.77 ( 1.84 - 4.19 ) 214 / 65 3.54 ( 2.25 - 5.56 )
rs8031 T/A never drinkers 38 / 75 1.00 (ref) 79 / 205 0.84 ( 0.51 - 1.40 ) -0.97
>0 to <134,699 59 / 139 0.58 ( 0.34 - 0.98 ) 150 / 327 0.71 ( 0.44 - 1.15 )
134,699 to <757,550 101 / 113 1.14 ( 0.68 - 1.93 ) 217 / 247 1.15 ( 0.71 - 1.86 )
757,550+ 155 / 40 3.73 ( 2.08 - 6.71 ) 350 / 133 2.61 ( 1.59 - 4.30 )
rs5746134 C/T never drinkers 113 / 264 1.00 (ref) 4 / 16 0.55 ( 0.16 - 1.87 ) 4.29
>0 to <134,699 201 / 447 0.73 ( 0.54 - 0.99 ) 8 / 19 0.80 ( 0.31 - 2.08 )
134,699 to <757,550 299 / 342 1.25 ( 0.91 - 1.71 ) 19 / 18 1.47 ( 0.68 - 3.18 )
757,550+ 446 / 163 2.96 ( 2.09 - 4.19 ) 59 / 10 6.80 ( 3.03 - 15.26 )
rs2758331 C/A never drinkers 38 / 82 1.00 (ref) 79 / 198 0.92 ( 0.55 - 1.52 ) -1.51
>0 to <134,699 60 / 151 0.58 ( 0.34 - 0.98 ) 149 / 315 0.78 ( 0.48 - 1.24 )
134,699 to <757,550 108 / 127 1.14 ( 0.68 - 1.90 ) 210 / 233 1.26 ( 0.78 - 2.03 )
757,550+ 179 / 44 4.23 ( 2.39 - 7.50 ) 326 / 129 2.64 ( 1.61 - 4.34 )
c ICRs were calculated using cancer odds ratios of subjects in three categories: (1) the highest drinking category and no minor allele (i.e., those singly exposed to drinking only -- OR01); (2) never-
drinkers with at least one minor allele (i.e., those singly exposed to only the variant allele -- OR10); and (3) subjects in the highest drinking category and at least one minor allele (i.e., those doubly 
exposed to both alcohol and the variant allele -- OR11), compared to never-drinkers homozygous for the major allele (i.e., the referent group that was not exposed to either the variant allele or to 
drinking -- OR00 = 1.0). ICRs statistically different from 0 indicate departure from additive interaction. p-values for each ICR (not shown) were Bonferroni-adjusted for 64 statistical tests.
b Cases and controls do not sum to 1227 and 1325, respectively, because (1) 4 cases and 3 controls are missing information on duration of cigarette smoking, (2) 77 cases and 45 controls are 
missing information on lifetime alcohol consumption, and (3) a few subjects are missing genotype information for some SNPs
a Conditional logistic regression models conditioned on sex, race, and age category (age in years: 20-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-80), and adjusted for continous duration of smoking in 
years (rounded to nearest year)
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